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6Summary 
African sleeping sickness, also called human African trypanosomiasis (HAT), results from 
the infection of humans with either of two protozoan parasites, Trypanosoma brucei gambiense and 
T. b. rhodesiense. HAT is transmitted by tsetse flies (Glossina spp) and, like the vector, is found 
exclusively in Africa between the latitudes 14° North and 29° South. A total of 50 million people 
live in foci where active transmission is possible and are therefore at risk of infection; however, the 
annual incidence and estimated prevalence currently stand at 7139 and 30 000 cases respectively. 
When trypanosomes are inoculated into a human host, the resulting clinical disease is classified into 
a first (early) stage in which trypanosomes are localised within the haemo-lymphatic system and a 
second (late) stage in which trypanosomes have crossed the blood brain barrier (BBB) and invaded 
the central nervous system (CNS).  
Currently, pentamidine and suramin are used to treat the first stage of T. b. gambiense and 
T. b. rhodesiense HAT, respectively. On the other hand, eflornithine and the nifurtimox eflornithine 
combination therapy (NECT) are the preferred treatments for second stage T. b. gambiense HAT. 
The organo-arsenic drug melarsoprol may be used for both forms of HAT but is mainly used 
against T. b. rhodesiense. Clearly, the therapeutic options for HAT are very limited. In addition, 
available drugs are associated with different levels of toxicity, especially melarsoprol which causes 
a post treatment reactive encephalopathy (PTRE) in 5-10% of treated patients, up to 50% of PTRE 
patients may die. There are also reports of high melarsoprol treatment failure rates in some foci and 
there is a lack of easy to use oral formulations for all the drugs. We have carried out biological and 
pharmacological investigations of potential new drug candidates in animal models of HAT with the 
objective of contributing to the development of safe, efficacious and easy to use treatments for 
HAT. The studies were carried out in the context of a PhD programme at the Swiss TPH/University 
of Basel and were anchored onto an ongoing diamidines development project of the Consortium for 
Parasitic Drug Development (CPDD). Vervet monkeys (Chlorocebus [Cercopithecus] aethiops) 
were the main model for this study. 
To prepare for the studies in monkeys, one prodrug (DB289) was evaluated in mouse 
models of first stage HAT. We obtained good activities against different trypanosome isolates, 
including the one that is used in the monkey model, T. b. rhodesiense KETRI2537. We further 
evaluated the metabolism of the prodrugs in monkey liver microsomes. In all cases, prodrugs were 
metabolized to generate expected intermediate and active metabolites, thus allowing us to proceed 
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to test the compounds for safety in un-infected monkeys. We determined that in monkeys: i) 
diamidine toxicity was dependent on the dose and duration of dosing, ii) the plasma concentrations 
of active metabolites were potentially therapeutic for HAT, and iii) the dose level at which there 
were no observed adverse effects (NOAEL). Three prodrugs (DB289, DB844 and DB868) and one 
active compound (DB829) were subsequently evaluated for efficacy at dose rates that were equal or 
below NOAEL. In general, the prodrugs were highly active against first stage HAT after oral 
administration and one prodrug (DB844) had additionally an improved activity (43%) in the second 
stage monkey HAT model in comparison with pentamidine (0%). The intramuscularly administered 
parent compound DB829 was fully curative in the second stage HAT model at 2.5 mg/kg x 5 days. 
 
Our findings suggest that the two compounds (oral DB868 and intramuscular DB829) 
should be recommended to enter the regulatory phase of development as potential HAT drugs. Oral 
DB868 cured the first stage HAT model at a daily dose of 3 mg/kg for 7 days (cumulative dose, CD 
= 21 mg/kg) compared to a maximum tolerated daily dose of 30 mg/kg for 10 days (CD = 300 
mg/kg). The efficacy, safety and pharmacokinetic profiles suggest that this compound would be a 
useful clinical candidate using an optimal dosing duration of 5-7 days. The second compound, 
intramuscular DB829, cured the second stage HAT model at a daily dose of 2.5 mg/kg for 5 days 
and was tolerated at 5 mg/kg for 5 days (CD = 25 mg/kg). Pharmacokinetic analysis indicated the 
intramuscular administration of DB829 resulted in better systemic bioavailability, thus accounting 
for the improved efficacy in comparison with oral dosing. 
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Zusammenfassung 
 
Die Afrikanische Schlafkrankheit, auch humane Afrikanische Trypanosomose (HAT) 
genannt, wird im Menschen durch eine Infektion mit einem der zwei einzelligen Parasiten, 
Trypanosoma brucei gambiense und T. b. rhodesiense verursacht. HAT wird durch Tsetsefliegen 
(Glossina spp) übertragen und kommt wie der Vektor ausschließlich in Afrika zwischen den 
Breitengraden 14° Nord und 29° Süd vor. Insgesamt 50 Millionen Menschen leben in den Gebieten, 
in denen eine aktive Übertragung möglich ist, und sie sind somit dem Risiko einer Infektion 
ausgesetzt. Die Inzidenz lag 2010 bei 7139 gemeldeten Fällen und die Prävalenz wurde auf 30 000 
Fälle geschätzt. Wenn Trypanosomen in einen menschlichen Wirt gelangen verläuft die 
Erkrankung in zwei Stadien. In einer ersten (akuten) Phase sind die Trypanosomen im hämo-
lymphatischen System lokalisiert, in der zweiten (chronische) Phase überwinden die Trypanosomen 
die Blut-Hirn-Schranke und infizieren das zentrale Nervensystem (ZNS). 
 
Derzeit werden Pentamidin und Suramin verwendet, um das erste Stadium einer T. b. 
gambiense Infektion respektive einer T. b. rhodesiense Infektion zu behandeln. Eflornithin und die 
Nifurtimox-Eflornithin Kombinationstherapie (NECT) sind die bevorzugten Medikamente für das 
zweite Stadium einer T. b. gambiense HAT. Das arsenhaltige Medikament Melarsoprol kann für 
beide Formen von HAT verwendet werden, wird aber hauptsächlich nur bei der durch T. b. 
rhodesiense verursachten Schlafkrankheit verwendet. Die therapeutischen Möglichkeiten zur 
Behandlung von HAT sind eindeutig begrenzt. Zusätzlich sind die verfügbaren Medikamente in 
unterschiedlichem Masse toxisch. Insbesondere Melarsoprol kann bei 5-10% der behandelten 
Patienten eine  reaktive Enzephalopathie (PTRE) verursachen, die in 50% der Fälle tödlich ist. 
Zusätzlich gibt es Berichte von Behandlungsmisserfolgen mit Melarsoprol, in manchen 
Schlafkrankheitsgebieten bis zu 30%. Die bisher verfügbaren Medikamente müssen intramuskulär 
oder intravenös verabreicht werden. Es fehlen leicht verabreichbare orale Formulierungen. Mit dem 
Ziel, eine verträgliche, wirksame und leicht zu verabreichende Medikation gegen HAT zu finden, 
haben wir biologische und pharmakologische Untersuchungen von potentiellen neuen 
Wirkstoffkandidaten in Tiermodellen durchgeführt. Die Studien waren Teil eines laufenden 
Diamidin-Entwicklungsprojekts des „Consortium for Parasitic Drug Development“ (CPDD) und 
wurden im Rahmen einer Doktorarbeit am Swiss TPH / Universität Basel durchgeführt. Meerkatzen 
(Chlorocebus [Cercopithecus] aethiops), eine Affenart, waren das Hauptmodell für diese Arbeit. 
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Während der Vorarbeit, wurde eine Substanz (DB289), ein Prodrug, in Mausmodellen  mit 
dem ersten Krankheitsstadiums untersucht. Die Substanz zeigte gute Aktivitäten, einschliesslich 
gegen den Parasitenstamm T. b rhodesiense KETRI2537, der ebenso im Affenmodell verwendet 
wird. Zusätzlich haben wir die Metabolisierung der verschiedenen Prodrugs in Affen-
Lebermikrosomen untersucht. In allen Fällen wurden die Prodrugs wie erwartet in Zwischen-und 
aktive Metabolite umgesetzt. Die Ergebnisse ermöglichten es uns, die Verträglichkeit der 
Substanzen in uninfizierten Affen zu prüfen. Wir stellten fest, dass in Affen: i) die Toxizität der 
Diamidine von der Dosis und der Dauer der Dosierung abhängig war, ii) die Plasma-
Konzentrationen der aktiven Metaboliten potentiell therapeutisch für HAT sind und konnten iii) die 
Dosis bestimmen, die keine erkennbaren und keine messbaren Schädigungen hinterlässt (NOAEL: 
no observed adverse effect level). Die drei Prodrugs DB289, DB844 und DB868 und das aktive 
Diamidin B829, wurden anschließend auf ihre Wirksamkeit untersucht. Die verwendete Dosis war 
entweder gleich oder unterhalb NOAEL. Im Allgemeinen waren die Prodrugs hochaktiv gegen das 
erste Schlafkrankheitsstadium bei einer oralen Verabreichung. Eine Substanz (DB844) wies im 
Vergleich zu Pentamidin (0%) zusätzlich eine verbesserte Aktivität (43%) im chronischen 
Affenmodell (mit ZNS- Infektion) auf. Das intramuskulär verabreichte Diamidin DB829 konnte bei 
einer täglichen Dosis von 2.5 mg/kg für 5 Tage das chronische Affenmodell vollständig heilen. 
 
Unsere Ergebnisse legen nahe, dass die beiden Wirkstoffe (DB868 oral und DB829 
intramuskulär) als potenzielle HAT Medikamente weiterentwickelt werden sollten.  Oral 
verabreichtes DB868 heilte das akute HAT Affenmodell bei einer täglichen Dosis von nur 3 mg/kg 
und einer 7 Tage Behandlung (kumulative Dosis, CD = 21 mg/kg).  Im Vergleich dazu lag die 
maximal tolerierte  Dosis von DB868 bei 30 mg/kg für 10 Tage (CD = 300 mg/kg). Die 
Wirksamkeit, Verträglichkeit und das pharmakokinetische Profil zeigen, dass diese Verbindung ein 
guter klinischer Kandidat für das erste Stadium sein könnte, mit einer optimalen Dosierungsdauer 
von 5-7 Tagen. Die zweite intramuskulär verabreichte Verbindung DB829, heilte das zweite 
Krankheitsstadium im Affenmodell bei einer täglichen Dosis von nur 2,5 mg/kg und einer 5 Tage 
Behandlungsdauer. Die tolerierte Dosis lag bei 5 mg/kg für 5 Tage (CD = 25 mg/kg). Die 
pharmakokinetische Analyse zeigte, dass die intramuskuläre Verabreichung von DB829 zu einer 
verbesserten systemischen Bioverfügbarkeit führt und damit zur verbesserten Wirksamkeit im 
Vergleich zur oralen Dosierung. 
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Chapter 1: General Introduction 
The Problem of Human African Trypanosomiasis (HAT) 
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a debilitating 
disease that is caused by two flagellated protozoan parasites, Trypanosoma brucei (T. b.) 
gambiense and T. b. rhodesiense.  The two pathogens are native to the African continent. Not 
surprisingly, Africa has borne the blunt of the losses attributable to sleeping sickness since only a 
limited number of infections have been diagnosed in tourists or travellers from other countries 
visiting areas where active disease transmission was occurring (Sinha et al., 1999; Jelinek et al., 
2002; Moore et al., 2002). HAT is ranked among the thirteen most neglected tropical diseases 
(NTDs), with disability adjusted life years (DALY’s) lost of 1 673 000 years (Vanderelst and 
Speybroeck, 2010). NTDs have in common, a lack or shortage of efficacious medicines that are 
also safe to use, easily administrable and inexpensive, in order to benefit patients in resource-poor 
settings where NTDs are common. 
 
HAT is transmitted by tsetse flies (Glossina spp), and as a result, is only found between 
latitudes 14° North and 29° South, the ecological limits of the vector.  Tsetse flies also transmit 
animal pathogenic trypanosomes that together with their vectors, cover an estimated area of 10 400 
000 km2 of agricultural land and are estimated to cost Africa an annual income of 4.5 billion USD 
(Wilson et al, 1963; DFID, 2010; Tesfaye et al., 2012). Indeed, successive African Governments 
from colonial times and the African Union (AU) have acknowledged that human and animal 
trypanosomiasis need to be controlled to improve health and economic development of Africa 
(Wilson, 1963; Simarro et al., 2008; African Union, 2002). 
 
A total of 36 countries are classified by the World Health Organization (WHO) as endemic 
for HAT (Simarro et al, 2008; WHO, 2012a).  A number of these countries have however not 
reported a single case of the disease in more than 10 years (WHO, 2012a) and according to Stuart et 
al., (2008) HAT is a significant public health problem in only 20 countries. However, this restricted 
number of countries may mask the fact that the disease is a threat to an estimated 50-60 million 
people who live in foci where active transmission is possible (Stuart et al., 2008; WHO, 2012a). 
The significance of this threat is amplified by the fact that a majority of the affected people are 
exposed to the tsetse fly menace in the course of eking out a livelihood in agriculture, fishing, 
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animal husbandry or hunting (Simarro et al., 2008; WHO, 2012a).  Preventing new infections is 
therefore a formidable challenge indeed. 
 
HAT occurs in cycles of epidemics interspersed with periods when the disease was almost 
decimated (Figure 1). During the most recent epidemic which peaked in 1998, a total of 37, 991 
new cases of HAT were reported to the World Health Organization (WHO), with an estimated 
prevalence of 300,000 to 500,000; these high numbers were considered to be the result of an 
underestimation of the true situation because of insufficient coverage by surveillance systems 
(Chappuis et al., 2010; WHO, 2012a). The extent of this human catastrophe was magnified by the 
fact that only an estimated 10-20% of infected persons are accessed by disease control authorities 
and put on treatment (Torreele et al., 2010; WHO, 2012a). Without treatment, it is widely accepted 
that HAT is invariably fatal (Kennedy 2004; WHO, 2012a). 
 
Yet sleeping sickness has been shown to be amenable to therapy. In the recent 1998 
epidemic, National disease control authorities were galvanised into action, supported by WHO and 
non-governmental organizations (NGOs) such as Medicines San Frontiers, philanthropic 
organizations such as Bill and Melinda Gates Foundation and bilateral donors (WHO, 2012a). The 
support was channelled to strengthening of disease surveillance activities, efficient supply of 
existing drugs and increased drug development activities (WHO, 2012a; Paine et al., 2010; 
Chappuis et al., 2010). The re-invigorated activities led to a major decline in HAT incidence, which 
by 2010, stood at 7, 139 cases, which was an 81% decline in comparison to the 1998 figures. The 
prevalence has similarly declined to an estimated 30, 000 cases, showing that, HAT is clearly in 
retreat. 
 
Unfortunately, the optimistic prediction that HAT could soon be eliminated as a disease of 
public health significance throughout Africa (Simarro et al., 2011) could yet prove to be a mirage. 
The trypanosome has shown itself to be quite resilient and is capable of exploiting weaknesses in 
disease surveillance and/or unavailability of the right tools (drugs and diagnostics) to make an 
unwanted comeback.  Historical data (Figure 1) capture this succinctly. In addition, one Belgian 
and one German tourist came down with sleeping sickness recently after visiting Maasai Mara 
Game Reserve in Kenya, an area not regarded as an active HAT focus (Clerix et al., 2012; Wolf et 
al., 2012); these cases serve as a portent reminder that the danger of HAT flare ups remains. 
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Figure 1: Human African trypanosomiasis from 1927 to 1998 (Source: Simarro et al., PLoS Med 
2008) 
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The Parasite 
Taxonomy 
Trypanosomes were first observed in a trout in 1841. The genus name Trypanosoma was 
however coined in 1843 when morphologically similar protozoan parasites were detected in the 
blood of a frog (WHO, 2012b). Trypanosomes were later confirmed to be pathogenic and to be the 
aetiological agents of surra in horses and nagana in cattle before being identified in a human patient 
with recurrent fevers in the Gambia in 1901 (WHO, 2012b). They were later confirmed to be the 
aetiological agent of sleeping sickness, then known as sleepy distemper or African lethargy (WHO, 
2012b).  
 
Trypanosomes are classified under Kingdom Protista, sub-Kingdom protozoa, Phylum 
Sarcomastigophora and Class Mastigophora although there is some difference of opinion among 
taxonomists on exact application of these terms (Hoare, 1972). Trypanosomes are then placed into 
the order Kinetoplastida, family Trypanosomatidae and genus Trypanosoma (Hoare, 1972).  Genus 
Trypanosoma is further subdivided into two sections, Salivaria and Stercoraria. Salivarian 
trypanosomes mature in the salivary medium of the “anterior station” and are transmitted by 
inoculation into susceptible vertebrate hosts (Hoare 1972); the exact location of this maturation is 
in the salivary glands (e.g. T. brucei spp) or in the proboscis (T. congolense and T. vivax) (Hoare, 
1972; Vickerman, 1985; Peacock et al, 2012). Section Salivaria consists of four subgenera, 
including Trypanozoon (T. brucei brucei, T. b. rhodesiense, T. b. gambiense, T. evansi and T. 
equiperdum, T. equinum), Duttonella (T. vivax and T. uniforme); Nannomonas (T. congolense and 
T. simiae) and Pycnomonas (T. suis) (Hoare 1972).  Apart from T. b. rhodesiense and T. b. 
gambiense which cause disease in humans, other members of section Salivaria cause disease in 
livestock and wildlife. Domestic and wild animals have further been identified as reservoirs of the 
zoonotic T. b. rhodesiense (Simarro et al., 2008) and less commonly of T. b. gambiense (Cordon–
Obroso et al, 2009); T. b. gambiense is mainly assumed to be anthroponotic (Simarro et al, 2011; 
WHO, 2012a). 
 
Section Stercoraria has only one pathogenic trypanosome, T. cruzi, which causes Chagas 
disease (American trypanosomiasis). T. cruzi matures in the faecal medium of the “posterior 
chamber” of the Triatomine insect, also called reduviid or kissing bug, and is therefore transmitted 
through contamination of bite wounds with the insect’s faeces (Hoare, 1972). T. cruzi infections are 
prevalent in Latin America with a prevalence of 12-16 million cases (Diaz, 2009) 
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Life Cycle 
The life cycle of trypanosomes involves two hosts, a mammal which acts as the definitive 
host and an insect vector which acts as the intermediate host (Vickerman, 1985; 
http://content.lib.utah.edu:81/cgi-bin/showfile.exe?CISOROOT=/EHSL-
NOVEL&CISOPTR=426&filename=900.pdf). In an infected vertebrate, the dividing trypanosome 
population are the long slender trypomastigotes, also called long slender bloodstream forms 
(BSFs). The long slender BSFs divide rapidly by binary fission, with a doubling time of 
approximately 6-8 hours (Vickerman, 1985). For their metabolic needs, BSFs rely exclusively on 
glucose which is freely and abundantly available in host blood. As a result, BSFs obtain their 
energy by glycolysis which occurs in spherical glycosomes. They have no capacity for cytochrome 
mediated terminal respiration since their tricarboxylic acid cycle (Krebs cycle) is silenced. The 
BSFs multiply unchallenged until the host mounts an immune (IgM) response against the 
predominant variant antigen type (VAT) which is then quickly decimated. However, this does not 
lead to cure, rather it allows another previously minor VAT to assume the dominant position and 
generate the next wave of parasitaemia. The different VAT types are generated through the process 
of antigenic variation that is encoded in trypanosome genome by up to 1000 genes. Thus, 
parasitaemia and associated trypanosome-induced host tissue pathology continue until terminated 
by death of the host or therapeutic intervention. Some authors however argue that the evolution of 
trypanosome infections could be ameliorated or stopped altogether through the action of host 
immune systems, a process called trypanotolerance. Trypanotolerance is well documented for cattle 
breeds such as the Orma Boran and Ndama (Grace Murilla, personal communication). It may also 
occur in some human T .b. gambiense infections (Chechi et al., 2008) although most authors 
support the view that HAT is invariably fatal unless patients are treated (Kennedy, 2004, Kuepfer et 
al., 2011). During peak and declining parasitaemia, a new morphological form, the short stumpy 
trypomastigote or short stumpy BSF is generated. These short stumpies are the tsetse fly infective 
forms. 
 
The short stumpy BSFs are picked up when the flies take a blood meal from an infected 
mammal. The blood is swallowed to the fly’s midgut where the short stumpy BSFs transform to 
procyclics while within the peritrophic membrane (endoperitrophic space) (Vickerman 1985). The 
transformation to procyclics is characterised by changes in morphology (elongation and loss of the 
VSG coat) and a biochemical switch from dependence on glucose to dependence on the amino acid 
proline for metabolism. This clever tactical switch by the trypanosome is necessitated by the fact 
that glucose is unavailable in tsetse flies which, instead of glucose, depend on proline for energy 
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metabolism. Furthermore, procyclics adapt to a cytochrome mediated terminal respiration by 
enlarging and activating their mitochondria (Vickerman, 1985). The procyclics invade the 
ectoperitrophic space within 4 days of an infective blood meal, multiply rapidly and subsequently 
migrate to the proventriculus. In the proventiculus, the procyclics transform to mesocyclics, re-
invade the endotrophic space and migrate to the salivary glands via the oesophagus, mouthparts and 
salivary ducts (Vickerman, 1985). In salivary glands, trypanosomes change to epimastigotes which 
proliferate while attached to the salivary gland epithelia. Finally, epimastigotes transform to 
premetacyclics and then to metacylics which acquire a variant surface glycoprotein (VSG) coat, 
thus acquiring the ability to survive in mammals. It takes 20-30 days for mature mammal infective 
metacyclics to be generated. When tsetse flies feed on a new host, the metacyclics are deposited in 
dermal or subcutaneous tissues where they rapidly transform to long slender trypomastigotes, thus 
completing the cycle. 
 
The trypanosome life cycle reveals the different strategies employed by trypanosomes 
against host defences. In tsetse flies, evasion: procyclics avoid migrating through the haemolyph, 
which contains anti-trypanosomal agents such as atacin and defensin. Despite this evasion tactic, 
many tsetse flies are still able to free themselves of infecting trypanosomes, which partly explains 
why trypanosome infection rates are only estimated at 0.1% (Vickerman, 1985). In mammals, the 
variant surface glycoprotein coat (VSG), which is attached to the plasma membrane via GPI 
anchors, serves as physical barrier against the innate immune system while antigenic variation 
enables the pathogen to survive the attacks of humoral immune system. The VSG coat covers the 
entire trypanosome with the possible exception of the flagellar pocket through which receptor 
mediated endocytosis of proteins and protein-drug complexes (e.g. for suramin) are thought to 
occur (Fairlamb and Bowman, 1980). The trypanosome defence against natural mammalian 
immune system is so effective that the mammals require assistance to be freed of the trypanosome 
invaders. 
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Figure 2: Development cycle of Trypanosoma brucei. Source: Hadjuk et al., Am J Med Sci 1992 
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Clinical Signs, Diagnosis and the Disease in Animal Models 
After the infective tsetse bite, a local inflammatory swelling (chancre) develops at the site of 
the fly bite within 5-15 days (Kennedy 2004; Sternberg et al., 2006). Trypanosomes establish 
infection in the haemo-lymphatic system, marked by general malaise, fluctuating fever and general 
lymphadenopathy. The enlargement of lymph nodes of the neck region (Winterbottom’s sign), is 
commonly observed in T. b. gambiense infection. Other clinical signs that may be observed during 
the 1st (early, haemolymphatic) stage of HAT include pale mucous membranes indicative of 
anaemia, headache, fever, pruritus, oedema, splenomegaly, hepatomegaly, and weight loss ( Moore 
et al., 2002; Kennedy, 2004). Clinical signs of 2nd (late, CNS) stage of HAT include altered sleep 
patterns, sensory disturbances, abnormal movements, limb tremors, muscle fasciculation, mental 
changes or psychiatric disorders, anorexia, coma and finally death (Kennedy, 2004). 
 
Diagnosis of HAT relies mainly on visualization by microscopy of the causative 
trypanosome parasites in stained smears of body fluids such as blood, cerebrospinal fluid (CSF) and 
lymph node aspirates (WHO, 1998; Kennedy, 2004). Microscopy has limited sensitivity due to low 
and fluctuating parasitaemias in HAT patients (Van Meirvenne, 1999). Specifically, examination of 
wet smears of blood by the matching method of Herbert and Lumsden (1976) can in theory detect 
up to 10,000 trypanosomes/ml of blood. In practice, however, observation of one trypanosome in 
20 microscopic fields corresponds to a parasitaemia of 250,000 trypanosomes/ml of blood 
(equivalent to antilog 5.4) and it is unlikely laboratory personnel will routinely examine more than 
20 microscope fields per sample. The most sensitive microscopic techniques include the mini-anion 
exchange centrifugation technique (mAECT) and haematocrit centrifugation technique (HCT) also 
called capillary tube centrifugation technique or buffy coat technique (Woo, 1970; Lumsden et al., 
1979; Cattand et al., 1988) for blood and the modified single centrifugation or double 
centrifugation techniques for CSF (Miezan et al., 2000). The centrifugation component in these 
techniques improves their sensitivity to approximately 1000 trypanosomes/ml of blood. In areas 
that are endemic for T. b. gambiense HAT, a serological test, the card agglutination test for 
trypanosomiasis (CATT) is routinely used as a screening test before microscopy (Simarro et al., 
2008). 
 
Animal models of HAT have been used to study different aspects of the disease including 
chemotherapy, pathogenesis, and pathology and to evaluate the potential of resultant host clinical 
and biological changes as diagnostic and disease staging markers (Jennings et al., 1977; Fink et al., 
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1983; Gichuki and Brun, 1999; Kagira et al., 2006). These models are based on experimental 
infection of various animal hosts with T. b. brucei, T. b. rhodesiense or T. b. gambiense. 
Confirmation that these parasites are able to establish infections and characterization of the 
resultant disease progression in terms of clinical signs, immunology and pathology are some of the 
indicators of a well developed animal model. The most commonly used models for HAT research 
are the mouse, rat and other rodents, and vervet monkey models. Characterisation of these HAT 
models shows that the disease occurs in two stages irrespective of the host: a first stage in which 
trypanosomes are localised in the haemo-lymphatic system and a second stage in which the central 
nervous system (CNS) is invaded by trypanosomes, indicating that the basic pattern is similar to the 
disease in humans (Jennings et al., 1977; Poltera et al., 1980). The T. b. brucei GVR 35 model, in 
which mice are treated at 21 days post infection (Jennings et al., 1977), is widely used in murine 
chemotherapy trials of second stage HAT. The vervet monkey model is similarly widely used in 
preclinical drug research, with treatments for first stage compounds initiated at 7 days post 
infection while those for second stage compounds are initiated at 28 days post infection (Gichuki 
and Brun, 1999). The monkey model has the added advantage of permitting collection of 
cerebrospinal fluid (CSF) for monitoring CNS infections and has been described as closely 
mimicking the human disease in terms of clinical signs, immunological status and pathology 
(Schmidt and Sayer, 1982). 
 
Taking the Fight to the Trypanosome 
Vaccination, chemotherapy, patient and vector management are in general key strategies 
that are employed to fight vector-borne infectious diseases. The phenomenon of antigenic variation 
displayed by mammalian stages of trypanosomes however makes it very difficult, if not impossible, 
to develop vaccines based on their variant surface glycoproteins (VSG’s) (Vickerman, 1985). The 
invariant surface glycoproteins on the trypanosome’s plasma membrane are also not useful vaccine 
candidates since they are protected from contact with components of the host’s immune system by 
the 12-15 nM thick VSG coat.  However, there are better prospects of success in developing 
transmission blocking vaccines that interfere with the maturation of the insect stages of the 
trypanosome (Aksoy et al., 2001; Macleod et al., 2007). The tsetse flies can also be targeted 
through mass spraying with insecticides followed by the sterile insect technique to eradicate 
residual fly populations. Tsetse eradication campaigns have been successfully carried out in 
Zanzibar and Botswana and are in progress in three tsetse belts, Lake Victoria basin, Mwea/Meru 
and Lake Bogoria, in Kenya. The eradication activities are carried out under the leadership of the 
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Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC) that was formed by 
African heads of state and Government in 2002. Indeed, the African Union believes that tsetse flies 
can actually be eradicated from the African continent (African Union, 2002). Currently, however, 
the fight against human infective trypanosomes, especially T. b. gambiense infection which 
constitute more than 95% of HAT cases (WHO, 2012a), relies heavily on surveillance and 
treatment of infected persons. The chemotherapy of HAT currently relies on the following drugs:  
 
Pentamidine 
Pentamidine was introduced for clinical use in 1941, becoming the first of its class to attain 
this milestone. Currently, 71 years later, it remains the only diamidine in clinical use and is 
recommended for the treatment of the 1st stage of T. b. gambiense-caused West African form of 
HAT (WHO, 2012a). The drug is available as pentamidine isethionate, Pentacarinat® (sanofi-
aventis) in 200 mg vials for deep intramuscular injection at a dose rate of 4 mg/kg x 7 days qd 
(Burri, 2010). Relative to other HAT drugs, pentamidine is well tolerated. However it still causes 
non-negligible side effects including pain and/or transient swelling at the injection site, abdominal 
pain, diarrhoea, nausea, vomiting and hypoglycaemia (Burri, 2010). Other less commonly 
encountered adverse reactions include QT-prolongation and hyperglycaemia (Burri, 2010). 
Available mechanistic data show that pentamidine is selectively accumulated by trypanosomes via 
the P2 amino-purine transporter aided by the high affinity pentamidine transporter (HAPT 1) and 
the low affinity pentamidine transporter (LAPT 1) ((Mäser et al, 1999; de Koning, 2001) Similar to 
other diamidines, pentamidine has a predilection for DNA containing organelles, including the 
kinetoplast and nucleus, where it binds onto the minor groove of DNA at AT rich sites (Wilson et 
al., 2008). What happens thereafter is not known; it is however thought that the drug catalyses 
kinetoplast fragmentation, inhibition of glycolysis and/or interference with DNA dependent 
enzymes such as topoisomerase II RNA (Denise and Barrett, 2001; Tidwell and Boykin, 2003; 
Wilson et al., 2008). 
Suramin 
Suramin was first used against sleeping sickness in 1921 (WHO 2012), capping a successful 
medicinal chemistry effort in which more than 1000 naphthalene urea compounds were synthesized 
and evaluated for efficacy against trypanosomes (Steverding, 2010). Suramin is marketed as 
Germanin® (Bayer) in ampoules of 1 g and is effective against the first stage of both forms of 
HAT. However, suramin is clinically, used almost exclusively for T. b. rhodesiense infections since 
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pentamidine is considered to be a better choice for T. b. gambiense HAT. The most commonly used 
dosage regimen consists of a test dose of 4–5mg/kg body weight at day 1, followed by five 
injections of 20 mg/kg intravenously every 3–7 days (e.g. days 3, 5, 12, 19, 26) of suramin with a 
maximum dose per injection of 1 g (Burri, 2010). Suramin is extensively (99.7%) bound to plasma 
constituents including albumin and low density lipoproteins (Fairlamb and Bowman, 1980) (Denise 
and Barrett, 2001). The suramin-protein complex is taken up by trypanosomes via receptor 
mediated endocytosis (Denise and Barrett, 2001). Its mode of action is uncertain but is thought to 
include inhibition of enzymes including those responsible for respiration and glycolysis (Fairlamb 
and Bowman, 1980; Denise and Barrett, 2001). Pharmacokinetic studies revealed that suramin has 
a long half-life of 44–92 days (Burri, 2010). While suramin is better tolerated than the drugs used 
for late stage disease treatment, its use is associated with hypersensitivity reactions, albuminuria, 
haematuria and peripheral neuropathy (Burri, 2010). A bloodstream stage-specific invariant surface 
glycoprotein (ISG75) family mediates suramin uptake, and the AP1 adaptin complex, lysosomal 
proteases and major lysosomal transmembrane protein, as well as spermidine and N-
acetylglucosamine biosynthesis, all contribute to suramin action (Alsford, 2012). 
 
Melarsoprol 
Melarsoprol, Arsobal® (sanofi-aventis), is a melaminophenyl based organic arsenical that 
was introduced as an anti-trypanosomal agent in 1949 (Pepin and Milord, 1994). It is accumulated 
into trypanosomes via P2, an aminopurine transporter that is encoded by the TbAT1 gene (Maser et 
al., 1999). Deletions or mutations in the TbAT1 gene lead to drug resistance (Maser et al., 1999) 
which may be one of the causes of high treatment failure rates that are sometimes reported from the 
field (Brun et al., 2001). Melarsoprol has for a long time been the first line treatment for late-stages 
of both T. b. rhodesiense and T. b. gambiense (WHO, 2012a). However the development of 
eflornithine in 1990 and the nifurtimox-eflornithine combination therapy (NECT) in 2009 (Priotto 
et al., 2009; WHO, 2012a), both better tolerated than melarspoprol, meant that clinicians now had 
better choices for management of West African sleeping sickness. Trypanosomes exposed to 
arsenicals lyse very rapidly, but the mode of action of the drug has also not been completely 
elucidated (Denise and Barrett, 2001). Melarsoprol has many undesirable side effects, the most 
significant being a post treatment reactive encephalopathy (PTRE) which occurs in 5-10% of 
treated patients and may be fatal in 50% of the affected patients (Kuzoe, 1993; WHO, 2012a). 
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Eflornithine 
Eflornithine (difluoromethylornithine [DFMO]), is the treatment of choice for second 
stage T. b. gambiense HAT, although it was first developed as an anti-cancer agent (WHO, 1998; 
Brun et al., 2009). The uptake of eflornithine in T. brucei occurs via passive diffusion across the 
plasma membrane (Bitonti et al., 1986). DFMO inhibits ornithine decarboxylase (ODC), which is 
involved in polyamine metabolism leading to cessation of trypanosomes growth. A functional 
immune system is required to kill the growth-arrested trypanosomes (Ghoda et al., 1990). Its lack 
of activity against T. b. rhodesiense is thought to be due to higher overall activity and a shorter 
half-life of ODC in this subspecies compared to T. b. gambiense (Iten et al., 1997). 
 
Nifurtimox-Eflornithine Combination Therapy (NECT) 
The Nifurtimox–Eflornithine Combination Therapy (NECT) has recently been included in 
the 16th WHO Essential Medicines list as treatment for 2nd stage sleeping sickness (Priotto et al., 
2009; WHO, 2012a). In NECT, eflornithine is administered intravenously at 200 mg/kg bid x 7 
days, compared to 100 mg/kg four times per day x 14 days for monotherapy eflornithine (Priotto et 
al., 2009; Burri, 2010; WHO, 2012a) while nifurtimox is administered at 10mg/kg x 10 days per os. 
Thus, the key advantages of NECT are the simplification of eflornithine treatment, reduction of 
costs and overall reduction in hospitalization time for patients. In addition, NECT was shown to be 
equally effective to monotherapy eflornithine and to have comparable safety profiles (Priotto et al., 
2009). However, NECT has not been evaluated against T.b. rhodesiense strains and is therefore not 
used for this indication. 
 
New drugs for HAT 
All the currently available HAT treatments have various shortcomings as highlighted above. 
The development of new drugs for HAT and other NTDs was however hardly being addressed in 
the period before year 2000 because these diseases do not offer good returns for the immense 
financial investments required to bring a drug to the market (www.thecpdd.org; Trouiller et al., 
2002; Adams and Brantner, 2006; Chirac and Toreele, 2006). The gap in development of drugs for 
NTDs was well captured in Chirac and Toreele (2006) who demonstrated that out of 1556 drugs 
developed over the period from 1975 to 2004, only 21 (1.3%) were for NTDs and tuberculosis 
although these diseases accounted for 11.4% of the world’s disease burden. Since the year 2000, 
public private partnerships (PPPs) which are also called product development partnerships (PDPs), 
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were formed to address the drug research and development (R&D) needs of NTDs with funding 
from public and philanthropic organizations and other donors (www.thecpdd.org. accessed July 24, 
2012; Chatelain and Ioset, 2011). As a result the following compounds are now at different stages 
of the drug discovery and development process: 
 
Fexinidazole 
Fexinidazole is a nitroheterocyclic molecule that has recently shown promising activity 
against T. brucei strains (Kaiser et al, 2011) and visceral leishmaniasis (Wyllie et al., 2012).  
Fexinidazole was originally shown to have anti-trypanosomal activity by the drug company 
Hoechst in the 1980s but its development was, for unknown reasons, not pursued to clinical testing. 
It has only recently been rediscovered through compound mining and subsequent screening of at 
least 700 nitroheterocycles by the Drugs for Neglected Diseases initiative (DNDi) (Torreele et al., 
2010). The in vitro activity of fexinidazole and its metabolites fexinidazole-sulfoxide and 
fexinidazole-sulfone are indicated by IC50 values ranging from 0.7 to 3.3 µM against both drug-
sensitive and drug-resistant T. brucei spp (Kaiser et al., 2011. Fexinidazole was subsequently 
shown to cure T. b. rhodesiense and T. b. gambiense acute and chronic mouse models (Kaiser et al., 
2011), was well tolerated in humans during phase I clinical trials (Torreele et al., 2010) and is 
scheduled to enter into phase II/III pivotal clinical trial in the third quarter of 2012 
(http://www.dndi.org/portfolio/fexinidazole.html, accessed on 6th August 2012). Apart from an 
Ames positive result and the need for high dose rates to achieve in vivo efficacy, the available 
pharmacological data are all positive (Maser et al., 2012), justifying optimism that fexinidazole 
might complete the drug development programme successfully. 
 
Benzoxaboroles  
The oxaboroles are a promising new class of antimicrobials that contain boron in their 
structure. Screening an oxaborole library against T. brucei at Scynexis (Research Triangle Park, 
NC) and further activity based structural modifications led to the selection of SCYX-7158 as a 
clinical drug candidate for second stage HAT (Jacobs et al., 2011; Maser et al., 2012). The 
compound has an IC50 against T.b. rhodesiense and T. b. gambiense strains between 0.2-1 µM. 
SCYX-7158 also cures mouse models of both 1st and 2nd stage HAT (Jacobs et al., 2011). Phase 1 
clinical trials were initiated in March 2012 by DNDi (Maser et al. 2012), ensuring that the HAT 
pipeline will not be empty even should an unexpected failure of fexinidazole occur. 
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Novel Diamidines 
The Consortium for Parasitic Drug Development (CPDD) has focused on the diamidines 
class of compounds in their search for potential new therapeutic agents for neglected tropical 
diseases such as HAT. This was largely influenced by the success of pentamidine against T. b. 
gambiense since 1941 (WHO, 2012a).  Continued interest in diamidines as antiparastic agents led 
the synthesis of novel aromatic diamidines by a group of researchers led by Dr David Boykin; six 
of these aromatic diamidines, including furamidine (DB75), were more active against T. b. 
rhodesiense than pentamidine (Das and Boykin, 1977). Despite their improved activity against 
trypanosomes, the new diamidines were, like pentamidine, not well absorbed after oral 
administration due to their positively charged amidine moieties. This was considered a significant 
limitation because of the need to develop easy to use oral drugs that would be more appropriate for 
the resource and infrastructure poor areas where HAT was endemic (Etchegory et al., 2001; Wilson 
et al., 2008). 
 
In 1999/2000, the CPDD obtained funding from the Bill and Melinda Gates Foundation to 
develop furamidine (DB75) and its analogues for NTDs, including HAT. Since then, prodrugs were 
synthesised by masking the amidine moieties with alkoxy groups (Boykin et al., 1996; Ismail et al., 
2003; Hua et al., 2009). The diamidine prodrugs were shown to be significantly more permeable 
across Caco-2 cell monolayers than their parent molecules (Ansede et al., 2005). In other studies, in 
vitro and in vivo (in mice) evaluation of prodrugs and/or active diamidines revealed that that these 
compounds had broad-spectrum activity against trypanosomes, Leishmania and Plasmodium 
species (Werbovetz, 2006), Pneumocystis carinii (jirovecii) pneumonia (Boykin et al., 1995, 1996; 
Hall et al., 1998; Tidwell and Boykin, 2003) and T. cruzi (Soeiro et al., 2011). Furthermore, over 
2000 diamidines were screened against a variety of T. brucei isolates in vitro, with 517 yielding an 
IC50 of less than 0.2µM and a selectivity of over 1000 against a mammalian cell line (L6) (Maser et 
al., 2012). These studies demonstrated the enormous potential of this class as source of potential 
new antiparasitic drugs. 
 
This PhD study was anchored onto the diamidines development project with the objective of 
identifying molecules with suitable biological and pharmacological properties to be recommended 
for further development as potential HAT drugs. 
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Chapter 2: Goals and Objectives 
Goal 
The goal of this thesis was to investigate the efficacy and pharmacology of selected novel 
diamidines in animal models in order to contribute to the development of safe, efficacious and easy 
to use treatments for both first and second stage human African trypanosomiasis (HAT). 
 
Objectives 
The study’s specific objectives were: 
1. To elucidate the oral bioavailability of prodrug DB289 and compare its efficacy with that of 
parenterally administered DB75 and pentamidine in different mouse models of first stage 
HAT. 
2. To evaluate the efficacy of DB289 against first and second stage T. b. rhodesiense 
infections in vervet monkeys in order to understand its therapeutic range in primates. 
3. To characterize the nature, target organs and determinants of DB844 toxicity in vervet 
monkeys and evaluate its pharmacokinetics and efficacy in the vervet monkey model of 
second stage HAT. 
4. To determine the utility of prodrug DB868 as a potential therapeutic agent for first stage 
HAT through metabolism studies in liver microsomes, toxicity study in un-infected 
monkeys and pharmacokinetics and efficacy evaluation in the first stage monkey model of 
HAT. 
5. To compare the efficacy and pharmacokinetics of an orally administered prodrug (DB868) 
with that of its intramuscularly administered active metabolite (DB829) against second 
stage T. b. rhodesiense infections in monkeys. 
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ABSTRACT 
The choice of drugs for the treatment of sleeping sickness is extremely limited. To redress 
this situation, the recently synthesised diamidines, 2,5-bis(4-amidinophenyl)-furan (DB75, 
Furamidine) and its methamidoxime prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-
methylamidoxime (DB289, Pafuramidine) were, together with pentamidine, evaluated for efficacy 
in rodent models.  The activity was compared in three common mouse models that mimic the first 
stage of human African sleeping sickness. The mice were infected with the pleormorphic T. b. 
rhodesiense strains KETRI2537 and STIB900 or with the monomorphic T. b. brucei strain 
STIB795. Importantly, DB75 showed enhanced activity over pentamidine at comparable doses in 
all three mouse models. Complete cures were achieved with oral dosing of the prodrug DB289 in 
all three models without any observed toxicity. This shows that the prodrug strategy was successful 
in terms of reducing toxicity and increasing efficacy and oral bioavailability.  Thus, both DB75 and 
especially its orally active prodrug, DB289, provide a promising new treatment approach for early 
stage human African trypanosomiasis. 
 
Key words: Furamidine, DB75, Pafuramidine, DB289, sleeping sickness, mouse models, African 
trypanosomiasis 
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INTRODUCTION 
The number of drugs available for the treatment of sleeping sickness is extremely limited. 
Pentamidine isethionate (Pentacarinat®) and suramin (Moranyl®, Germanin®) are the only two 
drugs currently registered for the treatment of early stage disease that is characterised by 
localization of trypanosomes within the haemolymphatic system. Both drugs are highly effective 
against the West African form of the disease that is caused by Trypanosoma brucei gambiense.  
However, only suramin is recommended for the treatment of the East African form that is caused 
by T. b. rhodesiense since pentamidine is considered less effective (Apted, 1980). Similarly, two 
drugs, melarsoprol (MelB, Arsobal®) and eflornithine (Ornidyl®), are recommended for the 
treatment of the late (meningoencephalitic) stage of the T. b. gambiense disease, but only 
melarsoprol is effective against T. b. rhodesiense infections (WHO, 1998). This situation is 
compounded by the fact that all the current therapies are unsatisfactory for various reasons, 
including poor efficacy, unacceptable drug toxicity, upcoming resistance, costs and undesirable 
route of administration (Fairlamb, 2003). 
 
Recently, renewed efforts in the development of new drugs for HAT and other pathogenic 
conditions, have led to the synthesis of an extensive collection of low toxicity pentamidine–like 
diamidines by an international consortium for parasitic drug development (CPDD) under the 
leadership of the University of North Carolina at Chapel Hill. The diamidine-appeal is based on 
their known broad spectrum of activity against protozoal and fungal pathogens, including African 
trypanosomes. Initially, these drugs were developed as treatment for the AIDS related 
Pneumocystis carinii pneumonia (PCP) and leishmaniasis (Tidwell et al., 1990, Hall et al., 1998). 
Since the year 2000 studies on these compounds have been extended to cover HAT with the double 
aim of i) increasing the number of chemotherapeutic agents available for this neglected disease and 
ii) developing a product that is orally administrable and can therefore be used in the rural African 
settings where HAT is a major problem. In this study, the orally active prodrug, 2,5-bis(4-
amidinophenyl)-furan-bis-O-methylamidoxime (Pafuramidine, DB289) was evaluated together 
with its active parent compound 2,5-bis(4-amidinophenyl)furan (Furamidine, DB75) and the related 
comparator, pentamidine. The compounds were evaluated for efficacy against early stage T. brucei 
(T. b. rhodesiense and T. b. brucei) infections, using established animal models at the 
Trypanosomiasis Research Centre of the Kenya Agricultural Research Institute (TRC-KARI) and at 
the Swiss Tropical Institute (STI). 
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MATERIALS AND METHODS 
Mice 
Adult female Swiss White mice were used in experiments for the KETRI 2537 model. The 
mice were obtained from colonies maintained at TRC-KARI. Adult female NMRI mice were used 
in experiments for the STIB900 and the STIB795 model at STI. The mice were obtained from 
RCC, Ittingen, Switzerland. They weighed between 20-30g at the beginning of the study and were 
house under standard conditions with pelleted food and water ad libitum.  
 
Trypanosomes 
T. b. rhodesiense KETRI2537 is a derivative of EATRO1989 (Fink and Schmidt, 1980). 
The isolate is stored as cryopreseved stabilates in the TRC cryobank.  
T. b. brucei STIB795, a derivative of S427 was received from the International Laboratory for 
Research on Animal Diseases, Kenya, and was originally isolated from a Glossina pallidipes in 
Uganda in 1960. After passages in a sheep, a tsetse fly and several passages in mice, a clone was 
adapted to axenic cultivation in vitro. T. b. rhodesiense STIB900 is a derivative of STIB704. The 
pathogen was isolated from a male patient at St. Francis Hospital in Ifakara/Tanzania in 1982. After 
several passages in rodents and a cyclical passage in Glossina morsitans morsitans, a cloned 
population was adapted to axenic culture in vitro. STIB795 and STIB900 isolates are maintained in 
the STI trypanosome cryobank. 
 
Trypanocidal Compounds 
The two experimental compounds, 2,5-bis(4-amidinophenyl)-furan-bis-O-
methylamidoxime) (DB289), and 2,5-bis(4-amidinophenyl)furan) (DB75), both yellow odourless 
powders, were obtained from Immtech International, USA through Professor Rick Tidwell of the 
University of North Carolina (UNC). Pentamidine isethionate, a white powder, was obtained from 
supplies donated by the WHO. At TRC, the compounds were reconstituted as per the 
manufacturer’s instructions using distilled deionised water (DB75) and commercially available 
water of injection (pentamidine). DB289 stock suspension was prepared in a solvent consisting of 
deionised water (99.4%), Tween 80 (0.1%), and carboxymethyl cellulose sodium (CMC, medium 
viscosity, 0.5%). All compounds were freshly prepared every two days, in concentrations ranging 
from 7.5 mg/ml to 0.078 mg/ml. At STI, all compounds were dissolved in DMSO and subsequently 
diluted with distilled sterile water to final maximal concentration of 10% DMSO for the STIB795 
and the STIB900 models. 
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Experimental Design 
KETRI2537 Mouse Model 
Two sub-lethally irradiated (600rads, 5 minutes) donor Swiss White mice were each 
inoculated intraperitoneally with 0.2 ml of the thawed T. b. rhodesiense stabilates, diluted in 
phosphate saline glucose (PSG). When these mice had a circulating parasitaemia of antilog 7.8 to 
8.1 as described by Herbert and Lumsden (1976), they were bled and used to infect the 
experimental group of Swiss White mice, each mouse receiving 1x104 parasites in 0.2 ml of PSG. 
Immediately after infection, mice were randomly assigned to groups comprising six mice each. 
Parasitaemia was monitored daily using smears of tail-snip blood, a minimum of 20 fields being 
examined before a sample was designated negative.  
 
Treatment was initiated on first detection of trypanosomes. Oral (per os, PO) treatments 
(DB289) were administered using a gavage needle for five consecutive days while intraperitoneal 
(IP) treatments (DB289, DB75 and pentamidine) were administered for four consecutive days. 
Intravenous (IV) DB75 was administered as a single injection only. Compound volume 
administered to the mice was maintained at 0.1ml /10g of mouse body weight (bwt). Six mice 
served as infected-untreated controls.  
Post treatment parasitaemia was monitored thrice a week for 60 days. Monitoring for deaths 
was carried out daily. When mice relapsed, they were promptly euthanised by carbon dioxide 
inhalation and incinerated. Median time to relapse (MTR) was calculated in days post last 
treatment. All protocols and procedures used in the current study were reviewed and approved by 
the Trypanosomiasis Research Centre (TRC) Institutional Animal Care. 
 
STIB795 and STIB900 Mouse Models 
Four female NMRI mice were used per experimental group. Each mouse was inoculated 
intraperitoneally with 1x105 bloodstream forms of STIB795 or STIB900 respectively. The 
cryopreserved stabilate containing 10% glycerol was suspended in PSG to obtain a trypanosome 
concentration of 4 x 105 /ml. Each mouse was injected with 0.25 ml. Compound treatment was 
initiated 3 days post infection on 4 consecutive days for all administration routes in a volume of 
0.1ml /10g mouse. Parasitaemia was monitored using smears of tail-snip blood twice a week after 
treatment followed by once a week until 60 days post infection. Mice were considered cured when 
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there was no parasitaemia relapse detected in the tail blood over the 60 days observation period. 
Four mice served as infected-untreated controls. Mean survival days (MDS) were calculated in day 
of death post infection of parasitaemic mice. All protocols and procedures used in the current study 
were reviewed and approved by the local veterinary authorities of the Canton Basel-Stadt. 
 
RESULTS 
Disease Pattern KETRI2537 
A pre-patent period of 3 (range = 3-5) days was observed. Peak parasitaemia was reached 
on day 8-9 post-infection. This first parasitaemia wave was well controlled, in some cases being 
reduced to below the detection limit of antilog 5.4 (Herbert and Lumsden, 1976). Subsequent waves 
were not as well controlled, with only slight fluctuations between peak and trough parasitaemia 
levels. At terminal disease stage the untreated control mice were euthanised when parasitaemia 
levels reached antilog 8.4. The mean survival times of the infected control animals was 33 (range = 
24-47) days. 
 
Disease Pattern STIB795 and STIB900 
A prepatent period of 3 days was observed for STIB795 and one of 2.6 days (range = 2-3) 
for STIB900. Peak parasitaemia for both strains was reached on day 4 to 5 post-infection. The mice 
could not control parasitaemia and consequently died with a mean survival time of 6 (range = 5-8) 
days.  
 
Efficacy against KETRI2537 Infections 
In mice that were treated with DB289, clearance of parasites from the peripheral circulation 
began 48 hours after initiation of treatment and was complete in all groups six days after the first 
drug dose. DB289 when administered orally or IP at dose rates equal or greater than 4mg/kg 
resulted in 100% cure rates (Table 1). However, at 4x3.125 mg/kg bwt, IP administration resulted 
in a higher cure rate of 4/6 (67%, CI=22.3-95.7%) as compared to a cure rate of 2/6 (33%, CI=4.3-
77.7%) for PO administration at 5x 3.125 mg/kg, but this difference was statistically not significant 
(P>0.05). DB289 was well tolerated with no toxicity detected at any of the dose levels tested, which 
was up to 5x75 mg/kg PO and 4x75 mg/kg IP. 
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DB75 achieved 100% cure rates at all IP dose regimes equal to or greater than 4x1.56 
mg/kg bwt and at the IV dose regimes tested (25, and 12.5 mg/kg bwt, single dose). At the lowest 
dose tested, 4 x 0.78 mg/kg bwt IP a cure rate of 3/4 (75%) was obtained. DB75 was significantly 
toxic when used at 4x50 mg/kg bwt IP (5/6 deaths). However, the lowest dose at which significant 
toxicity was detected (4x50 mg/kg) was 32 times higher than the minimum curative dose (4x1.56 
mg/kg), resulting in a reasonable therapeutic index. Pentamidine achieved 100% cure rate at 4x12.5 
mg/kg bwt IP. The results at lower doses tested demonstrated a clear dose response with 80% cures 
at 4x6.25 mg/kg and 40% at 4x3.125 mg/kg bwt. No signs of toxicity could be observed at 4x12.5 
mg/kg bwt. 
 
Efficacy against STIB795 Infection 
The data obtained with the T. b. brucei STIB795 model was comparable with the data of the 
T. b. rhodesiense KETRI2537 model.  
DB289 administered PO resulted in a good dose response. The minimum curative dose was 4x10 
mg/kg. At 4x5 mg/kg, 3/4 mice (75%) were cured. The total dose was equal to 5x4 mg/kg PO in the 
KETRI2537 infected mice, which was also the minimum curative dose. No cures were obtained at 
4x2.5 mg/kg PO. However the survival was extended compared to the untreated control mice, 
indicating that DB289 still exhibited some activity at this low dose. 
A good dose response with regard to cures was also obtained with IP treatment of DB75. A 
dose of 4x1.0 mg/kg resulted in cure of all animals while 4x0.5 mg/kg cured 3/4 mice (75%). The 
KETRI2537 data was comparable showing 3/4 cures at the similar dose of 4x0.78mg/kg IP. DB75 
failed to cure at 4x0.25mg/kg but could prolong the survival time significantly to >32.5days 
compared to the untreated control mice, which survived only for 6 days post infection. Pentamidine 
gave complete cures at the lowest tested dose of 4x5 mg/kg IP. 
 
Efficacy against STIB900 Infections 
The T. b. rhodesiense STIB900 model is significantly more stringent as compared to 
STIB795 or KETRI2537. A 10-times higher PO administered dose of DB289 was needed to 
achieve complete cure as compared to the STIB795 or a 20-times higher dose as compared to 
KETRI2537. DB289 failed to give any cures at ≤4x10 mg/kg but it prolonged the mice survival 
significantly and in a dose dependent manner. The untreated control mice died on average on day 6. 
DB289 was also administered IP in the STIB900 model and 3/4 cures were obtained at 4x50 mg/kg.  
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At half the dose, all mice developed a parasitaemia relapse but the relapses were late and all 4 mice 
survived the 60 days observation period.  
 
DB75 was not able to cure mice at doses up to 4x20 mg/kg bwt in the STIB900 mouse 
model. However, a clear dose response on the level of survival could be observed. The parasitaemia 
relapses occurred late particularly at 4x20 mg/kg IP indicating that this dose was close to the 
minimum curative dose. DB75 administration at 4x 20mg/kg IP was recently repeated and cure of 
single mice could be achieved (data not published).  
IV administration of DB75 did not result in cures of infected mice. The survival of the 
treated mice was dose-dependent and comparable to the IP administration. The toxicity limit was 
lower with IV administration as compared to IP.  
 
Pentamidine gave no cures up to the maximum dose of 4x25 mg/kg IP. The survival of the 
mice was in a similar range as after DB75 treatment but slightly shorter. 
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Table 1: Treatment of KETRI 2537 infections with DB289, DB75 and pentamidine 
 
Drugs 
Dose: mg/kg No 
cured/total  
MST (range)  
Pafuramidine (DB289, administered PO x 5 days) 
6.25 6/6  
4 6/6  
3.13 2/6  23.5 (16-32) 
1.56 0/6  9.0 (6-13) 
0.78 0/6  6.0 (4-9) 
Pafuramidine (DB289, administered IP x 4 days) 
6.25 4/4  
4 6/6  
3.13 4/6  25 (19, 31) 
1.56 1/6  16 (10-31) 
0.78 0/6 12.0 (5-15) 
Furamidine (DB75, administered   IP x 4 days 
6.25 6/6  
3.13 3/3  
1.56 5/5  
0.78 3/4  21 
Furamidine (DB75, administered IV x 1day 
25 6/6  
12.5 6/6  
Pentamidine (administered IP x 4 days)  
12.5 3/3  
6.25 4/5  10 
3.13 2/5  14 (7, 21) 
1.56 0/6 15 (5-15) 
Controls 0/6 33 (24-47) 
 
Key: Cure = mice survived for more than 60 days after last drug dose without showing a relapse 
MTR= median time to relapse post last treatment or mean time to death post infection for control 
mice 
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Table 2: Treatment of STIB795 and STIB900 infections with DB289, DB75 and Pentamidine 
 
Drugs T.b.brucei STIB 795 T.b.rhodesiense STIB 900 
Dose: 
mg/kg 
No 
cured/infected MSD (range) 
No 
cured/infected MSD (range) 
Furamidine (DB75, administered   IP x 4 
days     
4x  20  -   0/4 >52.5 (40->60) 
4x  10  -   0/4 46.5 (38-55) 
4x   5  -   0/4 35.5 (33-40) 
4x   2.5  4/4   0/4 32.75 (31-35) 
4x   1.0  4/4   -  
4x   0.5  3/4 >60 -  
4x 0.25  0/4 >32.5 (5, 
>60) -  
Furamidine (DB75, administered IV x 4 days   
4x  15  -    toxic 
4x  10  -   0/4 47.5 (32-58) 
4x   5  -   0/4 33.75 (29-36) 
4x   2.5  -   0/4 28.5 (24-34) 
4x   1.25   -   0/4 25.75 (21-31) 
Pafuramidine (DB289, administered IP x 4 
days)     
4x 50  -   3/4 >60 
4x 25  -   0/4 >60 
Pafuramidine (DB289, administered PO x 4 days)   
4x 100  - - 4/4  
4x  50  - - 2/4 >60 
4x  10  4/4   0/4 46.5 (31-55) 
4x    5  3/4 6 0/4 30 (24-38) 
4x 2.5  0/4 22 (5-53) 0/4 19.75 (14-26) 
Pentamidine (administered IP x 4 days)      
4x 25  - - 0/4 >60 
4x 20  - - 0/4 42.75 (39-47) 
4x 10  4/4   0/4 28 (18-35) 
4x   5  4/4   - - 
4x 2.5 4/4  -  
4x 1 3/4 > 60 -  
4x 0.5 3/4 58 -  
4x 0.25 0/4 >35 (24->60) -  
control 0/4 6 (5-8) 0/4 6 (5-7)  
 
Key:  MSD: mean survival days post infection of the mice that got a parasitaemia relapse 
Range: days of death post infection of the mice with parasitaemia 
Cure= mice survived for more than 60days after infection without showing a parasitaemia relapse 
Control: infected mice without any drug treatment 
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DISCUSSION 
Pentamidine and the diamidine DB75 and its prodrug DB289 showed excellent activities in 
the T. b. rhodesiense KETRI2537 mouse model of infection. This trypanosome strain is routinely 
used in the vervet monkey model at TRC (Schmidt and Sayer, 1982).  Importantly, 100% cure rates 
were achieved at dose rates of 4x12.5 mg/kg bwt IP with pentamidine, 4x4 mg/kg bwt IP and 5x4 
mg/kg bwt PO with DB289 and 4x1.56 mg/kg bwt IP with DB75. Comparable results were 
obtained using the T. b. brucei STIB795 mouse model. 100% cure rates were achieved at dose rates 
of ≤ 4x5 mg/kg bwt IP with pentamidine (testing of lower doses ongoing), 4x 10 mg/kg PO with 
DB289 and 4x1 mg/kg bwt IP with DB75. The T .b. rhodesiense STIB900 mouse model is very 
stringent and hard to cure as compared to STIB795 although both strains show similar in vitro drug 
sensitivity (Bernhard, 2006). High level of parasitaemia was reached more rapidly with STIB900 
and clearance after treatment with DB75 took more time compared to STIB795 (Bernhard, 2006). 
Pentamidine could not cure the STIB900 model, not even at the highest dose tested (4x25 mg/kg 
IP). Also DB75, which cured easily the KETRI2537 and STIB795 model, did not give any cures in 
the STIB900 model. However, DB75 prolonged the mice’s survival more than pentamidine at 
identical dosages. A higher dose of DB75 was not used as a preliminary toxicity test did show 
toxicity at 1x100 mg/kg IP. DB289, the prodrug of DB75, achieved complete cures in the STIB900 
mouse model without showing any toxicity at 4x100 mg/kg PO. Partial cure (50%) was achieved at 
4x50 mg/kg PO. Intraperitoneal administration of DB289 resulted in insignificantly higher activity. 
Approximately 10-times more prodrug was needed to achieve comparable cure rates in the 
STIB900 model as compared to KETRI2537 and STIB795. 
 
Interestingly, DB289 showed good oral efficacy indicating that sufficient quantities were 
absorbed from the mouse gastrointestinal tract, confirming that the prodrug approach is an effective 
way of delivering dicationic drugs across the gut mucosa (Tidwell et al., 1990; Hall et al., 1998). 
Oral efficacy presents the exciting new possibility to treat HAT patients without the need for 
hospitalisation, thus making the treatment of a neglected tropical disease that affects the world’s 
poorest people easier to manage and cheaper (WHO, 1998; Etchegorry et al., 2001). Oral diamidine 
activity has earlier been reported for diminazene aceturate (Berenil®) in a substantial number of 
HAT patients (Abaru et al., 1984) although this drug is not registered for human use.  
 
All the drugs were well tolerated, except intravenous administered DB75 had toxic effects 
at 4x15 mg/kg or intraperitoneally at the high dose of 4 x 50 mg/kg bwt. No adverse effects were 
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noticed for the prodrug DB289 at dose levels up to 5 x 75 mg/kg bwt in the KETRI2537 model, a 
dose that is 18.8 times higher than the minimum curative dose. Also at 4 x 100 mg/kg bwt which 
cured the highly stringent STIB900 model no signs of toxicity could be observed. This compares 
well with pentamidine and diminazene aceturate which, when administered in mice at dose rates as 
high as 50 mg/kg did not cause overt signs of toxicity (Zweygarth and Rottcher, 1989). Thus, 
although susceptibilities of T. b. rhodesiense clinical isolates to drugs are known to vary widely 
(Bacchi et al., 1990, 1994 and 1997), the wide safety margin suggests that there is adequate room 
for adjustment of dose rates to cater for such differences between isolates.  
 
In conclusion, this study has shown that DB75 is much more potent than pentamidine and 
that the prodrug DB289 cures the T. b. rhodesiense mouse models when administered PO. This 
supports the expectation that DB289, which is currently in phase III clinical trials, may successfully 
become the first oral treatment of human African trypanosomiasis. 
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ABSTRACT 
Owing to the lack of oral drugs for human African trypanosomiasis, patients have to be 
hospitalized for 10 to 30 days to facilitate treatment with parenterally administered medicines. The 
efficacy of a novel orally administered prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-
methlylamidoxime (pafuramidine, DB289), was tested in the vervet monkey (Chlorocebus 
[Cercopithecus] aethiops) model of sleeping sickness. Five groups of three animals each were 
infected intravenously with 104 Trypanosoma brucei rhodesiense KETRI 2537 cells. On the 
seventh day postinfection (p.i.) in an early-stage infection, animals in groups 1, 2, and 3 were 
treated orally with pafuramidine at dose rates of 1, 3, or 10 mg/kg of body weight, respectively, for 
five consecutive days. The animals in groups 4 and 5 were treated with 10 mg/kg for 10 
consecutive days starting on the 14th day p.i. (group 4) or on the 28th day p.i. (group 5), when 
these animals were in the late stage of the disease. In the groups treated in the early stage, 10 mg/kg 
of pafuramidine completely cured all three monkeys, whereas lower doses of 3 mg/kg and 1 mg/kg 
cured only one of three and zero of three monkeys, respectively. Treatment of late-stage infections 
resulted in cure rates of one of three (group 4) and zero of three (group 5) monkeys. These studies 
demonstrated that pafuramidine was orally active in monkeys with early-stage T. brucei 
rhodesiense infections at dose rates above 3 mg/kg for 5 days. It was also evident that the drug 
attained only minimal efficacy against late-stage infections, indicating the limited ability of the 
molecule to cross the blood-brain barrier. This study has shown that oral diamidines have potential 
for the treatment of early-stage sleeping sickness. 
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INTRODUCTION 
Human African trypanosomiasis (HAT) (sleeping sickness) is caused by the flagellated 
protozoan parasites Trypanosoma brucei gambiense and T. brucei rhodesiense and is inevitably 
fatal when untreated. The disease is endemic to sub-Saharan Africa, where an estimated 50 million 
people in more than 20 countries are considered to be at risk (23). WHO statistics show that from 
1998 to 2004, the number of HAT cases declined from 37,991 to 17,616 (30), and the estimated 
prevalence declined in the same period, from 300,000 to 500,000 cases to 50,000 to 70, 000, even 
though the number of people covered by active screening almost doubled in the same period (30). 
These declining trends are indicators that the partnerships between individual African governments 
and the WHO are having a positive impact on the control of HAT. However, these gains could 
easily be lost through political instability and/or the outbreak of wars, which inevitably lead to a 
breakdown in surveillance activities (10). At present, HAT remains a major health problem in 
certain foci in the Democratic Republic of Congo, Angola, and Southern Sudan (10, 30). Since the 
trypanosomes' remarkable ability to vary their major surface antigen makes successful vaccine 
development unlikely in the near future (26), the only recourse available is to intensify research and 
the development of new drugs. 
Current drugs that are used to treat HAT include pentamidine, suramin, melarsoprol, and 
eflornithine (5). These are far from ideal, since they elicit substantial toxic effects and/or require 
parenteral application, which makes them difficult to administer in the rural African settings where 
the disease typically occurs. Furthermore, melarsoprol, the only drug available that is effective 
against the late stages of both T. brucei gambiense and T. brucei rhodesiense disease, has shown 
incidences of treatment failure of >25% in epidemic areas of northern Uganda and northern Angola 
(4, 7, 8). Both melarsoprol and eflornithine require long periods of hospitalization and monitoring 
owing to the complicated treatment schedules needed (1). In addition, melarsoprol may cause 
reactive encephalopathy; this occurs in 5 to 10% of treated patients and has a fatality rate of ∼50% 
(5). The provision of an oral drug of low toxicity for sleeping sickness would allow an effective 
administration of the required doses with minimal supervision from medical personnel. This is an 
important consideration, since enough qualified people are rarely available in those parts of Africa 
where the disease is endemic. 
A recently synthesized novel prodrug, 2,5-bis(4-amidinophenyl)-furan-bis-O-
methlylamidoxime (pafuramidine, DB289) exhibited excellent oral activity and reduced acute 
toxicity in acute and chronic mouse models of trypanosomiasis (3, 12, 27). The enhanced oral 
activity of DB289 is attributed to an improved oral absorption of the prodrug in which the cationic 
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functionalities are masked and to its conversion to the active compound 2,5-bis(4-
amidinophenyl)furan (furamidine; DB75) in the liver. DB75 strongly binds to the minor groove of 
DNA at AT-rich sites and weakly binds by intercalation at the GC sites of DNA (25). 
Consequently, its subsequent mode of action involves interference with the normal function of the 
pathogen's DNA-dependent enzymes, perhaps topoisomerase II (2). In spite of pafuramidine being 
an analogue of pentamidine, it appears to possess two properties that would overcome the two 
disadvantages of pentamidine, namely, parenteral administration and lack of efficacy against 
central nervous system (CNS) infection. 
Recently, following prolonged administration with the drug in a clinical trial for AIDS 
related Pneumocystis cariini pneumonia, abnormal liver enzyme values were found in several 
volunteers. However, no subject required any treatment or hospitalization for this abnormality. 
Despite this, pafuramidine is evidently a promising candidate for use as a new drug for oral 
administration. It was therefore tested in the vervet monkey model of sleeping sickness at the 
Trypanosomiasis Research Centre of the Kenya Agricultural Research Institute. This nonhuman 
primate model is known to mimic the human disease closely (21) and is a valuable tool for 
preclinical chemotherapeutic studies. Experiments were conducted to determine the efficacy of 
DB289 after multiple oral doses against both early- and late-stage infections with T. brucei 
rhodesiense. 
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MATERIALS AND METHODS 
Experimental Animals 
Fifteen vervet monkeys (Chrolocebus [Cercopithecus] aethiops) of both sexes and weighing 
between 2.5 and 4.5 kg were obtained from the Institute of Primate Research in Kenya. They were 
housed in quarantine for a minimum of 90 days and screened for evidence of disease, including 
zoonotic infections. They were also dewormed using albendazole (Valbazen; Utravetis Ltd., 
Kenya) and treated for ectoparasites using carbaryl (1-naphthyl methylcarbamate) (Sevin; Bayer 
Ltd., Kenya). During that period, the monkeys became accustomed to staying in individual 
squeeze-back stainless steel cages and to being handled. They were fed twice daily on fresh 
vegetables and commercial monkey cubes (Unga Ltd., Kenya) and given water ad libitum. Before 
the study, the animals were transferred to experimental wards and acclimatized for a further 2 
weeks. 
 
Trypanosomes 
The T. brucei rhodesiense stabilate used was KETRI 2537, a derivative of EATRO 1989, 
isolated from a patient in Uganda by direct inoculation of blood and lymph node aspirates into a 
monkey and later cryopreserved (9). 
 
Test Drug.  
Pafuramidine (DB289) [2,5-bis(4-amidinophenyl)-furan-bis-O-methlylamidoxime; 
MediChem, Lemont, IL] was provided by Immtech Pharmaceuticals, Inc., as a yellow powder. 
 
Drug Preparation 
DB289 was prepared as a 1% suspension in distilled water containing 0.5% (wt/vol) 
carboxymethylcellulose sodium and 0.1% (wt/vol) Tween 80. The preparation was stored at 4°C 
and used for up to 3 days before a fresh preparation was made. 
 
Drug Administration 
The DB289 suspension was administered orally using a gavage needle once daily for 5 or 
10 days depending on the treatment regimen for each group. 
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Experimental Design 
The 15 monkeys were randomized into five treatment groups without sex bias (Tables 1 and 
2). The monkeys were all infected by intravenous injection of 104 trypanosomes diluted from the 
infected blood of immunosuppressed donor mice using phosphate-buffered saline as previously 
described for the vervet monkey model (11, 17). On the seventh day postinfection (p.i.) in an early-
stage infection, animals in groups 1, 2, and 3 were treated orally with pafuramidine at dose rates of 
1, 3, and 10 mg/kg, respectively, for five consecutive days. The animals in the remaining two 
groups, groups 4 and 5, were treated with 10 mg/kg for 10 consecutive days, starting on the 14th 
day p.i. (group 4) or on the 28th day p.i. (group 5). The monkeys were monitored for clinical 
changes and for the presence of trypanosomes in body fluids. Once parasites were detected in any 
of the body fluids, the monkeys were removed from the study through humane euthanasia. 
 
Table 1: Body weight and PCV changes in vervet monkeys infected with T. brucei rhodesiense and 
treated with different regimens of pafuramidine 
Group (dose 
[mg/kg]) 
Mean 
preinfection 
wt (kg) ± SE 
% Wt change at a   Mean 
preinfection 
% PCV ± SE 
% Change in PCV at a  
Day 0 
p.t. b  
Day 
28p.t.c  
End 
point 
Day 0 
p.t. b 
Day 28 
p.t.c  
End 
point 
1 (1) 3.15 ± 0.45 −2.20 −2.1 d  0 47.0 ± 4.4 −4.30 −17.0 d  −23.40 
2 (3) 3.18 ± 0.33 −5.00 −6.60 −1.60 46.0 ± 4.4 −9.40 −2.90 −3.60 
3 (10) 2.88 ± 0.43 −6.30 0 +3.50 40.3 ± 2.5 −5.80 −1.60 +13.20 
4 (10) 4.25 ± 0.52 −4.20 −5.20 −0.70 51.7 ± 6.1 −25.80 −13.50 −7.70 
5 (10) 3.32 ± 0.60 −10.50 −8.10 −2.10 47.7 ± 1.5 −41.30 −9.10 +1.40 
 
a 
= Percent change in body weight or PCV from preinfection values, – indicates a decline, + 
indicates an increase; b = Values taken before the first treatment dose, i.e., on the 7th day p.i. for 
groups 1 to 3, 14th day p.i. for group 4, and 28th day p.i. for group 5; c = Data for groups 2 to 5 at 
28 days p.t.; d = Percent change in body weight and PCV at 1 day p.t. for group 1. 
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Table 2: Outcomes of treatment of T. brucei rhodesiense-infected vervet monkeys with different 
regimens of pafuramidine (DB289) 
Group Dose (mg/kg) (length 
of treatment [days]) 
Monkey Time to detection of 
trypanosomes in biological 
fluids (days p.t.) 
No. of cured 
monkeys/no. of total 
monkeys 
Blood CSF 
MIT 
WS + 
HCT MIT 
HC + 
CT 
1 1 (5) 463 7 9 NC NC 0/3 
  484 NC 4 7 14  
  485  3 14 21  
2 3 (5) 482 55 79  21 1/3 
  483 69 66 69 55  
  411 Cured     
3 10 (5) 454 Cured    3/3 
  468 Cured     
  486 Cured     
4 10 (10) 471 56 87 NC NC 1/3 
  478 Cured     
  488 ND  42 ND  
5 10 (10) 490 ND  21 42 0/3 
  501 56 73 NC   
  520 ND  119 119  
ND, not detected for >180 days p.t.; WS, wet smear; HC, hemocytometer counting; CT, 
concentration techniques for CSF; NC, trypanosome not cleared. 
 
Monitoring and Sample Collection 
Physical examinations and sampling of body fluids were carried out weekly for the first 28 
days and then once every 2 weeks up to 100 days post treatment and monthly thereafter until the 
end of the experiment. Physical examinations and collection of blood and cerebrospinal fluid (CSF) 
were undertaken on monkeys anesthetized with diazepam (May and Baker, United Kingdom) at 1 
mg/kg body weight and with ketamine hydrochloride (Rotexmedica, Trittau, Germany) at 15 mg/kg 
body weight. Post treatment monitoring was maintained for a period of 180 days. 
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At each time point, approximately 1 ml of blood was collected into EDTA by inguinal 
venipuncture. In addition to blood samples, 1.5 ml of CSF was collected by lumbar puncture of the 
anesthetized monkeys (11). Blood collected by inguinal venipuncture was used for determinations 
of the packed cell volume (PCV) using the microhematocrit method. White cells in the CSF were 
counted using a hemocytometer chamber. 
 
Determination of Parasitaemia 
The determination of parasitaemia started 3 days p.i. It was done by examination of wet 
films of ear prick blood according to a method described previously by Herbert and Lumsden (13) 
(detection limit, 105 trypanosomes/ml of blood) or by the hematocrit centrifugation technique 
(HCT) according to methods described previously by Woo (31) (detection limit, 103 
trypanosomes/ml of blood). Blood collected by inguinal venipuncture was used for parasitemia 
determinations using both the wet-film and HCT methods. 
For estimation of parasites in the CSF, some of the free-flowing CSF was collected into a 
capillary tube and immediately transferred into a hemocytometer chamber to count the number of 
trypanosomes and white cells. Negative CSF samples were then centrifuged and reexamined for 
trypanosomes. In cases where no parasites were detected in either blood or CSF by the above-
described methods, Swiss white mice were used to test for the presence of trypanosomes (11). 
Samples of 0.2 ml of blood or CSF were inoculated intraperitoneally into two mice per sample. 
 
RESULTS 
Clinical Disease before Treatment 
Following infection, trypanosomes were detected in wet smears of peripheral blood with a 
mean period of 4.2 days (range, 3 to 5 days). Enlargement of peripheral axillar and inguinal lymph 
nodes was observed by the seventh day p.i., and enlargement of the spleen was observed by the 
14th day p.i. The monkeys became dull, had rough hair coats, and showed a transient loss of 
appetite. The rectal body temperature rose from a preinfection (0 days p.i.) value of 38.2°C ± 0.2°C 
to 38.9°C ± 0.2°C (mean ± standard error). The rise in temperature was significant (P = 0.01) and 
coincided with peak parasitemia levels of 7 × 107 trypanosomes/ml of blood. Other clinical signs 
included loss of body weight as the infection progressed. The decrease in mean body weight was 
marginal (<6% of preinfection weight) for animals treated while in the first stage of disease at 7 to 
11 days p.i. (groups 1 to 3), and a more substantial change (10.5%) was found for animals (group 5) 
treated during late-stage disease at 28 days p.i. (Table 1). The changes in mean PCV were similarly 
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marginal for animals treated while in the early stage but more pronounced for those treated while in 
the late stage of disease (Table 1). Animals that were treated in the late stage of disease also had 
confirmed trypanosomes in CSF (1 to 6 trypanosomes/µl) and elevated white cell counts (mean, 10 
cells/µl of CSF; range, 4 to 20 cells/µl of CSF). 
 
Results of Treatment with Pafuramidine 
Pafuramidine treatment was shown to benefit most of the monkeys. Body weights and PCV 
improved in all monkeys by the time of termination of the experiment except for those in group 1 
(Table 1). In some individuals, there was clearance of both parasitemia and CSF parasitosis (Table 
2). However, the onset and durability of the beneficial effects of pafuramidine treatment varied in 
the different groups. 
 
Group 1 (1 mg/kg for 5 days per os) 
In group 1, trypanosomes became undetectable in the blood by direct microscopy or HCT a 
day after the last (fifth) drug dose and remained so for a mean of 5 days (range, 3 to 9 days). 
However, even during this period of apparent aparasitemia, viable trypanosomes were isolated from 
the monkeys' blood by the mouse inoculation test (MIT), indicating that blood parasites were never 
completely eliminated. In the CSF, trypanosomes were detected first by MIT on 7 to 14 days 
posttreatment (p.t.) or 14 to 21 days p.t. by microscopy (direct hemocytometer counting or 
concentration techniques), indicating that the drug treatment delayed the onset of trypanosomes in 
the CSF. Clinical data, especially the PCV, continued to decline (Table 1), indicating that at the low 
dose of 1 mg/kg of body weight, pafuramidine treatment did not cure any of the monkey infections. 
The monkeys were humanely euthanized. 
 
Group 2 (3 mg/kg for 5 days per os) 
Animals in group 2 became parasitologically negative by both blood and CSF on the fifth 
day of dosing. However, two of the three monkeys experienced recrudescence of trypanosomes, 
first in the CSF and later in the blood (Table 2). In these two animals, CSF trypanosomes were first 
detected by the MIT at 21 days p.t. and then by direct microscopy (Table 2). In this group, 
treatment led to improvement in both mean weight and mean PCV (Table 1) although only one of 
three the monkeys fulfilled the criteria of cure at 180 days p.t. The two monkeys that relapsed were 
humanely euthanized. 
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Group 3 (10 mg/kg for 5 days per os) 
Animals in group 3 became parasitologically negative by the fifth day of dosing and 
remained so until the end of the experimental period. Similarly, no trypanosomes were recovered 
by MIT throughout the 180 days of p.t. monitoring. Meanwhile, weight and PCV returned to 
preinfection levels by 28 days p.t. (Table 1), and all clinical aberrations resolved, underlining that 
all three of three monkeys were cured of the infection. 
 
Group 4 (10 mg/kg for 10 days per os starting 14 days p.i.) 
In group 4, following treatment, both weight and PCV improved, although not to 
preinfection levels (Table 1). All three monkeys in this group became aparasitemic by day 5 of 
dosing, but only two of three monkeys (monkeys 478 and 488) remained free of blood parasites 
until 180 days p.t. In the CSF, either trypanosomes were not cleared (monkey 471) or 
recrudescence occurred within the first 42 days p.t. (monkey 488) (Table 2). Only monkey 478 
remained free of trypanosomes in both blood and CSF as determined by HCT and MIT and was 
considered to be cured (Table 2). The results were confirmed by the pattern of white cell changes in 
the CSF; these oscillated between 0 and 12 cells/µl of CSF for monkey 478, which was cured, but 
occasional peaks of above 25 cells/µl of CSF, which declined to lower peaks below 15 cells/µl of 
CSF, were observed in monkey 488, where there was recrudescence of the infection (Fig.1). 
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FIG. 1: CSF white cell changes in vervet monkeys 478 (▴) and 488 (□) after treatment with 
pafuramidine at 10 mg/kg for 10 days while in the late stage (14 days p.i.) of disease. Note 
that in vervet monkey 478, levels of white cells declined after treatment and remained low 
throughout the observation period, while in vervet monkey 488, the drop in white cell 
number was transient and showed recrudescences to >25 cells/µl of CSF 
 
Group 5 (10 mg/kg for 10 days per os starting at 28 days p.i.) 
In group 5, all the animals became aparasitemic by day 4 of dosing. However, only two of 
three of them remained free of blood trypanosomes by the end of the 180 days of p.t. monitoring 
(Table 2). In the CSF, trypanosomes were not cleared in monkey 501, while in the remaining two 
monkeys, the trypanosomes disappeared after treatment, and recrudescence occurred (Table 2). The 
significant improvement in weight and PCV (Table 1) was probably due to the absence of 
trypanosomes from the hemolymphatic system in spite of the presence of trypanosomes in the CNS. 
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DISCUSSION 
In this study, the oral administration of pafuramidine (DB289) had a profound effect on 
established T. brucei rhodesiense infections in vervet monkeys. In the acute disease stage, when the 
monkeys showed high parasitemia levels, treatment with 10 mg/kg orally for five consecutive days 
cleared three of the three monkeys in group 3 of their trypanosome infections and kept them 
trypanosome free for the entire monitoring period of 180 days. In addition, the treatment reversed 
the clinical symptoms of trypanosomiasis, thus fulfilling all criteria for confirmation of cure. 
Comparison of this group of monkeys with groups 1 and 2, which also had an early-stage 
infection with a 5-day treatment schedule (days 7 to 11), shows a clear dose response to 
pafuramidine. At 3 mg/kg, only one of three animals was cured, and at the lowest dose, 1 mg/kg, all 
animals relapsed within 1 week after treatment or did not clear parasitemia at all. 
The clinical signs described in this report for acute infection mirror those described in 
previous reports for syringe passage of T. brucei rhodesiense infections in vervet monkeys (15, 21), 
tsetse-transmitted infections in vervet monkeys (28), and early-stage infections in sleeping sickness 
patients (16, 18, 22). These clinical manifestations are evidence of hemolymphatic system 
involvement. The fact that the clinical manifestations were reversed when pafuramidine was 
administered in sufficient concentrations indicates that the drug was able to access and eliminate 
trypanosomes from all hemolymphatic sites. 
In the two groups of monkeys with a late-stage infection, treatment with 10 mg/kg for 10 
days cured only one of three monkeys treated from 14 days p.i. (group 4) and none in the group 
treated from 28 days p.i. onwards. In group 4, the presence of trypanosomes and white cell counts 
above the 5-cell/mm3 cutoff for confirmation of late-stage disease (29) was demonstrated in the 
CSF of the infected monkeys. The fact that trypanosomes were eliminated from the CSF in one 
animal and the mean PCV in the group was improved (from −25.8% to −13.5%) (Table 1) suggests 
that orally administered pafuramidine has some ability to cross the blood-brain barrier. Although 
the levels of pafuramidine (DB289) and its active form, furamidine (DB75), in CSF were not 
determined in the present study, it is likely that the variation in individual responses resulted from 
variation in the CSF levels of the drugs. Generally, the activity of a drug may show considerable 
interanimal variation, which results in different concentrations at the site of action (kinetic 
differences) or different responses to a given drug concentration (dynamic differences) (19). 
Studies with melarsoprol, the drug used to treat late-stage sleeping sickness, similarly indicated that 
the peak levels attained in the CSF of monkeys were about 50 times less than peak levels in plasma 
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and were insufficient in some animals to eliminate all trypanosomes from the CSF compartment 
(6). 
The fact that none of the animals treated with pafuramidine at 10 mg/kg for 10 days starting 
at 28 days p.i. was cured shows that as the residence time of trypanosomes in the CSF increased, 
the infections became more difficult to treat. It has been postulated that the invasion of the CSF by 
trypanosomes progressively leads to parasite invasion of the perivascular spaces (Virchow-Robin 
spaces) and from there to the parenchyma of the CNS (20). Further evidence of the importance of 
the residence time of trypanosomes in CSF was provided previously by Schmidt and Sayer (21), 
who found that one monkey with a disease duration of 107 days had histologically demonstrable 
meningoencephalitis. Although our study had no component of histology and could therefore not 
confirm or rule out the presence of meningoencephalitis at 28 days p.i., it is clear that the levels of 
the active drug (DB75) attained in the CSF were inadequate to eliminate trypanosomes from the 
sites to which they were sequestered, making the CNS the main source of relapse parasites, as 
previously observed for mice (14). Even in this group of monkeys, however, the drug cleared 
bloodstream-form trypanosomes and maintained two of three monkeys trypanosome free 
throughout the monitoring period, which provides further evidence of the ability of pafuramidine to 
access hemolymphatic but not CNS sites of the infected monkeys. 
To conclude, the study showed that the novel prodrug pafuramidine (DB289) was effective 
against early T. brucei rhodesiense infection in monkeys. In addition, the drug was well tolerated 
by all the infected monkeys, confirming previous observations of uninfected vervet monkeys (John 
Thuita, TRC-KARI, personal communication). The drug was generally not effective against late-
stage disease and may therefore not be indicated for this use. However, Sturk et al. (24) previously 
observed that after intravenous administration in mice, there was a fivefold increase in brain levels 
of pafuramidine with parenchymal localization of compound fluorescence, which suggested that the 
unaltered prodrug does penetrate the blood-brain barrier and may be subject to in situ 
biotransformation. Since the present study showed that pafuramidine was efficacious in clearing 
trypanosomes from the bloodstream, it would be worth considering the testing of parenteral 
treatment regimens to improve the bioavailability of the drug in the CNS in nonhuman primates. 
However, the issue of recently found human toxicity should be taken in consideration in further 
nonhuman primate studies. 
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ABSTRACT 
Novel drugs to treat human African trypanosomiasis (HAT) are still urgently needed despite the 
recent addition of nifurtimox-eflornithine combination therapy (NECT) to WHO Model Lists of 
Essential Medicines against second stage HAT, where parasites have invaded the central nervous 
system (CNS).  The pharmacology of a potential orally available lead compound, N-methoxy-6-{5-
[4-(N-methoxyamidino) phenyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated in a vervet 
monkey model of second stage HAT, following promising results in mice. DB844 was 
administered orally to vervet monkeys, beginning 28 days post infection (DPI) with Trypanosoma 
brucei rhodesiense KETRI 2537. DB844 was absorbed and converted to the active metabolite 6-[5-
(4-phenylamidinophenyl)-furanyl-2-yl]-nicotinamide (DB820), exhibiting plasma Cmax values of 
430 and 190 nM for DB844 and DB820, respectively, after the 14th dose at 6 mg/kg qd. A 100-fold 
reduction in blood trypanosome counts was observed within 24 h of the third dose and, at the end of 
treatment evaluation performed four days post the last drug dose, trypanosomes were not detected 
in the blood or cerebrospinal fluid of any monkey.  However, some animals relapsed during the 300 
days of post treatment monitoring, resulting in a cure rate of 3/8 (37.5%) and 3/7 (42.9%) for the 5 
mg/kg x 10 days and the 6 mg/kg x 14 days dose regimens respectively. These DB844 efficacy data 
were an improvement compared with pentamidine and pafuramidine both of which were previously 
shown to be non-curative in this model of CNS stage HAT. These data show that synthesis of novel 
diamidines with improved activity against CNS-stage HAT was possible. 
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AUTHOR SUMMARY 
New drugs are needed to treat sleeping sickness, especially the second stage of the disease, which is 
characterised by the presence of parasites (trypanosomes) in the brain. The purpose of this work 
was to determine whether DB844, a new drug that is converted to the active form (DB820) after 
oral administration, has the potential to treat second stage sleeping sickness. Two dosing regimens 
of DB844 were evaluated in two groups of vervet monkeys that were infected experimentally with 
trypanosomes. Treatment was initiated four weeks after infection, when the monkeys were in 
second stage sleeping sickness, as confirmed by the presence of trypanosomes in brain fluid. Orally 
administered DB844 was well absorbed, tolerated and resulted in a decrease of trypanosomes in 
both the blood and brain fluid. However, some monkeys relapsed after treatment, with an overall 
cure rate of approximately 40% in both study groups. For at least two days after last dosing, the 
active drug, DB820, achieved blood concentrations known to be at least 19 times more than the 
minimum concentration that has been shown to be effective against a stringent human infective 
trypanosome isolate (STIB 900). These results represent an advance in efforts to develop new 
related compounds as oral treatments for sleeping sickness. 
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INTRODUCTION 
Human African trypanosomiasis (HAT, sleeping sickness) is a debilitating disease that is 
caused by the protozoan parasites, Trypanosoma brucei gambiense and T. b. rhodesiense.  The 
disease is transmitted by tsetse flies (Glossina spp) and is therefore endemic only in geographical 
areas (foci) where both the parasite and vector are present; these foci are distributed in ∼20 sub-
Saharan African countries and are home to at least 50 million people who are at risk of contracting 
HAT [1]. The spatial and temporal distribution of HAT is further determined by emergence of 
virulent parasite strains, breakdown in control and/or surveillance activities, changes in climate and 
vegetation and movements of carrier livestock species across borders [2]. As a result, the 
epidemiology of HAT is characterised by periodic epidemics interspersed with periods of near total 
eradication [3]. In 2009, the annual incidence dropped below 10,000 reported cases for the first 
time in 50 years, a success credited to the World Health Organization (WHO), national disease 
control programmes, bilateral co-operation and non-governmental organizations [4]. However, 
control activities must be maintained and new diagnostics and drugs developed to have a realistic 
chance of eventually eliminating HAT, a disease which has a history of reversing previous gains [2, 
5-7]. 
 
Modern drug research and development activities for HAT have recently increased 
markedly, primarily through the efforts of public private partnerships (PPP’s), which are funded by 
governmental and philanthropic organizations. A first success of these PPP’s is the nifurtimox-
eflornithine combination therapy (NECT), a product that has was recently added to the WHO 
essential medicines list for the management of T. b. gambiense CNS-stage infections [4, 8]. In 
addition, the dimethoxyamidine prodrug pafuramidine (DB289), a pentamidine-like compound 
developed by the Consortium for Parasitic Drug Development (CPDD), became the first oral drug 
to enter phase III clinical trials for 1st stage HAT [9]. Clinical and preclinical investigations on 
pafuramidine (DB289) demonstrated that oral diamidine prodrugs could achieve efficacy equal to 
or better than pentamidine in the management of 1st stage HAT [9-12]. However, the development 
program was terminated after some subjects (6%) in an extended phase I clinical trial (14 day dose 
regimen of 100 mg bid) developed delayed renal insufficiency [9]. Like pentamidine, pafuramidine 
did not achieve cure against 2nd stage HAT in animal models [11, 12]. 
 
In an effort to develop a compound that was well tolerated and with efficacy against 2nd 
stage HAT, a next-in-class dimethoxyamidine prodrug, N-methoxy-6-{5-[4-(N-methoxyamidino) 
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phenyl]-furan-2-yl}-nicotinamidine (DB844), was evaluated. Similar to the biotransformation of 
DB289, DB844 was shown to be sequentially O-demethylated and N-dehydroxylated in human 
liver microsomes to form its active metabolite, 6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-
nicotinamide (DB820) [13]. In mice, oral DB844 appeared to be well absorbed and converted to 
DB820, and cured all animals (5/5) in the GVR35 CNS model of HAT [11]. In vitro, DB820 was a 
potent trypanocide with an IC50 value of 2.4 ng/ml (5.2 nM) against T. b. rhodesiense STIB900 
[11]. DB820 also accumulated in the DNA containing organelles and bound to DNA molecules 
preferentially at AT rich sites, thus likely sharing the same mechanism of action with pentamidine 
[14-16].  The purpose of this study was to further evaluate the potential of DB844 as a novel oral 
treatment against 2nd stage HAT by characterizing its pharmacology in vervet monkeys, a species 
commonly used as a preclinical model for HAT [12]. The specific study objectives were to (a) 
characterize the metabolic profile of the prodrug in vervet monkey liver microsomes; (b) evaluate 
the toxicity of orally administered DB844 in un-infected monkeys to understand tolerability and to 
define an appropriate dose range for efficacy studies in the monkey HAT model; and (c) evaluate 
the pharmacokinetics, efficacy and safety of DB844 in the infected vervet monkey model, which 
closely mimics human sleeping sickness. 
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MATERIALS AND METHODS 
Ethics Statement 
Studies were undertaken in adherence to experimental guidelines and procedures approved 
by the Institutional Animal Care and Use Committee (IACUC), the ethical review committee for 
the use of laboratory animals at the Trypanosomiasis Research Centre of the Kenya Agricultural 
Research Institute (TRC-KARI). The experimental guidelines also complied with National 
guidelines of the Kenya Veterinary Association. 
 
Trypanocidal Test Compound 
The test compound N-methoxy-6-{5-[4-(N-methoxyamidino) phenyl]-furan-2-yl}-
nicotinamidine (DB844) (Figure 1) was synthesized in the laboratory of Dr. David Boykin (Georgia 
State University, Atlanta, GA, USA) as previously reported [17]. The current study used DB844 
(lot D, C19H19N5O33HClH2O) with a purity of > 95% as determined by both NMR [17] and high 
performance liquid chromatography (HPLC)/UV (described below). DB844 was supplied to KARI-
TRC through CPDD in the form of yellow powder in opaque and water tight bottles. Once 
received, the drug containing bottle was wrapped in aluminium foil and refrigerated at 4-8°C. 
Dosing formulations were prepared daily by dissolving the drug in de-ionised distilled water to 
render concentrations of 5 and 6 mg/ml. Reconstituted drug was protected from light by wrapping 
drug-containing vials with aluminium foil. 
 
 
Figure 1: Chemical structure of DB844 and DB820, doi:10.1371/journal.pntd.0001734.g001 
 
Trypanosome Isolate 
A pleomorphic isolate, T.b rhodesiense KETRI 2537, a derivative of EATRO 1989 that was 
isolated from a patient in Uganda by direct inoculation of blood and lymph node aspirate into a 
monkey and later cryopreserved at KARI- TRC [18], was used. This isolate is the basis of the 
KETRI vervet monkey and mouse models and has been widely used for drug efficacy trials [19, 
20]. 
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Experimental Animals 
Adult vervet monkeys [Chlorocebus (Cercopithecus) aethiops syn. African green monkeys] 
(n = 22) weighing between 2.5 and 5.5 kg were acquired from the Institute of Primate Research 
(IPR) in Kenya. Monkeys were quarantined, screened, acclimated for the study for a minimum of 
90 days while being screened for evidence of disease as previously described [12, 20, 21]. They 
were also de-wormed, treated for ectoparasites, and acclimated to staying in individual squeeze-
back stainless steel cages and human handling. The monkeys were fed a diet of fresh vegetables and 
commercial monkey cubes (Unga feeds, Nakuru Kenya) twice daily and provided water ad libitum.  
 
Metabolism of DB844 in Vervet Monkey Liver Microsomes 
The metabolism of DB844 was investigated using liver microsomes, prepared from a male 
vervet monkey by XenoTech, LLC (Lenexa, KS), in the presence of NADPH as described 
previously [22] with modifications. Briefly, incubation mixtures (1 ml at pH7.4, in triplicate) 
contained 10 µM DB844 and 0.2 mg/ml monkey liver microsomes. After a 5-min equilibration 
period at 37°C, reactions were initiated with the addition of NADPH.  Aliquots (50 µl) of the 
reaction mixtures were removed at 0, 5, 10, 15, 30, 60, 90, and 120 min and mixed with 25 µl of 
ice-cold acetonitrile.  The mixtures were centrifuged (10,000 x g for 5 min at 4°C) and the 
supernatants were analyzed by HPLC/UV using the same method as previously described for 
DB289 [22].  Metabolite identification was performed by comparing retention times to those of 
synthetic standards, which include M1A (DB1284), M1B (DB1058), M2A (DB1285), M2B 
(DB1212), M3 (DB821), and DB820 [13]. DB844 and metabolites were quantified using a single-
concentration calibration curve generated using synthetic standards.  
Toxicity Study in Uninfected Monkeys 
The toxicity of DB844 was evaluated in uninfected vervet monkeys with the aim of defining 
the appropriate dose-range for the compound, identifying target organs of toxicity and 
characterizing the nature of drug-induced toxicity in this species.  Six monkeys were used to 
evaluate the tolerability of 10-day oral dose regimens. Baseline clinical and haematology data were 
collected during a 14-day period, after which two monkeys (one male and one female) per dose 
group were administered with DB844 at 5, 10 or 20 mg/kg/day for 10 days via oral gavage. A dose 
volume of 1 ml/kg was administered.  Daily ward rounds were conducted to assess feed intake 
(appetite), demeanour, posture and stool composition and consistency. Feed intake was assessed by 
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scoring the proportion of the daily ration consumed by each monkey based on a scale of 1 (full 
ration eaten), 3/4, 1/2, 1/4 and 0 (no feed eaten) as previously described [21]. 
Monkeys were monitored for 28 days post dosing. They were anaesthetized through 
intramuscular (IM) injection with ketamine HCl (10-15 mg/kg) and Valium® (0.5 mg/kg) to 
facilitate physical examination, body weight measurements and sample collection. Blood was 
collected from the femoral vein via inguinal venipuncture as described previously [20, 23] and 
divided into aliquots: 1 ml in EDTA for full haemogram determination and 2 ml in EDTA for 
plasma separation. Plasma was separated using a cool spin centrifuge (4°C, 1500 
revolutions/minute), separated into aliquots and stored at -20°C pending analysis for DB844/DB820 
concentrations.  
 
When overt drug related toxicity was detected, drug administration was withdrawn from the 
affected monkey(s) to allow the affected individuals to recover. Monkeys that failed to recover 
were humanely euthanized using 20% pentobarbitone sodium (Euthatal®, Rhone Merieux) for 
gross and histopathology examination. Euthanasia was carried out when monkeys were judged to 
have deteriorated to the in extremis condition, characterised by inability or reluctance to perch and 
very low feed intake (less than 1/4 of daily ration) for 2-3 consecutive days [21, 24]. Organ 
specimens from these monkeys were preserved in 10% formalin and later sectioned for 
histopathogy. The processed slides were stained with haematoxylin and eosin. 
 
Monkey Infections 
Sixteen vervet monkeys in two groups of eight monkeys each (four males and four females) 
were used. After a 14-day baseline weight, clinical and haematology data collection period, the 
sixteen monkeys were infected by intravenous injection of approximately 104 trypanosomes diluted 
from infected blood of immuno-suppressed donor Swiss white mice [12]. Parasitaemia post 
infection was determined by examination of wet film of ear prick blood and/or examination of 
buffy coat after centrifugation of blood collected in a heparinised capillary tube as described 
previously [25]. Parasitaemia in wet film was estimated using the rapid matching method of 
Herbert and Lumsden [26]. In addition, monkeys were confirmed to be in second stage disease by 
detection of trypanosomes in the CSF with or without elevated white cell counts above 5 cells/µl [4, 
20, 21, 23]. At 28 days post infection (DPI), the animals were treated with DB844 via oral gavage 
at 5 mg/kg qd x 10 days (group I, n = 8) or 6 mg/kg qd x 14 days (group II, n = 8), utilising a dose 
volume of 1 ml/kg.  The monkeys were examined for parasitaemia every day during drug treatment 
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and then twice weekly until ≥ 300 days post dosing, at which point monkeys were considered cured 
if they remained clinically normal and parasite-free as determined below. 
Pre and Post Treatment Monitoring 
Daily ward rounds were conducted throughout the study to assess feed intake, demeanour, 
posture, and stool composition and consistency. Feed intake was assessed by scoring the proportion 
of the daily ration consumed by each monkey on a scale of 1 (full ration eaten), 3/4, 1/2, ¼, and 0 
(no feed eaten) as previously described [21]. Monkeys were anaesthetised weekly by intramuscular 
injection of ketamine HCl (10-15 mg/kg) and Valium® (0.5 mg/kg) for physical examination, body 
weight measurements and collection of whole blood in EDTA and cerebrospinal fluid (CSF) 
samples. Blood samples (1 ml) were thereafter collected for preparation of plasma for 
pharmacokinetic studies at 1, 2, 4, 8, 24, 48, 96 and 168 h and then weekly until 28 days, while 
CSF samples (0.7-1.5 ml) were collected at 1, 24, 96, 168 h and then weekly until 28 days post last 
dosing. Samples were collected by inguinal venipuncture (blood) or lumbar puncture (CSF) of 
anaesthetised monkeys as previously described [12]. Plasma was separated using a cool spin 
centrifuge (4°C, 1500 RPM). After 28 days post last dosing, blood and CSF samples were collected 
once every two weeks up to 100 days, then once per month until 300 days post dosing for 
haematology and parasite detection only.  During sampling, some of the free-flowing CSF was 
collected into a capillary tube and immediately transferred onto a haemocytometer (Neubaeur) 
chamber for counting of trypanosomes and/or white blood cells. Samples that were negative for 
CSF trypanosomes by direct microscopy were concentrated and examined according to the 
modified single centrifugation technique [21, 27]. All the CSF samples that remained negative for 
trypanosomes after the concentration step were then sub-inoculated into Swiss white mice (2 mice 
per sample) to further aid in diagnosis of infected fluids. Similarly, blood samples that were 
negative for trypanosomes after concentration [26] were inoculated into Swiss white mice. When 
trypanosomes were detected in blood and/or CSF or when monkeys were diagnosed to have 
attained in extremis condition as previously described [21, 24], they were humanely euthanized 
using 20% pentobarbitone sodium (Euthatal®, Rhone Merieux) for post mortem examination. 
Haematology samples (1 ml) were analysed using an AC3diffT Coulter Counter (Miami, 
Florida, USA). Clinical chemistries were determined using a Humalyzer analyser system. Finally, 
plasma and CSF were analyzed for drug and metabolite concentrations using an HPLC-tandem 
Mass Spectrometry (HPLC-MS/MS) procedure as described below.  
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Sample Preparation and HPLC-MS/MS Quantification 
Monkey plasma and CSF samples were prepared and quantified for DB844 and DB820 
using previously described methods [22, 28] with modifications. Briefly, plasma or CSF samples 
(25 µl) were extracted with 200 µl of 7:1 (v/v) methanol:water containing 0.1% (v/v) trifluoroacetic 
acid and deuterated internal standards (30 nM each for DB844-d4 and DB820-d4), followed by 
centrifugation, evaporation, and reconstitution before HPLC-MS/MS analysis [28]. HPLC-MS/MS 
quantification of DB844 and DB820 was performed on an Applied Biosystems (Foster City, CA) 
API 4000 triple quadruple mass spectrometer equipped with a Turbo IonSpray interface in positive 
ion mode (MDS Sciex, San Francisco, CA).  Reconstituted samples (4-5 µl) were separated on an 
Aquasil C18 analytical column 2.1 × 50 mm, 5 µm (Thermo Electron, Waltham, MA) with mobile 
phases consisting of HPLC-grade water containing 0.1% formic acid (A) and methanol containing 
0.1% formic acid (B).  After a 0.4-min initial hold at 15% B, mobile phase composition began with 
15% B and was increased to 80% B over 1.6 min, followed by a 1.0-min hold, at a flow rate of 0.5 
ml/min.  The column was then washed with 95% B for 1.3 min at a flow rate of 0.5 ml/min and was 
re-equilibrated with 15% B at a flow rate of 0.5 ml/min for 0.5 min before injection of the next 
sample.  The characteristic SRM transitions for DB844 and DB820 were m/z 366.2  319.2 and 
306.2  289.2, respectively.  The calibration curves for DB844 ranged from 2.5 – 2500 nM and 1 
– 1000 nM in plasma and CSF, respectively, using a quadratic equation with 1/x weighting. The 
calibration curves for DB820 ranged from 10 – 2500 nM and 1 – 1000 nM in plasma and CSF, 
respectively, using a quadratic equation with 1/x weighting. 
 
Data Analysis 
Data were analysed statistically using Statview for Windows Version 5.0.1 (SAS Institute 
Inc, Cary, NC). Repeated measures ANOVA, with Fishers PLSD post hoc test, was used to test the 
effects of trypanosomal infection, as well as DB844, on haematology and clinical chemistry 
parameters in comparison with respective baseline values (α = 0.05). Confidence intervals [95%] 
were derived to further test the significance of observed findings. Pharmacokinetic outcomes were 
determined using standard non-compartmental methods performed using Phoenix WinNonlin 
(version 6.2, Pharsight, Mountain View, CA).  
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RESULTS 
Metabolism Profiles in Monkey Liver Microsomes 
DB844 was rapidly metabolized in vervet monkey liver microsomes (MLM) with a 
microsomal half-life of approximately 14 min to form at least seven metabolites over a 120 min 
incubation period (Figure 2). The first two metabolites to be detected, M1A and M1B, were likely 
formed through the oxidative O-demethylation of either the pyridyl or phenyl side of DB844 [13]. 
M1A and M1B gave rise to M2A and M2B respectively, through reductive N-dehydroxylation, or 
further O-demethylation to form the bis-amidoxime metabolite, M3. The O-demethylation of M2A 
and M2B resulted in M4A and M4B, respectively, which could also be generated by N-
dehydroxylation of M3. At last, the N-dehydroxylation of M4A and M4B gave rise to the active 
metabolite DB820 (Figure 2). Metabolites M1A and M1B attained the highest concentrations 
during the initial 20 minutes of incubation after which M3 became the metabolite with the highest 
concentration in the drug/liver microsome mixture (Figure 2). 
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Figure 2: HPLC/UV chromatograms and concentration-time profiles of DB844/metabolites 
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following incubation of DB844 with male vervet monkey liver microsomes. A: HPLC/UV 
chromatograms; B: Concentration-time profiles of DB844 and metabolites. Incubation mixtures (1 
ml at pH7.4, in triplicate) contained 10 µM DB844 and 0.2 mg/ml monkey liver microsomes. 
Aliquots were taken at 0.2, 5, 15, 30, and 120 min and evaluated for concentrations of DB844 and 
six metabolites (M1A, M1B, M2A, M2B, M3, and DB820). Metabolites M4A and M4B were not 
quantified due to lack of synthetic standards 
 
Toxicity 
Uninfected monkeys were orally dosed with DB844 at 5, 10 or 20 mg/kg/day for 10 days. 
The lowest, 5 mg/kg, did not elicit adverse clinical signs of toxicity in 2/2 monkeys (Table 1).  
Overt toxicity was however observed in 1/2 and 2/2 monkeys to which DB844 was administered at 
10 and 20 mg/kg, respectively (Table 1). In the high dose group, overt toxicity was confirmed, at 
the earliest, after eight daily doses (cumulative dose [CD] = 160 mg/kg). Drug administration to 
these monkeys was immediately withdrawn to allow clinical recovery which, however, did not 
occur. As a result, the monkeys were humanely euthanized 1-2 days later (9-10 days post first 
dosing) (Table 1). Both monkeys from the middle (10 mg/kg) dose group completed the 10-day 
dose regimen successfully (CD = 100 mg/kg) after which 1/2 developed signs of overt toxicity and 
was eventually euthanized 16 days post first dosing (Table 1). The adverse clinical events included 
anorexia, gastrointestinal disturbances (vomiting or changes in stool consistency), jaundice and 
weight loss of up to 10.5% (Table 1). Haematology revealed nothing significant except for vervet 
578 (10 mg/kg); in this monkey, the red cell distribution width (RDW) rose from 15 to 18.4 (23%) 
while mean corpuscular volume (MCV) rose from 76.6 to 86.9fl (13%). At histopathology 
examination, lesions observed included inflammation and erosions of the gastrointestinal tract 
(GIT), fatty change (steatosis) in the liver, hydropic degeneration of renal tubular cells and 
haemorrhage and haemosiderosis in multiple organs (Table 1). Toxicokinetic analysis revealed that 
in the two monkeys that were dosed at 5 mg/kg, DB844 and DB820 achieved average 
concentrations of 215 nM and 41.6 nM respectively at 1 h post last dosing. However, other 
toxicokinetic measurements could not be determined due to the limited sampling. 
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Table 1: Adverse events in monkeys treated orally with DB844. 
 
Parameters evaluated I: DB 844 at 5 mg/kg x 10 
days orally 
II: DB844 at 10 mg/kg x 
10 days orally 
III: DB844 at 20 mg/kg x 
10 days orally 
572F 582M 541F 578M 543F 606M 
Adverse clinical 
events 
Reduced feed intake None None Yes (11) Yes (14) Yes (8) Yes (9) 
 GIT changes None None None Yes (16) Yes (8) Yes (8) 
 Jaundice None None None yes yes yes 
 % weight loss 1.8 4.9 4.6 10.5 9.1 6.5 
 Daily doses completed 10/10 10/10 10/10 10/10 8/10 8/10 
 Euthanised due to 
toxicity 
No No No Yes (16) Yes (9) Yes (10) 
Liver histology Fatty change (Steatosis) NA NA NA +++ +++ +++ 
 Inflammation  NA NA NA ++ ++ +++ 
 Focal necrosis NA NA NA +++ +++ +++ 
 Haemosiderosis NA NA NA ++ + +++ 
GIT histology Ulcers/erosions NA NA NA +++ +++ +++ 
 Inflammation NA NA NA +++ +++ +++ 
 Haemosiderosis NA NA NA ++ + +++ 
Spleen histology Expanded red pulp NA NA NA +++ ++ ++ 
 Haemosiderosis NA NA NA +++ +++ +++ 
Kidney histology Hydropic degeneration/ 
interstitial oedema 
NA NA NA +++ + + 
Key: GIT = gastrointestinal system; numbers in parenthesis = time in days post first drug dose when an adverse clinical event was observed; NA 
= not assessed since the monkeys were not euthanized; F = female; M = male 
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Progression of the T.b. rhodesiense Infection 
The pre-patent period of the experimental T. b. rhodesiense infection in both groups of 
monkeys was approximately 5-6 days (Table 2). Parasitaemia rose to a peak of 5.0 x 107 
trypanosomes (antilog 7.7) within 2-3 days (7-8 DPI) but subsequently fluctuated to give 
characteristic waves of parasitaemia (Figure 3). Monkeys developed a classical T. b. rhodesiense 
clinical disease characterised by reduction in feed intake, raised hair coats, reduced activity, 
dullness and/or excitability when the clinical signs were first observed at 4-7 DPI. Anorexia and 
inactivity were transient, lasting a maximum of 3 days before normal appetite and activity were 
regained. Enlargement of peripheral lymph nodes (especially axillar and inguinal lymph nodes) and 
splenomegaly (up to 3 times compared to pre-infection) were also observed 7-14 DPI while facial, 
scrotal or eyelid oedema were observed in 8/16 (50%) of the infected monkeys from 20 DPI. 
Average (± SE) weight before infection was 3.6 ± 0.4 (range = 2.6-5.5) and 3.1 ± 0.3 (range = 2.3-
4.2) kg for group I and II, respectively. Four weeks after infection, weight decreased significantly 
(p = 0.0003) by 6.4% and 5.6%, respectively. Time to parasitization of the cerebrospinal fluid 
(CSF) was a median 21 days (range = 7-27) for both groups of monkeys (Table 2). At 27 DPI, one 
day before initiation of treatment with DB844, trypanosome numbers ranged from 1-8/µl of CSF; 
median cell numbers were 5.0 (range = 0-45) and 6.0 (range =1-20) cells/µl of CSF in groups I and 
II respectively. During previous weekly samplings, white cell counts in some monkeys increased to 
152/µl of CSF (Table 2).  
 
Efficacy 
At 28 DPI when monkeys had shown characteristic features of 2nd stage infection (i.e., 
presence of trypanosomes and elevated white blood cell counts above 5/µl of CSF), they were 
treated with DB844 at 5 mg/kg x 10 days (group I) or 6 mg/kg x 14 days (group II).  At 24 h post 
third drug dose (i.e., 4th day of treatment), trypanosomes were not detected in wet smears of 
peripheral blood (Figure 3), showing that at least 100-fold reduction in parasitaemia had been 
achieved, from 107 to 105 trypanosomes/ml of blood which is the detection limit of the matching 
method of Herbert and Lumsden [23]. End of treatment (EoT) evaluation was conducted at 1 and 4 
days post last dosing time points. At the one day post dosing time point, trypanosomes were 
detected in some monkeys using sensitive trypanosome concentration techniques for both blood 
and CSF [25, 27] as evidenced by provisional cure rates of 7/8 (group I) and 5/7 (group II) (Table 
2). The three monkeys with persisting low numbers of trypanosomes in the blood and/or CSF 
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eventually tested negative at the 4 days post dosing time point (Table 2), demonstrating an EoT 
provisional cure rate of 100% for both groups. 
Post treatment follow-up was carried out for at least 300 days post dosing. During this 
follow-up period, nine monkeys relapsed demonstrating an overall test of cure rate of 3/8 (37.5%) 
and 3/7 (42.5%) for the 5 mg/kg and 6 mg/kg dose groups respectively (Table 2). Trypanosomes 
were observed exclusively in the CSF in five of the relapsed monkeys. In three of the four 
remaining relapse cases, trypanosomes were detected in the CSF earlier than in the blood. Overall, 
the median (range) time to trypanosome recrudescence was 133 (35-322, n = 9) days for CSF and 
261 (239-322, n =3) days for blood trypanosomes. Despite trypanosomes becoming cleared from 
the peripheral blood by eighth day of dosing, monkey 625 (Table 2) developed toxicity and was 
humanely euthanized 2 days after administration of 10th dose of DB844 at 6 mg/kg (CD = 60 
mg/kg). At post mortem examination, liver and gastrointestinal toxicity were observed, comparable 
to findings in 1/2 (10 mg/kg) and 2/2 (20 mg/kg) un-infected monkeys euthanized due to DB844 
toxicity. 
 
Haematology Changes in the Infected Monkey Model 
The trypanosome infection provoked a reduction in erythrocytes (red blood cells, RBC) and 
associated parameters. Average haemoglobin concentration declined by 32.1% in group II 
monkeys, from 13.4 ± 0.6 [95% CI = 12.4-15.1] g/dl at baseline (day 0) to 9.1 ± 0.6 [95% CI =7.9-
10.3] g/dl (p < 0.0001] at 27 DPI (Table 3). Erythrocyte counts and haematocrit concentration, 
declined significantly (p < 0.0001, Table 3) by 28.7% and 32.1%, respectfully. Mean corpuscular 
volume (MCV) and mean corpuscular haemoglobin (MCH) decreased significantly (p < 0.0001) 
(Table 3). Erythrocyte associated parameters of group I monkeys exhibited similar trends (data not 
shown), indicating that the infection caused a microcytic hypochromic type of anaemia. Monkeys 
also experienced significant thrombocytopenia and leucopaenia (Table 3) related to the 
experimental T. b. rhodesiense infection. Upon treatment with oral DB844, no drug related 
haematology changes were observed. Trypanosome induced anaemia, thrombocytopenia and 
leucopaenia resolved rapidly. Baseline white cells numbers were re-established by end of treatment 
while platelet and RBC associated parameters were re-established within seven and 28-63 days 
respectively (Table 3; Figure 4). 
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Table 2: Treatment outcome in monkeys treated with DB844 while in second stage T. b. rhodesiense infection 
Group Monkey 
ID 
PP (DPI) Time to CSF 
parasitization 
(DPI) 
Tryps/µl 
CSF at  
27 DPI 
WC/µl of 
CSF at 27 
DPI 
EoT test at 1 day 
post last dose 
EoT test at 4 days 
post last dose 
TOC test at  300 
days post last dose 
I 566 5 7 1 4 [17] Neg Neg Cured 
 568 5 27 1 45 [45] Neg Neg Cured 
 576 5 21 1 2 [12] Neg Neg Relapsed 
 599 6 14 8 39 [152] Pos Neg Relapsed 
 601 6 21 1 0 [6] Neg Neg Relapsed 
 603 6 21 1 6 [44] Neg Neg Relapsed 
 607 5 14 2 1 [28] Neg Neg Relapsed 
 609 6 21 1 8 [8] Neg neg Cured 
Median (range) 5.5 (5-6) 21 (7-27) 1(1-8) 5 (0-45) Cure rate = 7/8 
(88%) 
Cure rate = 8/8 
(100%) 
3/8 (37.5%) 
II 571 6 21 1 4 [11] Neg Neg Cured 
 596 5 7 1 8 [19] Neg Neg Cured 
 600 5 14 1 6 [6] Neg Neg Cured 
 624 5 7 1 4 [4] Pos Neg Relapsed 
 625 5 21 1 1 [20] WD 
 630 5 21 4 20 [20] Pos Neg Relapsed 
 652 5 21 2 10 [11]  Neg Neg Relapsed 
 653 5 28 2 6 [141] Neg Neg Relapsed 
Median (range) 5.0 (5-6) 21 (7-27) 1 (1-4) 6 (1-20) Cure rate 5/7 
(71%) 
7/7 (100%) 3/7 (42.5%) 
 
Key: ID = identity in the laboratory; PP = pre-patent period; DPI = days post infection; CSF = cerebrospinal fluid; Tryps = trypanosomes;  
WC = white cells; EoT = end of treatment; ToC = test of cure; Neg = Negative; Pos = positive; WD = withdrawn from the experiment after  
10th drug dose due to toxicity; Numbers in square brackets = maximum number of white cell counts observed during any of the four  
weekly samplings between 0 -27 DPI; I: DB844 5 mg/kg x 10 days per os; 28-37 DPI; II: DB844 6 mg/kg x 14 days per os; 28-41 DPI 
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Figure 3: Parasitaemia pattern in monkeys infected with T.b. rhodesiense KETRI 2537 
and subsequently treated with DB844. 
Symbols and error bars represent means and SEs, respectively, of 7 animals; monkeys 
were treated with DB844 at 6 mg/kg x 14 days, from 28-41 days post infection; Log 
parasitaemia values were determined by microscopic examination of wet smears of blood 
using the matching method of Herbert and Lumsden, 1976 [23]. 
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Table 3: Haematologic effects of T. b. rhodesiense KETRI2537 infection and treatment with DB844 in 
vervet monkeys 
Parameters Days post infection (days post last drug dose) 
 0 27 41 (0) 48 (7) 69 (28) 104 (63)  
RBC (x 106/µl) 5.8 ± 0.2 4.2 ± 0.2,  
p < 0.0001 
4.8 ± 0.3,  
p < 0.0001 
4.9 ± 0.2,  
p < 0.004 
5.5 ± 0.2,  
p = 0.55 
6.1 ± 0.3  
p = 0.02 
Hemoglobin (g/dl) 13.4 ± 0.6 9.1 ± 0.6,  
p < 0.0001  
11.2 ± 0.7,  
p < 0.0001 
11.5 ± 0.6,   
p < 0.0001 
12.8 ± 0.5,  
p = 0.15 
14.1 ± 0.8,  
p = 0.11 
Haematocrit % 43.9 ± 2.0 29.8 ± 1.7,  
p < 0.0001 
31.6 ± 1.6, 
p < 0.0001 
31.8 ± 1.6,  
p < 0.0001 
43.8 ± 1.6,  
p = 0.91 
46.7 ± 2.7,  
p = 0.91 
Mean corpuscular 
volume (fl) 
78.2 ± 1.5 70.8 ± 0.8,  
p < 0.0001 
65.3 ± 0.9,  
p = 0.0001 
64.8 ± 0.9,  
p = 0.0001 
79.8 ± 1.4,  
p = 0.11 
77.0 ± 1.5,  
p = 0.21 
Mean corpuscular 
haemoglobin (g/dl) 
23.9 ± 0.4 21.6 ± 0.3,  
p < 0.0001 
23.0 ± 0.3  
p < 0.008 
23.3 ± 0.4  
p = 0.07 
23.4 ± 0.6,  
p = 0.13 
23.3 ± 0.5  
p = 0.21 
Platelet counts (x 
103/µl) 
346.5 ± 13.1 183.5 ± 24.6  
p = 0.002 
406.5 ± 22.5 
p = 0.05 
390.7 ± 32.4, 
p = 0.11 
332.2 ± 11.9, 
p = 0.78 
294.3 ± 17.4 
p = 0.55 
WBC counts (x 
103/µl) 
5.8 ± 0.5 3.0 ± 0.4,  
p= 0.003 
7.1 ± 1.0,  
p= 0.12 
5.6 ± 1.2,  
p= 0.9 
5.9 ± 0.8,  
p = 0.8 
5.1 ± 0.1,  
p = 0.4 
 
Key: RBC = red blood cells; WBC = White blood cells; g/dl = grams/decilitre; fl = femtolitres; p-values 
< 0.05 indicate values that were significantly different from pre-infection baseline (day 0) values 
(Repeated measures Anova with Fishers PLSD post hoc test); Monkey were treated with DB844 at 6 
mg/kg x 14 days, from 28-41 days post infection 
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Figure 4: Changes in red cell distribution width in monkeys following infection and 
subsequent treatment with DB844. 
Symbols and error bars represent means and SEs, respectively, of seven monkeys that 
were treated with DB844 at 6 mg/kg x 14 days, from 28-41 days post infection. 
 
Clinical Chemistries 
Plasma from infected monkeys treated with DB844 at 6 mg/kg (group II) was 
analyzed for several biomarkers of liver and kidney function. Plasma aspartate 
aminotransferase (AST) did not change significantly following infection but peaked 
transiently during drug administration (Figure 5, Figure S1). At 24 hours post dosing, 
mean (± SE) plasma AST increased to 3.3 times above baseline, from 37.0 ± 4.8 IU [95% 
CI = 26.7-46.8] (day 0) to 121 ± 21.6 IU [95% CI = 65.5 -176.5, p = < 0.0001]. Mean 
plasma alanine aminotransferase (ALT) exhibited an increasing trend immediately after 
infection (day 0) and peaked after 7 daily drug doses (34 DPI) (Figure 5). At its peak, 
mean plasma ALT increased by 2.7 times above baseline, from 4.5 ± 0.9 IU [CI = 2.1-
6.9] (day 0) to 13.6 ± 3.8 IU [CI = 3.8-23.4; p = 0.008].  Aberrations in ALT resolved 
rapidly after treatment.  Monkeys further demonstrated a significant infection-related 
25.8% decrease in mean plasma albumin concentration, from 35.3 ± 1.9 [CI = 30.4-40.3] 
g/l at baseline to 26.2 ± 4.2 [95% CI = 15.4-37.0, p = 0.02] g/l at 27 DPI.  Plasma 
albumin concentration stabilized during the treatment period, then decreased transiently 
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to a nadir at 48 h post dosing (43 DPI, Figure 5).  Total bilirubin and direct bilirubin 
concentrations fluctuated in a pattern comparable to the transaminases (Figure 5), but 
none of the changes were statistically significant. Mean alkaline phosphatase was 6.3 
±1.9 at baseline and 4.1± 0.8 at 27 DPI (p = 0.25) and showed no significant changes 
both during and after drug administration. Two indicators of renal function, blood urea 
nitrogen (BUN) and creatinine, were evaluated. BUN indicated a mild and reversible 
decrease in kidney function from 48 h post dosing (43 DPI) (Figure 5). Mean plasma 
concentration of creatinine fluctuated in a similar pattern to BUN, but the change from 
baseline was not significant (data not shown). 
 
 
Figure 5: Transient infection and DB844 induced changes in clinical chemistry indicators of liver 
and kidney function.  
Symbols represent mean ± SE (n = 7) of aspartate aminotransferase (AST, ■), alanine 
aminotransferase (ALT, □), total bilirubin (●), direct bilirubin (0), blood urea nitrogen (BUN, ▲) 
and albumin (◊); monkeys were treated with DB844 at 6 mg/kg x 14 days, from 28-41 days post 
infection. 
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Pharmacokinetics 
Plasma and CSF collected from group II monkeys (6 mg/kg) were analyzed for 
various pharmacokinetic outcomes using traditional non-compartmental methods. After 
the last (i.e. 14th) dose of DB844, geometric mean (90% CI) concentrations of DB844 
peaked at 1 h in plasma with a Cmax of 430 (100-1800) nM (Table 4, Figure 6) with 
modest individual animal variations in PK profiles (Figure S2). The active metabolite, 
DB820, peaked at 4 h in plasma with a Cmax of 190 (110-320) nM. Exposure to DB820 
was three-fold higher than that of DB844, as assessed by the metabolite:parent AUC ratio 
(Table 4). DB844 concentrations decreased at a faster rate than DB820 concentrations, 
with a geometric mean (90% CI) apparent terminal elimination half-life of 5.8 (3.4-9.6) 
h. DB820 was detected in plasma up to 28 days after the last dose of DB844 with a 
geometric mean (90% CI) concentration of 35 (14-86) nM. Given the protracted decline 
in DB820 plasma concentrations, the duration of plasma collection was insufficient for 
accurate estimation of the terminal half-life of DB820 for all monkeys (Figure 6). DB844 
was detected in CSF 1 h post dose, with a geometric mean (90% CI) concentration of 17 
(7.3-39) nM, and was not detected thereafter. DB820 was not detected in the CSF, with 
only 2/7 monkeys (monkeys 571 and 624) showing sporadic low concentration (< 4 nM) 
between 24 and 96 h post dose. 
 85
Table 4: Pharmacokinetics of DB844 and DB820 in vervet monkeys after the 14th oral 
dose at 6 mg/kg (n = 7) 
Outcome Units DB844 DB820 
AUC(0-∞) nmol/L•day 70 (16, 290) NC* NC 
AUClast nmol/L•day 68 (16, 300) 1400 (760, 2500) 
Metabolite: 
Parent AUC 
Ratio 
NA -- -- 3 (1.1, 6.5) 
Cl/F L/day/kg 240 (56, 1000) NC NC 
Cmax nmol/L 430 (100, 1800) 190 (110, 320) 
t1/2 day 0.24 (0.14, 0.40) NC┼ NC 
Tmax day 0.04 (0.04, 0.17) 0.17 (0.08, 0.17) 
 
Key: Values are geometric mean (90% CI) except for metabolite:parent AUC ratio 
and Tmax, which are reported as median (range). Metabolite:parent AUC ratio was 
derived using the AUC from time zero to the last common time point for DB844 and 
DB820.; *% AUC extrapolated to infinite time >25%. ┼Duration of sample collection 
was insufficient to derive an accurate estimate of terminal half-life; AUC(0-∞), AUC 
from zero to infinite time; AUClast, AUC from time zero to the last measurable 
concentration; Cl/F, apparent (oral) clearance; Cmax, maximum concentration; t1/2, 
terminal half-life; Tmax, time to reach Cmax; NA, not applicable; NC, not calculable. 
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Figure 6: Plasma concentration-time profiles following oral administration of the last (14th) daily 
dose of DB844. 
Symbols and error bars represent geometric means and SEs, respectively, for DB844 (△) and 
DB820 (○). The monkeys (n = 7) were treated with DB844 at 6 mg/kg x 14 days, from 28-41 days 
post infection. The insert graph shows the extended profile up to 28 days post the last daily dose of 
DB844. 
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Figure S1: Individual monkey activity/concentration-time profiles of aspartate amino transferase 
and blood urea nitrogen in plasma.  
The monkeys were treated with DB844 at 6 mg/kg x 14 days, from 28-41 days post infection with 
T.b. rhodesiense KETRI2537. 
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Figure S2: Individual monkey concentration-time profiles of DB844 and DB820 in plasma. 
The monkeys were treated orally with DB844 at 6 mg/kg x 14 days, from 28-41 days post 
infection with T.b. rhodesiense KETRI2537. The insert graph shows the extended profiles 
up to 28 days post the last daily dose of DB844 
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DISCUSSION 
The current study has shown that the novel diamidine prodrug (DB844) was 
effectively metabolized by male vervet monkey liver microsomes to yield at least seven 
metabolites which were also detected when DB844 was incubated with human liver 
microsomes [13]. The order in which metabolites were generated in the monkey liver 
microsomal/drug mixtures and their relative concentrations, dominated by M1A 
(DB1284) and M1B (DB1058) within the first 20 minutes and by M3 (DB821) thereafter, 
were also similar to the pattern observed in human liver microsomes [13] suggesting that 
vervet monkeys would be a useful animal model for evaluation of a drug (DB844) that 
was in development as a potential therapeutic agent for a human disease (HAT). Our 
study did not investigate the enzymes responsible for the conversion of DB844 to DB820. 
It has however been previously shown that conversion of pafuramidine (DB289) to 
furamidine (DB75) was catalysed by cytochrome P450 enzymes and cytochrome b5/b5 
reductase in the human liver [22, 29]. Liver microsomes derived from female vervet 
monkeys and Cynomolgus monkeys metabolized DB844 as efficiently as those derived 
from male vervets (data not shown), thus justifying evaluation of DB844 in monkeys. 
 
The prodrug (DB844) was well tolerated when tested in uninfected vervet 
monkeys at the lowest dose (5 mg/kg x 10 days) but was toxic to both monkeys when 
administered at the highest dose (20 mg/kg x 8 days). The middle dose (10 mg/kg x 10 
days) was well tolerated by 1/2 monkeys, suggesting that this dose was slightly more than 
the maximum tolerated dose in uninfected monkeys. Clinical signs of overt toxicity were 
detected either after completion of dose regimen (10 mg/kg group) or late into the 
treatment regimen (20 mg/kg group), suggesting that overt toxicity was dependent on 
both the daily drug dose and duration of drug administration. These results were 
consistent with a previous report in which several pentamidine derivatives were 
associated with acute to chronic toxicity in rodents, which was cumulative in nature with 
respect to drug exposure [30]. The no observed adverse effects level (NOAEL) for oral 
DB844 in un-infected monkeys was therefore in the range 5 - < 10 mg/kg, and as a result, 
daily dose levels of 5 and 6 mg/kg were chosen for the subsequent efficacy study.  
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DB844/DB820 concentrations in plasma samples from un-infected monkeys (5 
mg/kg group), though limited in scope, demonstrated that the prodrug was absorbed after 
oral administration and converted to the active metabolite (DB820). Similarly, when 
Cynomolgus monkeys were dosed orally with DB844 at 3 or 10 mg/kg, the drug was 
absorbed and the resulting plasma DB844/DB820 concentration-time profiles were 
comparable to those achieved in mice that were dosed at 25 and 100 mg/kg, respectively 
(Michael Z. Wang, personal communication). These findings were significant since 
DB844 at 25 or 100 mg/kg was subsequently determined to be curative for 1st and 2nd 
stage experimental murine HAT infections respectively [11], suggesting that 
comparatively low dose levels could be efficacious in primates. A period of dosing of 10-
14 days was selected for the vervet DB844 efficacy study, partly informed by a report 
that during clinical trials of the related 1st stage investigational HAT drug DB289, the 
duration of dosing had to be increased from 5 to 10 days in order to increase efficacy 
(Sonja Bernhard, Personal communication). In addition, the fact that in humans 2nd stage 
HAT is treated for 10 days with melarsoprol or NECT) and 14 days with intravenous 
eflornithine [4] was considered since these dosing periods are partly influenced by the 
tissue invasive nature of the human infective parasites. 
 
Oral DB844 achieved up to 43% cure rate in the vervet monkey model of 2nd 
stage HAT. Prior to initiation of treatment at 28 DPI, all 16 monkeys in this study were 
confirmed to have trypanosomes and pathological white cell numbers in their CSF, 
confirming that the model fulfilled the criteria for classification of CNS (late, 2nd) stage 
disease [4]. Pathophysiology studies have shown that trypanosome entry into the CSF 
initiates meningitis and leads to elevated CSF nitric oxide and IgM concentrations, all 
further indicating CNS disease [31, 32].  Although occurrence of histologically 
demonstrable meningoencephalitis may not be guaranteed in the course of primary T. b. 
rhodesiense infections [31, 33], previous studies have shown that when treatment was 
initiated at 28 DPI in this monkey model, pafuramidine (DB289) and pentamidine did not 
cure any monkey ([12]; unpublished TRC-KARI data).  The data reported in this study, 
therefore, indicates that DB844 had an improved activity in the CNS stage monkey model 
compared to the other diamidines. 
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Biological activity of orally administered chemotherapeutic agents against tissue 
invasive parasites such as T. b. rhodesiense is dependent upon absorption in the gut and 
attainment of effective exposure levels of the prodrug and/or active metabolites in body 
fluids and tissues. Pharmacokinetic evaluation of efficacy study (6 mg/kg group) 
monkeys confirmed that marked DB844 concentration was attained in plasma within 1 hr 
of the last dose. Peak plasma levels of DB820 were attained within 4 h post last dosing 
showing that metabolic conversion of DB844 to DB820 was comparable to previous 
observations in rats and cynomolgus monkeys involving the related prodrug/active 
metabolite pair, DB289/DB75 [34]. The peak plasma concentrations of the active drug 
(DB820) were 37 times (190/5.2) higher than the IC50 for T. b. rhodesiense STIB900; the 
DB820 concentrations remained at least 19 times (100/5.2) higher than the IC50 for T. b. 
rhodesiense STIB900 for at least 48 h post dosing, suggesting that alternative dose 
regimens in which the drug was dosed once every two days may be sufficient for 
bloodstream trypanosomes. The plasma Cmax achieved by DB844 in our study was 
significantly higher than the 30-35 nM Cmax values obtained when DB289 was dosed 
orally to cynomolgus monkey at 5 mg/kg [34]), consistent with similar observations 
when both DB844 and DB289 were dosed to mice [35]. 
 
Detection of DB844 in the CSF indicated BBB penetration and was likely 
responsible for observed reduction in trypanosome densities in CSF of all monkeys to 
below the limit of detection for varying periods and eventual cure of 3/7 (43%) group II 
monkeys. The active metabolite (DB820) was, however, detected only sporadically in 
CSF of two of the group II monkeys, one of which was eventually cured and one of 
which was not. The discordance between the CSF PK data and observed activity may 
result from three possibilities: i) No CSF samples were collected between 1-24 h post 
dosing. The reduced sampling time points, though justified due to ethical considerations, 
may have resulted in underestimation of DB820/DB844 in CSF; ii) Some of the 
intermediate metabolites of DB844, including the monoamidines DB1212, DB1285, 
M4A and M4B have been shown to have anti-trypanosomal activity in vitro [11]. 
Unfortunately, these were not quantified in the vervet CSF in our study; iii) trypanosomes 
were shown to be capable of accumulating DB820 and DB75 up to 15,000 times above 
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mouse plasma concentrations [36], suggesting that trypanocidal drug concentrations 
could accumulate and reduce the density of trypanosomes in CSF despite low 
concentrations of the active metabolite/s.  
 
Trypanosome recrudescence in the CSF preceded that in the blood (133 vs. 261 
days), indicating that CSF/CNS remained a major sanctuary/source of relapse 
trypanosomes despite the improved efficacy of DB844 compared with other diamidines. 
This was consistent with the generally low CSF: plasma ratio of 1:27 (3.7%) for DB844 
at 1 h post last dosing. In addition, and in spite of the limitations highlighted above, that 
DB820 was hardly quantified in CSF while it was detected in plasma in relatively high 
concentrations, accounts for the observation that trypanosomes were eliminated more 
rapidly from the blood than from the CSF (data not shown). An alternative dosing 
regimen in which higher daily DB844 doses were administered once every two days as 
discussed above could possibly result into more DB844/DB820 crossing the BBB and 
improve CNS activity as observed in the GVR 35 mouse model [11].  The rationale for 
higher daily drug doses would be based on the fact that drug transport across BBB is 
influenced by concentration dependent passive diffusion, presence of efflux aiding P-
glycoprotein transporters or multidrug resistance-associated protein transporter [37, 38]. 
Importantly, however, structure activity relationship studies need to be continued to 
identify molecules with superior activity against second stage HAT. 
 
No DB844-related haematological aberrations were observed in the infected 
monkey model, indicating that low doses (5 and 6 mg/kg) were safe. Erythrocyte and 
platelet associated parameters recovered rapidly indicating that erythropoesis and 
thrombocytogenesis remained robust. White blood cells were similarly not adversely 
affected, suggesting that DB844 was not myelotoxic. However, trypanosome-induced 
anaemia, thrombocytopenia and leucopoenia were observed. These are common features 
of experimental T.b. rhodesiense infections in monkeys [12, 21, 39] and natural HAT 
infections in humans [40-42] whose severity is determined by parasite virulence, time lag 
from infection to therapeutic intervention and individual host differences. The 
haematology changes before treatment were comparable to those reported in previous 
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infections with the KETRI2537 stabilate, indicating good reproducibility of the monkey 
model. Furthermore, resolution of haematology aberrations such as haemoglobin 
concentration and RDW was clearly related to treatment showing that these were 
additional indicators of therapeutic efficacy. In un-infected monkeys, the low dose 
regimen (5 mg/kg x 10 days) similarly did not manifest haematologic toxicity. At high 
doses (> 10 mg/kg), however, bleeding and haemosiderosis were observed in multiple 
organs possibly due to damage of endothelial membranes, increased sequestration of 
damaged erythrocytes and their subsequent destruction by tissue macrophages [43, 44]. 
 
Clinical chemistry results (group II, efficacy study) showed modest (2-3 fold) 
increases in plasma transaminases (AST and ALT) but not alkaline phosphatase, 
consistent with hepatocellular pathology. Importantly, these elevations in transaminases 
were reversible within 4-7 days after the last drug dose, indicating that they were likely 
caused by transient changes in the permeability of hepatocyte cell membranes (rather 
than necrosis). In contrast high doses (> 10 mg/kg) caused significant hepatotoxicity that 
was mainly characterized by fatty degeneration (steatosis), focal necrosis, mononuclear 
infiltration and haemorrhages. Steatosis is a common toxicity of many other drugs, 
including tetracyclines, corticosteroids, non-steroidal anti-inflammatory drugs and 
diamidines [45-48]. Steatosis in the un-infected monkeys was likely caused by 
impairment of mitochondrial fatty acid ß-oxidation causing microvesicular steatosis and 
resulting in accumulation of lipid vesicles in the cytoplasm of hepatocytes as previously 
reported for other drugs [45-48]. 
 
Analysis of clinical chemistry indicators of renal pathology in efficacy group II (6 
mg/kg) monkeys revealed that blood urea nitrogen (BUN) was minimally elevated while 
plasma creatinine was not, indicating that kidney function was only transiently affected. 
In contrast, histopathology results from the un-infected monkeys revealed evidence of 
renal tubular degeneration in the 10 and 20 mg/kg, showing that a more significant renal 
pathology resulted from the higher drug doses. Similarly, no lesions were seen at low 
doses in the GIT while moderate to severe gastroenteritis were observed at high doses. 
Overall therefore, toxicity was dose-dependent and, taken together with results of the 
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efficacy study, indicated that there was a lack of therapeutic window for DB844. As a 
result of toxicity, alternative dose regimens to improve efficacy were not attempted. 
 
In summary, this study showed that the prodrug DB844 achieved a moderate cure 
rate in the vervet monkey model of 2nd stage HAT, which was in contrast with studies in 
mice in which much higher DB844 doses (ie 100 mg/kg x 5 days) were tolerated and 
cured all 5/5 mice [11]. This is perhaps the main reason why new chemical entities 
(NCEs) that are targeted against HAT are preferably evaluated in both rodent and 
monkey models to obtain a more comprehensive understanding of safety, efficacy and 
pharmacokinetics before being forwarded for clinical trials in man. Although further 
development of DB844 against 2nd stage HAT was discontinued due to the lack of a 
therapeutic window, DB844 has demonstrated that structural modifications of amidines 
could eventually result in molecules with promising CNS activity at tolerated dose levels. 
Indeed, novel amidine analogues with better efficacy and safety profiles have been 
identified and are currently being evaluated in this vervet monkey model of HAT, which 
will be reported in due course.  
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ABSTRACT 
There are no oral drugs for human African trypanosomiasis (HAT, sleeping 
sickness). A successful oral drug would have the potential to reduce or eliminate the need 
for patient hospitalization, thus reducing healthcare costs of HAT. The development of 
oral medications is a key objective of the Consortium for Parasitic Drug Development 
(CPDD). In this study, we investigated the safety, pharmacokinetics, and efficacy of a 
new orally administered CPDD diamidine prodrug, 2,5-bis[5-(N-methoxyamidino)-2-
pyridyl]furan (DB868, CPD-007-10), in the vervet monkey model of first stage HAT. 
DB868 was well tolerated at a daily dose up to 30 mg/kg for 10 days, a cumulative dose 
(CD) of 300 mg/kg. Mean plasma levels of biomarkers indicative of liver injury (alanine 
aminotransferase, aspartate aminotransferase) were not significantly altered by drug 
administration (p > 0.05). In addition, no kidney-mediated alterations in creatinine and 
urea concentrations were detected. Pharmacokinetic analysis of plasma confirmed that 
DB868 was orally available and was converted to the active compound DB829, in both 
uninfected and infected monkeys. Treatment of infected monkeys with DB868 began 7 
days post-infection. In the infected monkeys, DB829 attained median Cmax values that 
were 12- (3 mg/kg for 7 days), 15- (10 mg/kg for 7 days), and 31-fold (20 mg/kg for 5 
days) greater than the IC50 (14 nmol/L) against T. b. rhodesiense STIB900. DB868 cured 
all infected monkeys, even at the lowest dose tested (3 mg/kg x 7 days; CD = 21 mg/kg). 
In conclusion, oral DB868 cured monkeys with first stage HAT at a cumulative dose 14-
fold lower than the maximum tolerated dose and thus, should be considered a lead 
preclinical candidate in efforts to develop a safe, short course (5-7 days), oral regimen for 
first stage HAT. 
 
 
Key words: human African trypanosomiasis; prodrug; diamidine; DB868; preclinical 
candidate; vervet monkeys; efficacy; toxicity; pharmacokinetics; pentamidine. 
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AUTHORS SUMMARY 
Development of orally administered medicines for human African 
trypanosomiasis (HAT) would potentially reduce the need for hospitalization of patients, 
thus lowering the cost of healthcare. In this study we investigated the potential of a novel 
diamidine prodrug, DB868 (CPD-007-10), to become an oral treatment for first stage 
HAT. When administered to uninfected monkeys by oral gavage, DB868 was well 
tolerated up to a maximum dose of 30 mg/kg/day for 10 days (total dose: 300 mg/kg). 
The compound (DB868) was confirmed to be absorbed from the monkeys’ alimentary 
canal and was successfully converted to the active compound (DB829) in concentrations 
that were potentially therapeutic for blood trypanosomes.  Subsequently, DB868 was 
evaluated for efficacy in the first stage vervet monkey model of HAT in which treatment 
was initiated at seven days post infection with T. b. rhodesiense KETRI2537. All the 
infected monkeys were cured, even at the lowest of the three dose regimens that were 
evaluated, 3 mg/kg/day for seven days (total dose 21 mg/kg), 10 mg/kg/day for seven 
days (total dose 70 mg/kg) and 20 mg/kg/day for 5 days (total dose 100 mg/kg). Analysis 
of plasma collected from the infected monkeys for drug levels revealed absorption of 
DB868 from the gut and subsequent conversion to the active compound (DB829) was 
comparable in both uninfected and infected monkeys. In view of its good safety and oral 
efficacy profile, we conclude that DB868 is a suitable candidate for development of a 
new treatment for first stage HAT. 
 104
INTRODUCTION 
Human African trypanosomiasis (HAT, sleeping sickness) is caused by two 
trypanosome species that are transmitted through the bite of blood-sucking tsetse flies 
(Glossina spp). Trypanosoma brucei (T. b.) gambiense is endemic to West and Central 
Africa, while T. b. rhodesiense is endemic to East and Southern Africa [1]. The disease is 
focal in distribution and is marked by wide temporal and spatial variations in incidence 
and prevalence [2-4]. HAT is characterised by two clinical stages. During the first (early, 
haemolymphatic) stage, trypanosomes proliferate at the site of the fly bite, travel to local 
lymph nodes and bloodstream, and progressively invade other tissues [5]. Approximately 
3-4 weeks post-infection with T. b. rhodesiense, or months to years with T. b. gambiense, 
trypanosomes invade the central nervous system (CNS), initiating the second (late, 
meningo-encephalitic) stage of HAT [5]. Second stage HAT is marked by neurological 
and endocrine disorders. If patients are not treated, they lapse into coma and die [6]. 
 
HAT chemotherapy is stage specific. Only two drugs have been approved for the 
treatment of first stage HAT, pentamidine and suramin. Pentamidine, a diamidine first 
used clinically in 1941, is used to treat first stage T. b. gambiense infections. Suramin, a 
naphthylurea first introduced for clinical use in 1921, is effective against both 
trypanosome species but is mainly used against first stage T. b. rhodesiense HAT [7,8]. 
Pentamidine is associated with hypoglycaemia, pain at the injection site, diarrhoea, 
nausea and vomiting, while suramin is associated with hypersensitivity reactions, 
albuminuria, haematuria and peripheral neuropathy [7]. In addition, these drugs must be 
administered via intramuscular injection or intravenous infusion in well-equipped 
hospitals, which are not readily available or accessible in rural areas where HAT typically 
occurs. To overcome these limitations, two orally active compounds, fexinidazole and the 
oxaborole SCYX-7158, have recently entered clinical development to treat both stages of 
the disease [9]. In addition, efforts by the Consortium for Parasitic Drug Development 
(CPDD) to address these limitations have resulted in the synthesis of a collection of 
diamidines with promising pharmacologic properties [10,11]. 
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One of the new aza diamidines, 2,5-bis(5-amidino-2-pyridyl)furan (DB829; 
Figure 1), exhibited an IC50 of 14 nmol/L against T. b. rhodesiense STIB900 in vitro [12]. 
In addition, it was shown to be 100% curative in both the acute (T. b. rhodesiense 
STIB900) and chronic CNS (T. b. brucei GVR35) mouse models of HAT after 
intraperitoneal administration [12]. However, the dicationic nature of DB829 and other 
diamidines (e.g., pentamidine and furamidine) contributes to poor permeation through 
biologic membranes and in turn, poor systemic exposure after oral administration [13]. 
As such, a prodrug of DB829 was designed, 2,5-bis[5-(N-methoxyamidino)-2-
pyridyl]furan (DB868; Figure 1), by masking the cationic functionalities of the active 
compound with methoxy groups [14]. Oral administration of DB868 was 100% curative 
in both the acute and chronic CNS mouse models of HAT [12]. Based on these desirable 
properties, DB868 progressed into our vervet monkey model to assess its potential as a 
new lead compound for oral treatment of first stage HAT. The purpose of this study was 
to evaluate DB868 metabolism in monkey liver microsomes, safety in uninfected 
monkeys, pharmacokinetics in both uninfected and infected monkeys, and efficacy in 
infected monkeys. 
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MATERIALS AND METHODS 
Ethics 
This study was conducted in accordance with experimental guidelines and 
procedures (Ref: C/TR/4/325/116) approved by the Institutional Animal Care and Use 
Committee (IACUC) at the Kenya Agricultural Research Institute’s Trypanosomiasis 
Research Centre (KARI-TRC). These IACUC regulations conformed to national 
guidelines provided by the Kenya Veterinary Association. 
 
Trypanocidal Test and Comparator Drugs 
The test drug, 2,5-bis[5-(N-methoxyamidino)-2-pyridyl]furan diacetate (DB868; 
CPD-007-10; Lot #2-JXS-28; Base MW = 366.37; FW = 564.37), was supplied by the 
University of North Carolina-led CPDD as a yellow powder stored in opaque, water tight 
bottles. In the laboratory, the drug-containing vials were wrapped in aluminium foil as 
further protection from light and stored at room temperature. The drug was dissolved 
fresh daily in distilled de-ionised water (pH 4.5 ± 0.2) at concentrations permitting 
administration of 2 mL/kg body weight per oral administration. For example, a 15 
mg/mL dose solution was prepared for animals receiving a dose of 30 mg/kg and a 10 
mg/mL dose solution for a dose of 20 mg/kg. Pentamidine isethionate, supplied by the 
World Health Organization (WHO), was used as the comparator drug. Pentamidine was 
dissolved in sterile distilled water and administered intramuscularly at 0.5 mL/kg body 
weight. 
 
 
Figure 1. Structures of the prodrug (DB868) and active compound (DB829). 
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Experimental Animals 
Eighteen vervet monkeys, also known as African green monkeys or Chlorocebus 
(Cercopithecus) aethiops, weighing from 2.0 to 4.5 kg, were acquired from the Institute 
of Primate Research in Kenya. To ensure animal welfare and ameliorate suffering, upon 
arrival at KARI-TRC, the monkeys were subjected to standard quarantine procedures, 
including screening for zoonotic and non-zoonotic diseases/infections and treatment for 
both endo- and ectoparasites, for a minimum of 90 days prior to study commencement as 
previously described [15,16]. They became accustomed to staying in individual squeeze-
back stainless steel cages during this time. The monkeys were maintained on a diet of 
fresh fruits and vegetables (bananas, tomatoes, carrots and green maize) and commercial 
monkey cubes (Unga Feeds®, Nakuru, Kenya) fed twice daily, and were given water ad 
libitum. The commercial monkey cubes were manufactured to have the following nutrient 
composition: crude protein, 19.4% (w/w); crude fiber, 5.6% (w/w); ether extracts that 
include fats and lipids, 4.2% (w/w); and nitrogen-free extracts, 66.5% (w/w).  
 
Metabolism of DB868 in Vervet Monkey Liver Microsomes 
DB868 metabolism was studied in male vervet monkey liver microsomes 
(custom-prepared by XenoTech, LLC, Lenexa, KS, USA) by adapting a previously 
published method [17]. Briefly, incubation mixtures contained 10 µM DB868, 0.5 
mg/mL monkey liver microsomes, and 3.3 mM MgCl2 in 100 mM phosphate buffer (pH 
7.4). Reactions were initiated by the addition of NADPH (1 mM final concentration). 
Control incubations were carried out without NADPH, DB868, or liver microsomes.  
Aliquots (100 µL) of the reaction mixtures were removed at 0, 5, 10, 15, 30, 60 and 120 
min and mixed with 100 µL of ice-cold acetonitrile. After centrifugation to pellet 
precipitated proteins, the supernatants were analyzed by HPLC/UV and fluorescence 
using the method previously described for pafuramidine (DB289) and furamidine (DB75) 
[18]. Metabolite identification was performed by comparing retention times to those of 
synthetic standards for M1 (DB1679), M2 (DB840), M3 (DB1712), and DB829. DB868 
and its metabolites were quantified using a calibration curve (0.1 – 10 µM) generated 
using synthetic standards. 
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Safety and Pharmacokinetics in Uninfected Monkeys 
Eight uninfected vervet monkeys, divided into two dose-groups of four monkeys 
(two females and two males) each, were used. Baseline weight and clinical and 
haematological data were collected over a 14-day period, after which the monkeys were 
orally administered DB868 at 10 mg/kg/day (group 1) or 30 mg/kg/day (group 2) for 10 
days (Table 1). Care was taken to avoid spillage and to minimise the time between drug 
preparation and dosing. Drug administration utilized a dose volume of 2 mL/kg body 
weight. The animals were monitored for indicators of overt toxicity, including changes in 
feed intake, weight, demeanour, posture and stool composition and consistency. Feed 
intake was assessed by scoring the proportion of the daily ration consumed by each 
monkey on a scale of 1 (full ration eaten), ¾, ½, ¼, and 0 (no feed eaten) as previously 
described [15]. To increase chances of detecting potential drug-related gastrointestinal 
toxicity, stool samples were collected and examined visually and by faecal occult blood 
tests conducted according to the modified guaiac method [19]. Post-last drug dose (LDD) 
monitoring extended to a minimum of 60 days. 
 
During pre- and post-dose monitoring, monkeys were anaesthetized by 
intramuscular injection of ketamine HCl (10-15 mg/kg) to facilitate physical 
examination, body weight measurements, and sample collection. Blood was collected 
from the femoral vein via inguinal venipuncture as described previously [16] and divided 
into aliquots: 1 mL blood into EDTA-containing tubes (1.5 mg EDTA/mL blood) for full 
haemogram determination and 2 mL blood into EDTA-containing tubes for plasma 
separation. Plasma was separated using a cool spin centrifuge (1500 rpm for 10 min at 
4°C). The harvested plasma was divided into aliquots for clinical chemistry 
determinations (500 µL), prodrug (DB868) and active compound (DB829) concentration 
measurement (150 µL), and preservation as a stock sample (approximately 250 µL). All 
plasma aliquots were frozen at -20°C before analysis. 
 
Efficacy and Pharmacokinetics in Infected Monkeys 
 The efficacy of DB868 administered orally at 20 mg/kg/day for 5 days was 
compared to that of pentamidine administered intramuscularly at 4 mg/kg/day for 7 days. 
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To obtain an indication of dose response, DB868 also was evaluated at 10 and 3 
mg/kg/day, administered orally for 7 days. The 10 and 3 mg/kg dose regimens were 
evaluated at a time when a regulator-imposed freeze on the acquisition of non-human 
primates was in force, hence only 2 animals were available per dose group. In each 
experiment, a 14-day baseline data collection period was observed, after which the 
monkeys were infected by intravenous injection of 104 T. b. rhodesiense KETRI 2537 
trypanosomes diluted from the infected blood of immuno-suppressed donor Swiss white 
mice [16]. Post-infection monitoring for the development of parasitaemia was initiated at 
three days post-infection (DPI) while treatment began 7 DPI, subsequent to confirmation 
of first stage HAT (defined as trypanosomes detectable in blood and not cerebrospinal 
fluid [CSF], and CSF white cell counts less than 5 cells/mm3) [16]. Ear-prick blood 
samples to determine parasitaemia were collected prior to daily drug administration. 
Clinical and parasitological cure was evaluated for at least six months as previously 
described [16]. In our studies with the related prodrug DB844, plasma samples collected 
out to 28 days post-LDD (6 mg/kg) were insufficient to recover a robust estimate of the 
elimination half-life of the active compound DB820 [20]; therefore, in the current study, 
plasma samples were collected for at least 60 days post-LDD for pharmacokinetic 
analysis. Haematology samples were analysed using an AC3diffT Coulter Counter (Miami, 
FL, USA). Clinical chemistry determinations were performed using a Humalyzer 
analyser system. Plasma was analyzed for prodrug and active compound concentrations 
using high performance liquid chromatography-tandem mass spectrometry (HPLC-
MS/MS) as described below. 
 
Handling of Moribund Infected Monkeys 
 Monkeys that were deemed as treatment failures/relapses or developed severe 
adverse clinical signs as defined in the protocol (e.g., inability or reluctance to perch, less 
than ¼ of normal daily feed intake for 2-3 consecutive days) were immediately 
withdrawn from the study and humanely euthanized for post-mortem examination. These 
monkeys were euthanized by intravenous administration of 20% (w/v) pentobarbitone 
sodium solution (150 mg/kg body weight; Euthatal®; Rhône-Mérieux, United Kingdom).  
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HPLC-MS/MS Quantification of DB868 and DB829 in Monkey Plasma 
Monkey plasma samples were processed for quantification of DB868 and DB829 
using previously described methods [21,22] with modifications made to the transition and 
mass spectrometer parameters. DB868-d6P (DB868 with deuterated pyridyl rings; 30 nM) 
and DB829-d6 (DB829 with deuterated pyridyl rings; 30 nM) were used as internal 
standards and were supplied by the CPDD. Prodrug and active compound were separated 
on an Aquasil C18 HPLC column (50 × 2.1 mm, 5 µm; Thermo Fisher Scientific, 
Waltham, MA, USA) and quantified using an Applied Biosystems API 4000™ triple 
quadrupole mass spectrometer equipped with a Turbo V™ source and electrospray probe 
(Foster City, CA, USA). The following transitions (in positive ion mode) were used in 
multiple reaction monitoring scans: 367.1→320.2 (DB868), 373.7→323.2 (DB868-d6P), 
307.1→290.1 (DB829), and 313.2→296.2 (DB829-d6). Calibration standards and quality 
controls were prepared in blank monkey plasma to mimic the matrix of the unknown test 
samples. Analyte concentrations were reported only for those samples that were between 
the standards and controls that had an accuracy and precision within 100% ± 20%. If 
samples were below this range, data are reported as below the limit of quantification. 
Data below the limit of quantification were not used for the pharmacokinetic analysis. 
 
Data Analysis 
Data were analysed statistically using StatView for Windows Version 5.0.1 (SAS 
Institute Inc., Cary, NC, USA) as previously published [20]. Repeated measures 
ANOVA, with Fisher’s PLSD post hoc test, was used to test the effects of trypanosomal 
infection, as well as DB868, on haematological and clinical chemistry parameters in 
comparison with respective baseline values (α = 0.05). Confidence intervals (95%) were 
derived to further test the significance of observed findings. The clinical data arising from 
the efficacy study are presented descriptively since the group sizes were too small for 
statistical analysis. Pharmacokinetic outcomes were determined with standard non-
compartmental methods using Phoenix WinNonlin (version 6.2; Pharsight, Mountain 
View, CA, USA). 
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RESULTS 
Conversion of Prodrug to Active Compound in Monkey Liver Microsomes 
The prodrug DB868 was metabolized in male vervet monkey liver microsomes to 
M1 (DB1679), M2 (DB840), M3 (DB1712), M4, and the active compound DB829 
(Figure 2). These metabolites were similar to those observed when DB868 was incubated 
with human liver microsomes [23]. Detection of these metabolites indicated that, like 
pafuramidine (DB289) and DB844, DB868 undergoes sequential O-demethylation and N-
dehydroxylation reactions to form the active compound DB829 in monkey liver 
microsomes. M2 (DB840), a bis-amidoxime metabolite, had the highest concentration at 
the end of the 120-min incubation. DB829 was at the limit of detection in UV mode; 
however, formation was confirmed by subsequent parallel fluorescence and mass 
spectrometric detection (data not shown). 
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Figure 2. HPLC/UV chromatograms (A) and concentration-time profiles (B) of the 
prodrug DB868, intermediate metabolites, and active compound (DB829) following 
incubation of DB868 with male vervet monkey liver microsomes.  
Incubation mixtures (1 mL at pH 7.4) contained 10 µM DB868, 0.5 mg/mL monkey liver 
microsomes, and 1 mM NADPH. Aliquots were removed at 1, 5, 15, 30 and 120 min, and 
analyzed for DB868, three intermediate metabolites (M1, M2, M3), and DB829 by 
HPLC/UV. Metabolite M4 was not quantified due to the lack of a synthetic standard. 
Symbols and error bars represent means and SDs of triplicate incubations. 
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Overt Toxicity and Haematology in Uninfected Monkeys 
Uninfected monkeys administered DB868 orally at 10 mg/kg/day for 10 days (n = 
4) did not exhibit any adverse clinical signs throughout the study. In addition, two of the 
four monkeys in the 30 mg/kg/day group did not display overt toxicity. The remaining 
two monkeys exhibited mild signs of toxicity, including excess mucous in the stool 
(monkey 567) and transient inappetance 1-2 days post-LDD (monkeys 567 and 546). In 
general, stool texture and consistency was unchanged and faecal occult blood tests 
revealed nothing significant in any study subject, suggesting that no notable 
gastrointestinal toxicity occurred. The mean body weight of monkeys in the 30 mg/kg 
group exhibited minimal variation (Figure 3), with a maximum decline of 6.5% from 
baseline (3.1 kg ± 0.3). A maximum decline of 6.2% from baseline (3.2 kg ± 0.5) was 
observed in the 10 mg/kg group (data not shown). Overall, the two oral DB868 dose 
regimens were well tolerated. 
 
Haematological parameters of the two treatment groups did not vary significantly 
from baseline throughout the study. For the 30 mg/kg group, the baseline mean red blood 
cell (RBC) and platelet counts (± SE) were 5.5 (± 0.1) x 106 and 3.7 (± 0.2) x 105 cells/µL 
of blood, respectively, and showed little change throughout the study (p = 0.10 and 0.06, 
respectively; Figure 3). Similarly, no significant variations were seen in the RBC or 
platelet counts for the 10 mg/kg group (data not shown). The mean white blood cell 
(WBC) count exhibited a minor transient increase post-LDD (1.5-fold over the baseline 
count (± SE) of 4.8 (± 0.5) x 103 cells/µL of blood; p = 0.05; Figure 3), which returned to 
baseline after 24 h. A comparable trend was seen in the WBC count of the 10 mg/kg 
group (data not shown), as well as in a separate monkey that was not administered drug 
or vehicle but had blood sampled at the same time as monkeys in the current experiment, 
suggesting that the change in the WBC count was not drug-related.  
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Figure 3. Changes in body weight and haematological parameters in un-infected vervet 
monkeys administered DB868.  
The monkeys (n = 4) were administered DB868 orally at 30 mg/kg/day for 10 days, between 
day -9 to day 0 post-last drug dose. Symbols and error bars represent means and SEs, 
respectively, of body weight, red blood cell count (RBC), white blood cell count (WBC), and 
platelet count (PLT). 
 
 
Clinical Chemistry 
Plasma biomarkers of liver injury, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and total and direct bilirubin, were monitored in uninfected 
monkeys prior to (baseline), during, and following completion of the 10-day DB868 
dosing regimens. At the two baseline time points (-16 and -10 days post-LDD), mean (± 
SE) ALT levels were 14.6 (± 3.1) and 11.1 (± 2.3) IU/L, respectively, for the 10 mg/kg 
group and 27.3 (± 13.0) and 16.0 (± 7.2) IU/L for the 30 mg/kg group. During and 
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following the completion of dosing, mean ALT levels varied considerably in the 10 
mg/kg group (Figure 4A). The highest post-treatment mean ALT values observed were 
2.8-fold (31.3/11.1) greater than the second baseline sample for the 10 mg/kg group and 
1.3-fold (20.5/16.0) for the 30 mg/kg group. Neither variation was statistically significant 
(p = 0.71, 10 mg/kg group; p = 0.37, 30 mg/kg group). Mean AST and total and direct 
bilirubin levels also exhibited variability prior to, during, and following dosing (Figure 4, 
B and C) but overall, were not statistically different from baseline values (p > 0.05). 
 
Two biomarkers of kidney injury, creatinine and urea, were also evaluated in 
plasma samples. Mean (± SE) creatinine concentrations at the two baseline time points 
were 63.6 (± 4.0) and 54.1 (± 5.5) µmol/L, respectively, for the 10 mg/kg group and 61.5 
(± 14.5) and 57.3 (± 6.0) µmol/L for the 30 mg/kg group. Post-dosing variations were 
minimal (Figure 5A) and not statistically significant (p > 0.05). However, mean urea 
levels exhibited a transient increase following the completion of each dosing regimen 
(Figure 5B; Figure S1). Plasma urea peaked 1-2 days post-LDD and was 2.1- and 2.7-
fold greater than baseline for the 10 mg/kg and 30 mg/kg groups, respectively (both p < 
0.05). To determine whether increases in plasma urea levels were due to kidney 
dysfunction, the blood urea nitrogen (BUN):creatinine ratio was calculated for the 1-2 
days post-LDD period. The peak mean urea concentration for the 10 mg/kg group was 
12.8 mmol/L, which is equivalent to 35.9 mg/dL of BUN. The mean creatinine 
concentration was 72.3 µmol/L (equivalent to 0.8 mg/dL). Therefore, the BUN:creatinine 
ratio was 45:1 (35.9:0.8). The BUN:creatinine ratio for the 30 mg/kg group was higher at 
48:1.  
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Figure 4. Changes in plasma biomarkers of liver injury in un-infected vervet monkeys 
administered with DB868.  
The two groups of monkeys (each n = 4) were  dosed with DB868 daily from -9 to 0 days 
post last drug dose. Symbols and error bars represent means and SEs, respectively of (A) 
Alanine aminotransferase (ALT), (B) Aspartate aminotransferase (AST) and (C) Total 
(T) and direct (D) bilirubin (BIL) levels.  
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Figure 5. Changes in plasma biomarkers of kidney injury in un-infected vervet monkeys 
administered with DB868.  
DB868 was administered orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 
days, between day -9 to day 0 post-last drug dose. Symbols and error bars represent 
means and SEs, respectively of (A) creatinine and (B) urea.  
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Pharmacokinetics in Uninfected Monkeys 
Following oral administration of the prodrug DB868 to uninfected monkeys, 
DB868 was detected in plasma at 4 h post-LDD (Figure 6; Table 1). DB868 
concentrations declined to below the limit of detection (BLD) within 1-2 days post-LDD 
for the 30 mg/kg group and in less than 1 day post-LDD for the 10 mg/kg group (data not 
shown). Accurate recovery of pharmacokinetic outcomes for DB868 was precluded for 
the 10 mg/kg dose group (Table 1). Greater inter-individual variability was observed for 
the 4 h post-LDD concentration (C4h) of DB868 than for DB829 (Table 1). The geometric 
mean DB868 C4h for the 30 mg/kg group (466 nmol/L) was 5.2-fold greater than that for 
the 10 mg/kg group (89 nmol/L). The geometric mean DB829 C4h for the 30 mg/kg group 
(320 nmol/L) was 1.6-fold greater than that for the 10 mg/kg group (185 nmol/L). The 
geometric mean AUClast and AUC0-∞ for DB829 in the 30 mg/kg group were 2.2-fold 
greater than that in the 10 mg/kg group. The geometric mean terminal elimination half-
life for DB829 was comparable between the two dose groups (29 and 31 days, 
respectively). 
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Figure 6. Plasma concentration-time profiles of the active compound DB829 following 
administration of the prodrug DB868 to un-infected vervet monkeys.  
DB868 was administered orally at 10 mg/kg/day (n = 4) or 30 mg/kg/day (n = 4) for 10 
days, between day -9 to day 0 post last drug dose. Symbols and error bars represent 
geometric means and SEs, respectively. The inset graph shows the plasma concentration-
time profiles starting at day 0 post-last drug dose on a logarithmic scale. 
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Table 1. Pharmacokinetics of DB868 and DB829 in un-infected vervet monkeys after the final (10th) oral dose of DB868 
Compound Outcome Units 
Oral DB868  
10 mg/kg x 10 days 30 mg/kg x 10 days 
  Monkey ID 643 659 675 677 546 567 668 679 
DB868 C4h nmol/L 50 130 39 250 1600 280 320 330 
 C24h nmol/L BLQ BLQ 6 BLQ 38 47 35 66 
 AUClast nmol/L•day NC NC NC NC 530 210 170 190 
 AUC0-∞ nmol/L•day NC NC NC NC 540 260 180 200 
 t1/2 day NC NC NC NC 1 1 1.3 0.4 
DB829 C4h nmol/L 240 160 180 170 290 300 270 440 
 C24h nmol/L 140 260 120 170 210 280 340 360 
 AUClast nmol/L•day 3000 2800 2100 2100 5700 4600 7100 4700 
 AUC0-∞ nmol/L•day 3700 3700 4100 2400 7000 6200 12100 5600 
 t1/2 day 30 30 55 18 24 29 47 22 
Key: C4h, concentration at 4h; C24h, concentration at 24 h; AUClast, area under the curve from time zero to the last measurable 
concentration; AUC0-∞, area under the curve from time zero to infinite time; t½, terminal elimination half-life; BLQ, below 
limit of quantitation; NC, not calculable. 
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Disease Progression and Efficacy 
Following inoculation, the median (range) prepatent period of T. b. rhodesiense 
infection in the monkeys was 4.5 (3-6) days (Table 2; Figure 7). The bloodstream form of 
T. b. rhodesiense KETRI 2537 trypanosomes multiplied rapidly, reaching a peak mean 
count of 1.1 x 107 trypanosomes/mL blood; in some monkeys, the count peaked as high 
as 1.3 x 108 trypanosomes/mL (antilog 8.1; Table 2). Classical signs of T. b. rhodesiense 
infection were observed, including rough hair coat, dullness, marked loss of appetite, and 
marginal declines in body weight (4% of pre-infection weight) and RBC count (7% of 
pre-infection value). Rectal body temperature increased from a pre-infection mean (± SE) 
of 38.3 (± 0.2)°C to a high of 38.7 (± 0.2)°C at 7 DPI; however, the increase was not 
statistically significant (p = 0.06). Trypanosomes were not detected, nor were white cell 
counts elevated in the CSF (data not shown), confirming that the monkeys were in the 
first stage of disease when treatment was initiated at 7 DPI. The prodrug DB868 was 
administered orally to three groups of monkeys: 20 mg/kg/day for 5 days (n = 3), 10 
mg/kg/day for 7 days (n = 2), or 3 mg/kg/day for 7 days (n = 2). A fourth group of 
monkeys (n = 3) was treated intramuscularly with the comparator drug, pentamidine, at 4 
mg/kg/day for 7 days (Table 2). Both oral DB868 and intramuscular pentamidine 
demonstrated efficacy against first stage infection as discussed below. Trypanosome-
associated waves of parasitaemaia were not observed (Figure 7), likely because all 
infections were treated during the first wave of parasitaemia. 
 
DB868 at 20 mg/kg/day x 5 days 
Three monkeys, 585, 658 and 686, were treated orally with DB868 at 20 
mg/kg/day for 5 days. In all monkeys, trypanosomes were undetectable in blood by direct 
microscopy or the haematocrit centrifugation technique [24] by the 4th day of drug 
administration. The monkeys remained trypanosome-free in body fluids (blood and CSF) 
for the remaining monitoring period (Table 2). Monkeys 686 and 585 were withdrawn 
from the study and humanely euthanized 4 and 145 days post-LDD, respectively (Table 
2), due to the continued deterioration of their health. Trypanosome recrudescence had not 
occurred in either monkey. Upon post-mortem examination, monkey 686 had peritoneal 
abscesses while monkey 585 had pneumonia, suggesting that their decline in health was 
 122
unrelated to drug therapy. The remaining monkey (monkey 658) was monitored over 525 
days post-LDD without any parasitological or clinical evidence of relapse and was 
declared cured. 
 
DB868 at 10 mg/kg/day x 7 days  
Upon treatment with 10 mg/kg/day DB868 orally for 7 days, monkey 691 was 
parasitologically negative on the 6th day of treatment while monkey 675 became 
consistently negative 7 days post-LDD. The two monkeys remained negative throughout 
the remaining post-treatment monitoring period (Table 2). Monkey 675, however, was 
only monitored up to 114 days post-LDD, at which time it was withdrawn from the study 
and euthanized due to clinical deterioration. Post-mortem examination indicated 
pneumonia to be the cause of declining health. Monkey 691 was monitored over 525 days 
post-LDD without a relapse and was declared cured. 
 
DB868 at 3 mg/kg/day x 7 days  
Two monkeys, 638 and 643, were treated orally with DB868 at 3 mg/kg/day for 7 
days. Monkey 638 was parasitologically negative on the 6th day of dosing, while monkey 
643 was 3 days post-LDD. Both monkeys remained trypanosome-free throughout the 
extended monitoring period of greater than 500 days and were declared cured (Table 2). 
 
Pentamidine at 4 mg/kg/day x 7 days  
Three monkeys, 541, 651 and 672, were administered pentamidine 
intramuscularly at 4 mg/kg/day for 7 days. Trypanosomes were not detected in monkeys 
541 and 651 immediately prior to the third dose. However, trypanosomes were observed 
intermittently in monkey 672, including 3 days post-LDD when its clinical condition 
deteriorated, necessitating euthanasia. Monkeys 541 and 651 were monitored over 600 
days post-LDD without any evidence of relapse and were declared cured (Table 2). 
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Figure 7. Changes in mean parasitaemia values of vervet monkeys infected with T. b. 
rhodesiense KETRI2537 and subsequently treated with DB868.  
Starting at 7 days post-infection, monkeys, confirmed to have first stage HAT, were 
treated with either DB868 orally or pentamidine intramuscularly. DB868 at 20mg/kg/day 
for 5 days (n = 2); DB868 at 10 mg/kg/day for 7 days (n = 2); DB868 at 3 mg/kg/day for 
7 days (n = 2); pentamidine at 4 mg/kg/day for 7 days (n = 3). Symbols and error bars 
represent means and interindividual differnces (range), respectively.  
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Table 2: Efficacy of oral DB868 and intramuscular pentamidine against 1st stage T. b. rhodesiense infection in vervet monkeys. 
Parameter/Outcome  
Oral DB868 Intramuscular Pentamidine 
20 mg/kg x 5 days 10 mg/kg x 7 days 3mg/kg x 7 days 4 mg/kg x 7 days 
Monkey ID 585 658 686 675 691 638 643 651 541 672 
Prepatent period (days post-
infection) 5 5 4 5 3 4 4 4 5 6 
Peak parasitaemia (Log10 P) 7.2 6.9 6.0 7.8 7.8 8.1 8.1 5.4 7.8 5.4 
Trypanosomes blood/CSF at EoT Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos 
Provisional efficacy at 100 days 
post-treatment  Cured Cured WD Cured Cured Cured Cured Cured Cured WD 
Duration of post-treatment 
monitoring  145 620 4 114 525 525 525 620 620 2 
Final efficacy assesment WD Cured WD WD Cured Cured Cured Cured Cured Not cured 
Key: P = parasitaemia; EoT = end of treatment; WD = withdrawn; Neg = negative; Pos = positive 
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Pharmacokinetics of DB868 and DB829 in Infected Monkeys 
The prodrug DB868 was detected in the plasma of all monkeys with first stage 
HAT, regardless of the dosing regimen, at 0.04 days (1 h) post-LDD (data not shown). 
The Tmax varied between individuals, with the majority (4/6 monkeys) occurring at 0.04 
days (1 h) post-LDD. DB868 concentrations declined rapidly. Only one monkey (monkey 
675; 10 mg/kg/day for 7 days) had detectable levels at 8 h post-LDD, precluding accurate 
recovery of pharmacokinetic outcomes for DB868. The median Cmax for DB829 for the 
20 and 10 mg/kg groups (435 and 205 nmol/L, respectively) were 2.6- and 1.2-fold 
higher, respectively, than that for the 3 mg/kg group (170 nmol/L) (Figure 8; Table 3). 
The median Tmax for the 20 and 3 mg/kg groups were similar (4 h), whereas that for the 
10 mg/kg group was longer (1 day). The median Tmax for DB829 in each dose group was 
longer than that for DB868. The mean AUClast for DB829 in the 20 and 10 mg/kg groups 
was 10- and 7-fold greater, respectively, than that in the 3 mg/kg group (Table 3). 
Accurate AUC0-∞ and terminal elimination half-life were only recoverable for the 20 
mg/kg group and one monkey in the 10 mg/kg group, precluding between-dose 
comparisons. The median AUC0-∞ and terminal elimination half-life for the 20 mg/kg 
group were twice those of the one (monkey 691) in the 10 mg/kg group (Table 3). 
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Figure 8. Plasma concentration-time profiles of the active compound DB829 following 
administration of the prodrug DB868 to vervet monkeys with first stage HAT.  
The monkeys were administered DB868 orally, beginning at 7 days post-infection, at 20 
mg/kg/day for 5 days, 10 mg/kg/day for 7 days,  or 3 mg/kg/day for 7 days, between day 
-9 to day 0 post-last drug dose. The inset graph shows the extended DB829 profiles up to 
150 days post-last DB868 dose. * denotes the time (4 days post-last drug dose) that 
monkey #686 was euthanized due to clinical morbidity (peritoneal abscesses).  
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Table 3: Pharmacokinetics of DB829 in vervet monkeys with first stage HAT after the 
final oral dose of BD868 
Outcome Units 
Oral DB868  
20 mg/kg x 5 days 10 mg/kg x 7 days 3 mg/kg x 7 days 
 Monkey ID 585 658 675 691 638 643 
Cmax nmol/L 370 500 210 200 110 230 
Tmax day 0.17 0.17 0.17 2.0 0.04 0.33 
AUClast† nmol/L•day 7300 4100 4000 3500 160 950 
AUC0-∞ nmol/L•day 10000 5300 NC 3900 NC NC 
t1/2 day 85 24 NC 25 NC NC 
Key: Cmax, maximum concentration; Tmax, time to reach maximum concentration; AUClast, 
area under the curve from time zero to the last measurable concentration; AUC0-∞, area 
under the curve from time zero to infinite time; t½, terminal elimination half-life; NC, not 
calculable due to >30% extrapolation of the AUC0-∞; † = last measurable concentration 
varied between monkeys (2-133 days). 
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DISCUSSION 
Consistent with observations involving human liver microsomes [23], vervet 
monkey liver microsomes metabolized the prodrug DB868 to four intermediate 
metabolites and the active compound DB829. Similar metabolic pathways have been 
reported for the related prodrugs pafuramidine and DB844 in rat, monkey and human 
liver microsomes [20,25-27], demonstrating that these alkoxy-type diamidine prodrugs 
[28] are converted to active compounds in different animal species. The low DB829 
concentrations in the microsomal samples were not unexpected, as similar results were 
observed with the active compound generated from the related prodrug pafuramidine 
[17]. The final metabolic steps in the formation of DB829, the N-hydroxylation of M2 
and subsequently M4, are analogous to those in the conversion of pafuramidine to 
furamidine. During microsomal pafuramidine metabolism, these steps are catalyzed by 
cytochrome b5/b5 reductase [29]. This enzyme is also abundant in mitochondria and 
Golgi [29,30], explaining why DB868 is more efficiently converted to DB829 in intact 
hepatocytes compared to the isolated microsomal system [27,31]. Collectively, these 
results provided justification for in vivo testing of the prodrug DB868 in uninfected and 
infected vervet monkeys.  
 
No significant overt toxicity was seen with up to 30 mg/kg/day DB868 orally for 
10 days (cumulative dose [CD] = 300 mg/kg) in the vervet monkey safety study, 
suggesting that this dose was below the maximum tolerated dose, but slightly above the 
no observed adverse effect level (NOAEL). Pharmacokinetic analysis of plasma from the 
uninfected monkeys showed that the geometric mean C4h of the active compound DB829 
in the 30 and 10 mg/kg groups were 23- and 13-fold greater than the IC50 (14 nmol/L) 
against T. b. rhodesiense STIB900, respectively. These results confirmed that 
DB868/DB829 are available systemically following oral administration, similar to 
pafuramidine/furamidine and DB844/DB820 [20,32], prompting further evaluation in the 
monkey model of first stage HAT. 
 
Based on the above observations, DB868 efficacy was evaluated in vervet 
monkeys with first stage HAT using doses below 30 mg/kg/day in order to minimise the 
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risk of unfavourable clinical outcomes. Dosing durations of 5-7 days were chosen based 
on the hypothesis that first stage disease can be cured using short treatment durations. 
DB868, administered orally, cured all monkeys of their experimentally introduced T. b. 
rhodesiense infection (Table 2). Post-treatment monitoring must be at least 180 days in 
order to declare a cure in the monkey model of first stage HAT [16]. All three DB868 
dosing regimens, including the lowest evaluated (3 mg/kg/day for 7 days; CD = 21 
mg/kg), effectively cleared the monkeys of their considerably high parasitaemia, which in 
some cases was as high as 108 trypanosomes/mL of blood. Elimination of the pathogens 
allowed the monkeys to return to their clinical and haematological baselines within one 
month post-LDD (data not shown), similar to what was observed in pafuramidine and 
DB844 efficacy studies conducted in this monkey model [16,20]. These results highlight 
the ability of diamidines to eliminate injurious trypanosomes, allowing the body to 
repair/heal itself. Furthermore, oral DB868 appears to be superior to oral pafuramidine in 
this first stage HAT monkey model, as a higher dose of pafuramidine than DB868 was 
required to achieve complete cure (10 mg/kg for 5 days vs. 3 mg/kg for 7 days, 
respectively) [16]. The longer dose regimen for DB868 compared to pafuramidine is 
consistent with the in vitro observation that DB829 required longer exposure periods than 
furamidine to kill T. b. brucei s427 trypanosomes [33]. For example, a 24-h exposure to 
DB829 (2.7 µM) was required, whereas a 1-h exposure to furamidine (3.2 µM) was 
required to kill these trypanosomes in culture. 
 
Based on a mg dose basis, DB868 has a larger therapeutic window than 
pafuramidine in vervet monkeys. No notable drug-induced overt toxicity was observed in 
either uninfected or infected monkeys administered DB868, except for mild excess 
mucous in the stool (n = 1) and transient inappetance (n = 2) in the group receiving 30 
mg/kg/day for 10 days. In comparison, similar mild adverse events were observed when 
pafuramidine was administered at 10 mg/kg/day for 10 days to vervet monkeys 
(unpublished data; JK Thuita). DB868, at all doses tested, did not cause significant 
elevations in plasma biomarkers of liver (ALT, AST, total and direct bilirubin; Figure 4) 
and kidney (creatinine; Figure 5) injury. These results contrasted with those of 
pafuramidine, which caused transient liver injury during an extended phase I clinical trial 
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in humans [11]. In addition, only a slight increase in ALT (less than 2-fold) was observed 
in female Sprague-Dawley rats administered DB868 orally (25 mg/kg/day for 3 weeks) 
compared to untreated rats, whereas an 18-fold increase was observed in rats 
administered pafuramidine (12 mg/kg/day for 4 weeks) [34]. In the current study, plasma 
urea concentrations, and therefore BUN levels, were transiently increased (2-3-fold; 
Figure 5B) shortly (1-2 days) after the last drug dose. However, the BUN:creatinine ratio 
was above the critical 20:1 ratio, suggesting that the elevations were likely due to pre-
renal causes such as dehydration. Direct comparison of plasma liver and kidney injury 
biomarkers between DB868 and pafuramidine in vervet monkeys are not possible due to 
insufficient data on pafuramidine. Nevertheless, the safety profile of DB868 is improved 
over that of the prodrug DB844, which caused significant liver injury when administered 
to monkeys at doses above 10 mg/kg/day [20], necessitating withdrawal of DB844 from 
further development.  
 
As discussed above, our study has demonstrated that oral DB868 has excellent 
efficacy and an improved therapeutic window in the first stage HAT monkey model, 
making it a promising lead candidate for further preclinical development. However, 
based on the previous lessons learned from the development of pafuramidine [11], 
several issues warrant mention. First, the kidney safety liability of DB868 needs to be 
further examined using more predictive models and biomarkers. Pafuramidine 
development was terminated due to an unexpected severe kidney injury that occurred in 
five patients (~6%), a liability not predicted by traditional preclinical safety testing in 
rodents [11]. Recently, Harrill et al. [21] showed, using a mouse diversity panel 
comprised of 34 genetically diverse inbred mouse strains, marked elevations of urinary 
kidney injury molecule-1 (KIM-1) in sensitive mouse strains following oral 
administration of pafuramidine, while classical kidney injury biomarkers, BUN and 
serum creatinine, remained unchanged. Hence, it may be prudent to screen DB868 for 
kidney injury liability using the sensitive mouse strains therein identified and KIM-1. 
Encouraging results from Sprague Dawley rats administered pafuramidine or DB868 
orally (12 mg/kg/day x 28 days) showed that DB868 had no effect on KIM-1 during the 
entire 4-month observation period (28 days of drug administration and 92 days of 
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recovery period), whereas pafuramidine caused a 13-fold increase in KIM-1 one week 
post-LDD [34].  
 
Second, treatment regimens should be optimized with the pharmacokinetics taken 
into consideration. The active compound DB829 was readily detected in the plasma 
following oral administration of the prodrug DB868 (Figures 6 and 8). Afterwards, 
DB829 was slowly eliminated from the blood with a terminal elimination half-life 
ranging from days to nearly three months depending on the dosing regimen (Tables 1 and 
3). This is similar to suramin [7], the only other first stage HAT drug besides 
pentamidine. Plasma concentrations of DB829 remained >100 nmol/L for long periods 
following the last DB868 dose, in some monkeys up to 7 days post-LDD. This finding 
was comparable to that reported for DB844 [20] and provides additional evidence that 1) 
prolonged treatment durations may not be necessary, especially for first stage HAT, and 
2) daily dosing of DB868 and other diamidine prodrugs may not be necessary. However, 
since trypanosomes are tissue invasive, a follow-up pharmacokinetic study is needed to 
determine if plasma active drug concentrations are predictive of tissue concentrations.  
 
Third, combined treatment of DB868 with a fast-acting trypanocide may 
accelerate recovery, improve efficacy and clinical outcomes, and prevent resistance. The 
time to clearance of trypanosomes from peripheral blood was shorter in monkeys treated 
with pentamidine intramuscularly (2 days after the 1st 4 mg/kg dose) than with oral 
DB868 (2-14 days after the 1st dose depending on the dose; Figure 7). It took longer for 
the lower DB868 dose regimen groups (3 and 10 mg/kg) to clear parasites from the blood 
than the 30 mg/kg group (6-14 days vs. 2-5 days after the 1st drug dose; Figure 7). The 
difference in parasite clearance between pentamidine and DB868 (or the active 
compound DB829) is consistent with observations in mouse models of HAT (Wenzler et 
al., Antimicrob Agents Chemother. under review). However, the slower parasite clearance 
by DB868 did not seem to compromise efficacy in the monkey model. Nevertheless, 
combining oral DB868 with another fast-acting trypanocidal agent, such as the oral drugs 
currently in clinical trials, may offer fast elimination of parasitaemia, the ease of oral 
pills, and a low probability of developing resistance. 
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In conclusion, oral DB868 demonstrated improved efficacy and safety profiles in 
the vervet monkey model of first stage HAT, in comparison to the previous clinical 
candidate pafuramidine. As such, DB868 should be considered a preclinical candidate for 
oral treatment of first stage HAT, supplementing the current drug development pipeline.  
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Figure S1: Individual plasma urea concentration-time profiles of un-infected vervet 
monkeys administered DB868.  DB868 was administered orally at 10 mg/kg/day 
(643, 675, 659, 677; blue symbols) or 30 mg/kg/day (567, 679, 546, 668; red 
symbols) for 10 days between day -9 to day 0 post-last drug dose. 
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Figure S2: Individual plasma concentration-time profiles of the active compound 
DB829 following administration of DB868 to un-infected vervet monkeys. DB868 
was administered orally at 10 mg/kg/day (643, 675, 659, 677; blue symbols) or 30 
mg/kg/day (567, 679, 546, 668; red symbols) for 10 days between day -9 to day 0 
post-last drug dose. 
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ABSTRACT 
Human African trypanosomiasis (HAT, sleeping sickness) ranks among the most 
neglected tropical diseases (NTDs), based on limited availability of safe and efficacious 
drugs especially for the late central nervous system (CNS) stage disease. Since 
approximately year 2000, considerable efforts have been made to redress this situation 
mainly by not-for-profit product development partnerships (PDPs) such as Drugs for 
Neglected Diseases initiative (DNDi) and the Consortium for Parasitic Drugs 
Development (CPDD). The CPDD in particular has developed novel parenterally 
administered diamidines and orally administered diamidine prodrugs which have shown 
potential for treatment of CNS stage HAT in murine studies. To provide a rationale for 
selection of either parenteral or orally administered compounds  for further development, 
the pharmacokinetics and efficacy of intramuscularly (IM) administered active drug 2,5-
bis[5-amidino-2pyridyl]furan (DB829, CPD-0802) and its orally administered prodrug 
2,5-bis [5-(N-methoxyamidino)-2-pyridyl] furan (DB868) were investigated in the vervet 
monkey model of CNS stage HAT. Treatments with either compound were initiated 28 
days post infection of monkeys with T. b. rhodesiense KETRI 2537. Results showed that 
IM DB829 at either 5 or 2.5 mg/kg/day for 5 days or as five doses of 5 mg/kg/day 
administered on alternate days cured 2/2 monkeys at each dose level. The prodrug 
(DB868) was less successful, with a cure rate of 1/4 at either 20 or 10 mg/kg/day x 10 
days per os and no cures at 3 mg/kg/day x 10 days. Pharmacokinetic analysis 
demonstrated that at 5 mg/kg of IM DB829, the plasma Cmax values were 25 times greater 
than DB829 Cmax values obtained after oral dosing of DB868 at 20mg/kg, suggesting that 
enhanced systemic availability of the active drug was the reason for better efficacy seen 
with IM dosing. These data show that the active diamidine DB829 should be considered 
for further development as a potential new treatment for CNS stage HAT. 
 
Key words: Novel diamidines, CNS stage HAT, chemotherapy, vervet monkeys, 
Pharmacokinetics 
 
Short title: Chemotherapy of CNS-stage HAT with parenteral or oral diamidines 
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INTRODUCTION 
Diamidines are widely used in the control of infectious diseases of both man and 
animals. In humans, pentamidine is used to treat first stage sleeping sickness (human 
African trypanosomiasis, HAT), leishmaniasis and Pneumocystis jirovecii (carinii) 
pneumonia which occurs mostly in AIDS patients (Tidwell et al., 1990). Diminazene 
aceturate, a diamidine that is primarily used in livestock medicine, has demonstrated 
activity against Babesia (bovis and bigemina) and a variety of animal infective 
trypanosomes. The development of the diamidines class of compounds was made 
possible by breakthrough discoveries that pathogenic trypanosomes required large 
amounts of sugar for their metabolism, indicating that their pathogenicity could be 
modulated by lowering plasma glucose levels (Sterverding, 2010). This was followed 
closely by findings that synthalin, a hypoglycaemic drug, exhibited antitrypanosomal 
activity in rodents that was independent of its ability to lower blood glucose levels (Bray 
et al., 2003; Steverding, 2010). The first aliphatic diamidines were made through 
structure-activity relationship studies (SARs) of the synthalin scaffold. 
 
Despite the proven utility of the aliphatic diamidine, pentamidine, as a therapeutic 
agent for first stage T. b. gambiense HAT (WHO, 2012), and the synthesis of aromatic 
diamidines such as furamidine (DB75) (Das and Boykin, 1977; Boykin et al, 1996), no 
new diamidines have entered clinical use for HAT or any other human diseases. Since the 
year 2000, however, there has been renewed research and development (R&D) focus on 
the diamidines with the objective/s of developing compounds with: i) good systemic 
bioavailability after oral administration since such compounds could be more readily 
used in the resource poor settings where HAT was common, ii) good activity against the 
difficult to treat second stage HAT that is characterised by trypanosome invasion of the 
cerebrospinal fluid (CSF), brain and associated membranes (meninges), causing 
menigoencephalitis (Kennedy, 2004). As a first step to address these objectives, novel 
diamidine prodrugs in which the positive charges on diamidines were masked by alkoxy 
molecules were developed (Ismail et al., 2003). The new prodrugs, including  DB289 and 
DB844, were subsequently shown to have improved transport across Caco-2 cell 
monolayers in comparison with their parent diamidines, DB75 and DB820 respectively 
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(Zhou et al., 2002; Ansede et al., 2004). They were also fully curative in mouse models 
of first and second stage HAT after oral administration (Boykin et al., 1996; Ansede et 
al., 2004; Thuita et al., 2008; Wenzler et al., 2009). In monkeys, pafuramidine (DB289) 
was shown to be fully curative against first stage HAT (Mdachi et al., 2009) thus 
providing additional evidence that the prodrug strategy was effective in delivering 
diamidines across biologic membranes in different animal species.  However, efficacy of 
the prodrugs against second stage HAT in monkeys ranged from a poor 0% for oral 
pafuramidine (Mdachi et al., 2009) to a moderately improved 43% for oral DB844 
(Thuita et al., 2012), suggesting the need to rethink the strategy to identifying potential 
therapies for second stage HAT. 
 
An alternative pair of active drug, 2,5-bis[5-amidino-2pyridyl]furan (DB829) and 
its orally administered prodrug 2,5-bis [5-(N-methoxyamidino)-2-pyridyl]furan (DB868), 
were also shown to be fully curative in the second stage GVR35 mouse model of HAT 
(Wenzler et al., 2009), suggesting that both molecules had good blood brain barrier 
(BBB) permeability in this species . On the basis of these data, DB868 progressed to the 
monkey model where we demonstrated that it was well tolerated in un-infected monkeys 
and was fully curative in the first stage vervet monkey model of HAT (Thuita et al., 
PLoS NTDs, in press). However, the activity of orally administered DB868 and 
parenterally administered DB829 against central nervous system (CNS) stage HAT in 
monkeys remained undetermined. In the current study, we therefore investigated the 
efficacy and pharmacokinetics of both DB829 after intramuscular (IM) administration 
and DB868 after oral administration in monkeys in order to determine which of the two 
test compounds would be better suited for treatment of second stage HAT. In addition, 
monkeys that relapsed after treatment with the diamidines were identified and retreated 
with the organo-arsenic drug melarsoprol to determine the continued sensitivity of the 
isolate (T.b. rhodesiense KETRI2537) to the recommended treatment for CNS stage 
eastern African HAT (WHO, 2012). Finally, monkeys were evaluated for time to relapse 
characteristics, haematological parameters and cerebrospinal fluid (CSF) white cell 
counts to gain insights on their utility as biomarkers of disease progression, resolution of 
disease post trypanocidal therapy and/or early detection of relapse in this model.   
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MATERIALS AND METHODS 
Ethics 
Studies were undertaken in adherence to experimental guidelines and procedures 
approved by the Institutional Animal Care and Use Committee (IACUC), the ethical 
review committee for the use of laboratory animals at the Trypanosomiasis Research 
Centre of the Kenya Agricultural Research Institute (TRC-KARI). The experimental 
guidelines also complied with National guidelines set by the Kenya Veterinary 
Association. 
 
Trypanocidal Drugs 
The test articles were two diamidines (DB868 and DB829) which were originally 
synthesised in the laboratories of Dr David W Boykin (Ismail et al., 2003). The drugs 
were presented in the form of yellow powder in opaque and water tight bottles. 
a) 2,5-bis[5-amidino-2pyridyl]furan (DB829 [CPD-0802] Lot # SP117-ACE-P5, 
MW = 451.648) which was synthesised by Solvias AG, Basel, Switzerland) and 
had a chemical purity of 97.2% as determined by 1H NMR and HPLC (Susan 
Jones, personal communication). In the laboratory, DB829 was reconstituted in 
5% dextrose (D5W) to render concentrations of 10 mg/ml and 5 mg/ml and 
administered to monkeys at 0.5 ml/kg intramuscularly (IM) as recommended 
(http://www.findthatpdf.com/search-19180523-hPDF/download-documents-
volume_guidelines.pdf.htm). Each dose was divided into two aliquots and 
administered at two sites on the same limb while the next day’s dose was 
administered on the alternate limb. Dosing formulations were prepared daily and 
protected from light (using aluminium foil) between preparation and actual 
injection into the monkeys which took a maximum of 30 minutes. 
b) 2,5-bis [5-(N-methoxyamidino)-2-pyridyl] furan (DB868, Lot # 2-JXS-28, MW = 
564.370) which was synthesised by Scynexis Inc., Research Triangle Park, NC, 
USA). It had a chemical purity of 95.6 as determined by NMR and High 
performance liquid chromatography (HPLC). In the laboratory, DB868 was 
wrapped in aluminium foil and stored at room temperature (23-25°C). Dosing 
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solutions were prepared daily by reconstituting the drug in distilled de-ionised 
water in three concentrations of 10, 5, and 1.5 mg/ml and administered to 
monkeys per os (PO) at 2 ml/kg body weight. 
c) Melarsoprol (Mel B, Arsobal), was supplied ready to use by the WHO in glass 
ampoules as a 3.6% solution in propylene glycol. It was administered to the 
monkeys intravenously (IV) at 3.6 mg/kg body weight for four days. 
 
Trypanosomes 
The isolate used in this study was T. b rhodesiense KETRI 2537 which was 
isolated in 1989 and cryopreserved in the TRC-KARI trypanosome bank as previously 
described (Fink and Schmidt, 1980). 
 
Experimental Animals 
A total of eighteen (18) vervet monkeys [Chlorocebus(Cercopithecus) aethiops , 
syn. African green monkeys] weighing between 2.5 and 5.5kg that were already in the 
colony maintained at TRC-KARI were used. These monkeys had initially been acquired 
from the Institute of Primate Research (IPR) in Kenya and had been subjected to the 
routine 90-day quarantine procedures that are designed to ensure their freedom from 
infectious diseases, especially the zoonotics (Gichuki and Brun, 1999; Thuita et al, 
2008b). The monkeys were housed in stainless steel cages and were fed a diet of fresh 
vegetables and commercial monkey cubes (Unga feeds, Nakuru Kenya) twice daily and 
given water ad libitum (Thuita et al, 2008b). 
 
Study Design 
The efficacies of the two test articles, orally administered prodrug DB868 and 
intramuscularly (IM) administered active drug DB829 (CPD-0802) were evaluated in two 
separate experiments. In each experiment, baseline data (weight, clinical and 
haematology parameters) were collected for 2 weeks after which monkeys were infected 
by intravenous injection of approximately 104 T. b. rhodesiense KETRI 2537 
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trypanosomes diluted from infected blood of immuno-suppressed donor Swiss white mice 
(Thuita et al., 2012). The matching method of Herbert and Lumsden (1976) and the 
haematocrit centrifugation technique (HCT) (Woo, 1970)  were used to collect 
parasitaemia data. Therapeutic intervention was initiated at 28 DPI after establishing that 
the animals had second stage disease using the presence of trypanosomes in CSF and 
elevated white cells (> 5 cells/µl) in CSF as biomarkers (WHO, 2012). CSF was 
processed as previously described (Miezan et al., 2000; Thuita et al., 2012). 
 
As a result of a regulator instituted freeze on acquisition of new non-human 
primates, only six monkeys were available for the IM DB829 study. These were divided 
into three treatment groups, each group consisting of two monkeys (one male and one 
female), to give a preliminary indication of dose response and compare consecutive-day 
with alternate-day dosing. They were treated at 5 mg/kg x 5 days consecutively (monkeys 
569 and 659), 5 mg/kg administered every alternate day for 5 days (monkeys 668 and 
676) and 2.5 mg/kg x 5 days consecutively (monkeys 546 and 693) (Table 1).  
Another 12monkeys were available for the efficacy study of oral DB868. These 
monkeys were divided into treatment groups, each consisting of two male and two female 
monkeys, for oral treatment with  DB868 at 20 mg/kg x 10 days consecutively (monkeys 
573, 679, 689 and 696) and 10 mg/kg x 10 days consecutively (monkeys 688, 690, 695 
and 697). A third treatment group, 3 mg/kg x 10 days consecutively, contained only two 
monkeys (numbers 670 and 687) (Table 1) since two other monkeys which had been 
allocated to this group did not become blood or CSF trypanosome positive at all and were 
consequently withdrawn from the study. 
Post treatment monitoring for clinical and parasitological cure as well as for 
haematologic and pharmacokinetic parameters, were carried out as previously described 
(Thuita et al., 2012). To facilitate collection of blood and CSF for these assessments, the 
monkeys were anaesthetised with ketamine HCl at 10-15 mg/kg and valium 0.5 mg/kg. 
 
HPLC-MS/MS Quantification of DB868 and DB829 in Monkey Plasma 
Monkey plasma samples were processed for quantification of DB829, DB868 or 
pentamidine using modifications of methods previously described in Harrill et al. (2012) 
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and Wang et al., 2010; the resultant modified methods used to assay monkey biological 
fluids for DB829/DB868 concentrations has been described in detail (Thuita et al., PLoS 
NTDs, in press).   
 
Data Analysis 
All clinical and haematological data were entered and managed using Microsoft 
Excel (Version 2003). The data were analysed using Statview for Windows Version 5.0.1 
(SAS Institute Inc, 1995–1998, Cary, NC). Repeated measures ANOVA was performed 
to test the effect of trypanosome infection on haematology and clinical chemistry 
parameters as well as the effect of IM DB829 and oral DB868 on the same parameters (α 
= 0.05). In addition, 95% confidence intervals were derived to further test the 
significance of observed findings. The PK data were analysed using the non-
compartmental analysis (NCA) with the aid of the WinNolin programme.  
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RESULTS 
Parasitaemia, CSF Parasitosis and Clinical Disease before Treatment 
Following intravenous injection of approximately 104  trypanosomes per monkey, 
median (range) pre-patent periods of 4.5 (4-7) and 4 (3-5) days were obtained for the 
monkeys in the efficacy studies of oral DB868 and IM DB829, respectively (Table 1).  
Thereafter, the parasitaemias were characterised by average peak values of 107 
trypanosomes/mL of blood (Table 1), with the characteristic fluctuations associated with 
trypanosome infections (Figures 1 and 2); these observations were similar to primary 
parasitaemia data previously reported for this model (Thuita et al., 2012). Clinically, the 
first stage disease was characterised by transient inappetance, rough haircoats, fluctuating 
fever and weight loss (< 5%). General lymphadenopathy and enlargement of the spleens 
(up to 3 times pre-infection sizes) were also observed.   
Cerebrospinal fluid (CSF) parasitosis was confirmed in all the monkeys before the 
last pre-treatment sampling point at 27 DPI (Table 1). The trypanosome densities were 
low at 1-2/µL of CSF (Table 1); in a majority of the monkeys, the parasites were however 
detected on more than one occasion during the weekly physical examination and sample 
collection activities before initiation of treatment (data not shown). In addition, white cell 
numbers in CSF were modestly elevated in comparison with baseline values as shown 
(Figure 3), thus confirming that the monkeys were in the central nervous system (CNS) 
stage disease (WHO, 1998; WHO, 2012). However, only a limited number of monkeys 
exhibited some clinical signs of late stage disease, including hind limb paresis, altered 
behaviour and chirping. They were treated with different dose regimens of either DB868 
or DB829 from 28 days post infection (DPI).  
 
Efficacy of DB829 Dose Regimens 
DB829 was administered intramuscularly (IM) at 5 mg/kg for 5 days 
consecutively (monkeys 569 and 659) or at 5 mg/kg every alternate day for 5 days 
(monkeys 668 and 676). A third group of monkeys was treated at 2.5 mg/kg for 5 days 
consecutively (Table 1). Monkeys that were treated using either of the 5 mg/kg dose 
regimens became blood and CSF parasite negative by the last day of dosing. In contrast, 
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trypanosomes were more persistent in the biological fluids of monkeys that were dosed at 
2.5 mg/kg; the trypanosomes were still detectable in blood and/or CSF for 4 days 
(monkey 693) and 7 days (monkey 546) post last dosing. Even in these two monkeys 
(546 and 693) however, trypanosomes were thereafter not detected in biological fluids, 
indicating that all the monkeys that were treated with DB829 were parasite negative at 
the last time point (14 days post last dosing) that could still be considered an end of 
treatment (EoT) evaluation (Table 1). All the monkeys subsequently regained their 
normal clinical condition. Five of the monkeys (569, 668, 676, 546 and 693) remained 
free of parasites in blood and CSF during the more than 300 days of post treatment 
monitoring (Table 1) and were therefore declared cured. However, monkey 659 of the 5 
mg/kg x 5 days consecutive daily dosing regimen, developed pneumonia and had to be 
euthanized 91 days post last dosing. Trypanosome recrudescence was not observed in 
blood or CSF collected from this monkey at any time point post last dosing. The monkey 
(659) was therefore classified as withdrawn from the study (Table 1). 
 
Efficacy of Oral DB868 Regimens 
The prodrug DB868 was dosed orally to groups of four monkeys using 10-day 
dose regimens of 20, 10 and 3 mg/kg, respectively. Monkeys in the 20 and 10 mg/kg 
dose-groups became blood and CSF parasite negative by the 7th day of dosing and all 
were therefore provisionally cured at the end of treatment (EoT) examination (Table 1). 
The two monkeys that were treated at 3 mg/kg (No 670 and 687) also experienced 
aparasitaemia after the 7th drug dose. However, the central nervous system (CNS) 
trypanosomes were not eliminated at all, indicating that the 3 mg/kg x 10 days regimen  
did not achieve cure (Table 1). 
 
Three of the four monkeys that were treated orally with DB868 at 20 mg/kg 
experienced trypanosome recrudescence at various times post last drug dose (LDD), 
giving a final cure of 1/4 for this group (Table 1). All three animals (monkeys 573, 689 
and 696) were confirmed to have CSF trypanosomes, CSF white cell aberrations and/or 
clinical signs of CNS disease (data not shown). However, only one, monkey 689, 
experienced trypanosome recrudescence in the blood (Figure 2). The median (range) time 
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to relapse was 133 (77-161) days. Clinical signs of CNS involvement included ataxia, 
circling and altered behaviour and were quite pronounced in monkey 696, necessitating 
humane euthanasia of the monkey. The remaining two monkeys (573 and 689) were 
successfully rescue-treated with melarsoprol (Mel B, Arsobal®) at 3.6 mg/kg x 4 days 
intravenously. 
Similarly, three out of the four monkeys that were treated with DB868 at 10 
mg/kg relapsed. The three monkeys (Monkey 688, 695 and 697) were all positive for 
blood trypanosomes (Figure 2) and two of them (688 and 697) also were positive for CSF 
trypanosomes and/or clinico-pathological indicators of late CNS stage disease. The 
median (range) time to relapse was 28 (28-56) days.  In these monkeys, relapse 
parasitaemia hovered around the limit of detection of Herbert and Lumsden (1976) and 
tended to be of a lower intensity in comparison with primary parasitaemia in the same 
monkeys (Figure 2). In contrast, CSF white cell aberrations were more pronounced in the 
relapsed monkeys, in comparison with the period before treatment (Figure 3 and data not 
shown). The three monkeys were also successfully rescue-treated with melarsoprol (Mel 
B, Arsobal®) at 3.6 mg/kg x 4 days intravenously.  
In all cases when monkeys were retreated with melarsoprol, trypanosomes were 
cleared from the peripheral blood by the second day of treatment confirming that 
melarsoprol is a fast acting trypanocide. The post treatment monitoring period was 
restarted after the last dose of melarsoprol and continued for at least 300 days before cure 
was declared. The monkeys remained free of trypanosomes and had normal clinical and 
haematology parameters; they were therefore confirmed cured. Monkey 687 was 
however not cured; its clinical condition deteriorated significantly after two daily doses 
of melarsoprol treatment, necessitating it to be euthanized.    
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Table 1: Efficacy of intramuscular DB829 and oral DB868 dose regimens in a second stage monkey model of HAT 
 
Experiment An # PP (DPI) Peak 
Log10P 
Time to 
parasitisation 
of CSF (DPI) 
# of 
tryps/ µl 
of CSF 
 
Dose 
regimen 
(mg/kg x # 
of days 
Time of 
treatment  
(DPI) 
Efficacy 
at EoT 
ToC at 
300 DPI 
Cured/ 
treated 
I: IM 
DB829 
569 4 7.2 27 1 5 x 5 28-32 Neg Cured 1/1 
659 4 7.8 27 1   Neg WD (91)  
668 5 7.8 21 1 5 x 5 28, 30, 32, 
34, 36 
Neg Cured 2/2 
676 5 7.5 21 1   Neg Cured  
546 4 7.5 27 1 2.5 x 5 28-32 Neg Cured 2/2 
693 3 8.1 14 1   Neg Cured  
Average 4 (3-5) 7.7 ± 0.1 24 (14-21) 1 NA NA NA NA  
          
I: Oral 
DB868 
573 4 8.1 14 2 20 x 10 28-37 Neg Relapsed 1/4 
679 5 7.8 27 1   Neg Cured  
689 5 7.8 27 1   Neg Relapsed  
696 4 7.8 7 1   Neg Relapsed  
688 5 7.5 21 1 10 x 10 28-37 Neg Relapsed 1/4 
690 5 7.8 14 1   Neg Cured  
695 4 7.5 7 1   Neg Relapsed  
697 4 7.8 7 1   Neg Relapsed  
670 7 7.2 NA NA 3 x 10 28-37 Neg WD  
687 4 7.8 21 2   Neg Not cured 0/2 
Average 4.5 (4-7) 7.8 ± 0.1 10.5 (7-27) 1 (1-2) N/A N/A N/A   
An #, animal number; PP, pre-patent period; DPI, days post infection; P, parasitaemia; IM, intramuscular; EoT, end of treatment; 
tryps, trypanosomes; CSF, Cerebrospinal fluid; WD, withdrawn; Neg, negative; N/A, not applicable; ND, not demonstrated; ToC, test 
of cure peforemd after 300 days post LDD 
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Figure 1: Parasitaemia progression in monkeys infected with T. b. rhodesiense KETRI 
2537 and later treated with DB829. DB829 was administered intramuscularly from 28 
days post infection at: - A:  5 mg/kg x 5 days consecutively; B: 5 mg/kg every alternate 
day; C:  2.5 mg/kg x 5 days consecutively.  
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Figure 2: Primary and relapse parasitaemia in monkeys infected with T. b. rhodesiense 
KETRI 2537 and subsequently treated with prodrug DB868. DB868 was administered 
orally from 28 days post infection at: - A:  20 mg/kg x 10 days consecutively; B: 10 
mg/kg x 10 days consecutively; C:  3 mg/kg x 10 days consecutively. 
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Figure 3: Cerebrospinal fluid white cell changes in monkeys that were treated with oral 
DB868 regimens. The monkeys were dosed from 28 (A) to 37 (B) days post infection 
with T.b. rhodesiense KETRI 2537. 
 
Infection and Treatment Induced Changes on Haematology 
Red blood cell (RBC) counts exhibited an infection-induced decline that was most 
prominent at 27 DPI, as shown by the mean (± SE) trends of all DB829 and DB868 
treatment groups (Figure 4). The average haematocrit (HCT) of the monkeys in the 
DB829 study (n = 6) was 35.5% (± 1.8) which was a 27.3% drop from the pre-infection 
mean value of 48.8% (±2.6). The monkeys in the oral DB868 study (n = 10) experienced 
a comparable 30.7% drop in mean haematocrit, from a pre-infection value of 42.4 (±1.5) 
to 29.4 (± 1.2) at 27 DPI. The mean corpuscular volume (MCV) and mean corpuscular 
haemoglobin (MCH) also declined significantly (p < 0.05), consistent with previous 
findings in monkeys infected with this strain (Thuita et al., 2012). Upon treatment with 
IM DB829 or oral DB868, the RBC counts recovered to baseline levels within 
approximately 1-2 months (Figure 4). In the monkeys that experienced trypanosome 
recrudescence in the blood (monkey 687 (DB868, 3mg/kg), monkeys 688, 695 and 697 
(DB868, 10 mg/kg) and monkey 689 (DB868, 20 mg/kg) (Figure 2), a second phase of 
declining RBC parameters was observed concurrently with the reappearance of 
trypanosomes in blood (data not shown). No such decline in RBC associated parameters 
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was observed for monkeys 573 and 696 in which trypanosomes reappeared only in the 
CSF.  
 Infection related thrombocytopenia was observed between 7-27 DPI, followed by 
recovery to baseline (pre-infection) levels within one week after therapeutic intervention 
(Table 2). Similarly, a significant leucopenia was observed at 7 DPI (Table 2). This 
leucopenia was largely determined by significant declines in lymphocyte numbers 
(Figure 5). However, unlike RBC and platelet counts which remained low as long as 
trypanosomes were still in the blood, white cell densities increased in some individuals 
and remained low in others (Table 2, Figure 5). Upon treatment with DB829/DB868, 
blood white cell counts remained somewhat elevated in those monkeys that eventually 
relapsed after variable periods of post treatment monitoring (Figure 5).  The strongest 
peaks of white blood cells were observed approximately 1-4 days post end of treatment 
with melarsoprol of relapsed individuals (Figure 5). These relapse-melarsoprol treatment 
associated peaks of blood white cells were mainly the result of increases in lymphocytes 
and granulocytes (Figure 5) and were observed only in those individual with 
trypanosomes in the blood but not those with only CSF trypanosomes.  
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Figure 4: Changes in density of red blood cells in blood of monkeys that were infected 
with T.b. rhodesiense and later treated with IM DB829 (A) or oral prodrug DB868 (B). 
DB829 was administered from 28 days post infection for 5 consecutive days or on 
alternate days (A).  DB868 was dosed orally for 10 consecutive days, starting 28 days 
post infection. 
 
 
 157
Table 2: Changes in blood platelet and white cell counts following infection of monkeys with T.b. rhodesiense and subsequent 
treatment with oral DB868 and intramuscular DB829. 
Drug Dose 
(mg/kg x d) 
DPI 
(DPT) 
0 7 27 38 (1) 44 (7) 65 (28) 100 (63) 137 (100) 224 (180) 
 20 x 10 a PLT 323 ± 42 112 ± 15 
(S) 
131 ± 32 
(S) 
410 ±14 362±57 334±52 318± 31 285± 51 243±50 
Oral 
DB868 
 WBC 8.1± 1.5 3.5 ± 0.8 
(S) 
4.3 ± 0.7 
(S) 
7.4 ± 0.8 6.5± 0.6 5.9 ± 0.3 
(S) 
6.9 ± 0.6 8.1 ± 0.6 9.7± 2.9 
 10 x 10a PLT 273 ± 76 75 ± 13 54 ± 4 292 ± 41 331 ± 90 307 ± 82 217 ± 32 451 ± 65 337 ± 19 
  WBC 5.7 ± 0.3   2.7 ± 0.2 
(S) 
4.3 ± 0.6  8.9 ± 0.3  7.1 ± 0.8 6.9 ± 0.7  7.9 ± 1.7  6.2 ± 0.5  6.4 ± 0.6 
 3 x 10a PLT 355 ± 
215 
259 ± 186 126 ±33 472 ±248 NA 
 
  WBC 5.7 ± 0.8 4.7 ± 0.6 6.4 ± 0.5 8.2 ± 0.6 NA 
 
 5 x 5a PLT 424 ± 60 112 ± 11 
(S) 
156 ± 42 
(S) 
464 ± 32  515 ± 39 419 ± 4.5 352 ± 44 367 ± 60 NA 
IM 
DB829 
 WBC 6.0 ± 0.4 3.4 ± 0.5  4.6 ± 0.2  7.8 ± 0.3 6.6 ± 0.5  7.3 ± 1.0 5.3 ± 1.1 4.5 ± 0.1 NA 
 5 x 5b PLT 312 ± 31 96 ± 12 
(S) 
200 ± 2 
(S) 
328 ± 7.5 395 ± 26 378 ± 71 246 ± 26 327±25 250 ± 53 
  WBC 4.8 ± 0.5 3.3 ± 1.1 4.7 ± 0.6 4.8 ± 0.6 5.6 ± 0.5 6.5 ± 0.7 5.8 ± 0.8 6.3 ± 0.3 6.0 ± 0.3 
 
 2.5 x 5a PLT 285 ± 23 54 ± 20 
(S) 
115 ± 32 
(S) 
265 ± 17 332 ± 27 292 ± 5 242 ± 64 327 ± 27 389 ± 13 
  WBC 5.8 ± 2.1 3.9 ± 1.4  
(S) 
5.4 ± 1.3 6.8 ± 1.5 8.9 ± 3.4 8.1 ± 2.1 6.3 ± 1.0 6.0 ± 1.6 6.7 ± 1.9 
IM, intramuscular; d, day; a, consecutive day dosing; b, alternate day dosing; DPI, days post infection; DPT, days post last treatment; 
WBC, white blood cell counts; PLT, Platelets; NA; not applicable; S, significant at p < 0.05, repeated measures ANOVA and post hoc 
tests;  
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Figure 5: White blood cell changes in three monkeys that were treated with oral DB868. 
DB868 was administered orally at 3 mg/kg x 10 days (M687); 10 mg/kg x 10 days 
(M688); and 20 mg/kg x 10 days (M689). When relapses were confirmed, the monkeys 
were retreated with melarsoprol at 3.6 mg/kg x 4 days intravenously; WBC, white blood 
cells; Ly, lymphocytes; Mo, monocytes; GR, granulocytes. Dashed arrows: last dose of 
DB868; bold arrows, last dose of melarsoprol. 
Pharmacokinetics 
Following intramuscular injection of the active drug DB829 at either 5 or 2.5 
mg/kg, similar Tmax values of 0.04 days (1 h) were obtained for all six monkeys, showing 
that the drug was rapidly absorbed into the blood. A geometric Cmax value of 13400 
(12000-15000) nmol/L was obtained for the 5 mg/kg x 5 days consecutive day dosing 
group while 5000 (4200-5900) nmol/L was obtained for the 2.5 mg/kg DB829 dose 
group. (2.7 fold). In the alternative day dosing regimen at 5 mg/kg, Cmax and Tmax were 
comparable to the consecutive day dosing (Table 2). The AUC for the 5mg/kg group was 
2.1-fold greater than that for the 2.5 mg/kg dose group. The terminal half-life for the 
consecutive day dosing regimens was an average of 38 days (32-44). The AUC and the 
terminal half-life for the alternative day dosing regimen were 5-fold and 3-fold greater 
than corresponding values for the consecutive day-dosing regimen at the same 5 mg/kg 
dose. 
For monkeys dosed with oral DB868, the prodrug was detected within 1 h post 
dosing in all monkeys at geometric mean values of 812 nmol/L (20 mg/kg group), 746 
nmol/L (10 mg/kg group) and 124.9 nmol/L (3 mg/kg group). The plasma values of the 
prodrug declined rapidly and were not detected after 8 h in any monkey. Thus, although 
the geometric mean values obtained at 1h were the highest plasma values for all the 
groups, accurate PK parameters could not be derived due to limited data points. On the 
other hand, the plasma Tmax for the active metabolite DB829 was an average of 0.33 days 
(8 h) for the three treatment groups, with a range of 0.04-2 days (1 – 44 h) (Table 3). The 
Cmax values were 526 (460-630) nM for the 20 mg/kg dose group, 269 (180-410) nmol/L 
for the 10 mg/kg dose group and 85 nmol/L for the 3 mg/kg dose group.   
CSF active drug (DB829) concentrations were determined only for the two groups 
of monkeys that were treated with DB829 at 5 mg/kg x 5 days IM. In the consecutive day 
dosing group, the geometric mean DB829 concentration was 13.6 nmol/L at the 1 h post 
LDD time point; the levels declined to about 5.7 nmol/L but were detected until 21-28 
days post LDD. In the alternate day dosing group, geometric mean DB829 concentration 
was 7.3 nmol/L at 1 h post LDD time point. The drug was detected at the same level until 
2 days post LDD before falling below the limit of quantification of the assay of 5 nmol/L. 
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DISCUSSION 
A variety of novel diamidines and their prodrugs have been synthesised (Das and 
Boykin, 1977; Ismail et al, 2003; Tidwell and Boykin, 2003) and subsequently shown to 
be highly active against African trypanosomes in vitro and in mouse models (Wenzler et 
al 2009; Ward et al., 2011). More recently, it was shown that one of the prodrugs, 
DB868, was significantly better tolerated in rats than the clinical candidate prodrug 
pafuramidine (Wolf et al., 2012). DB868 was also well tolerated in un-infected vervet 
monkeys and was highly active against first stage HAT in the vervet monkey HAT 
model, highlighting it as a potential new clinical candidate for first stage HAT (Thuita et 
al., PLoS NTDs, in press). In the current study, we compared the pharmacology 
(efficacy, pharmacokinetics) of orally administered DB868 to that of its intramuscularly 
administered parent drug (DB829) in the CNS stage vervet monkey model of HAT, in an 
effort to identify a suitable potential clinical candidate for the CNS stage human disease.      
The diamidine DB829, when administered IM at 5 or 2.5 mg/kg for five days 
consecutively or at 5 mg/kg x 5 days on alternate days, cured all monkeys with a CNS 
stage infection. These results were an indication of its superior efficacy compared to 
other previously evaluated diamidine prodrugs such as pafuramidine which cured 0/3 
(Mdachi et al., 2009) and DB844 which had a modest efficacy of 3/7 (43%) against 
similar CNS-stage infections in the monkey model (Thuita et al., 2012). The efficacy of 
IM DB829 was also in contrast to that of IM pentamidine which was shown to have good 
activity (2/3) in early stage disease (Thuita et al., PLoS NTDs, in press) but was not 
effective (0/3) when initiation of treatment was delayed to 14 days post infection with 
T.b. rhodesiense KETRI 2537 (unpublished data TRC KARI). In other studies, Schmidt 
and colleagues evaluated the efficacy of diminazene aceturate and several experimental 
diamidines against CNS-stage T.b. rhodesiense infections and reported unsatisfactory 
results (Schmidt and Sayer, 1982). The results we have reported therefore indicate that, 
unlike other diamidines and diamidine prodrugs previously evaluated in this monkey 
model, DB829 could potentially be developed as a therapy for CNS stage HAT. 
 
Oral DB868 had an excellent (4/4) end of treatment provisional cure rate for both 
10 and 20 mg/kg dose groups but not for the 3 mg/kg dose group (0/2). However, for the 
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10 and 20 mg/kg dose groups, the final efficacy result after more than 300 days of post-
dosing monitoring was only 1/4 (25%) cure rate. In contrast, both DB868 and DB844, 
when administered at 100 mg/kg x 5 days per os, cured 4/4 GVR 35 CNS stage infections 
in mice (Wenzler et al., 2009). A closer scrutiny of the treatment regimens used in the 
monkey and mouse studies suggests that the superior efficacies in the mouse model were 
likely related to the significantly higher daily drug doses employed (100 mg/kg [mouse] 
vs. 20 mg/kg [monkey]). Species differences (mouse vs. monkey) and the requisite 
scaling down of drug doses between species as well as results of toxicity studies of 10-
day oral DB868 regimens in un-infected vervet monkeys (Thuita et al., PLoS NTDs, in 
press) were considered when selecting the maximum dose of 20 mg/kg x 10 days for the 
monkey efficacy studies. However, on the evidence of our current results and comparable 
partial cures obtained after prodrug DB844 was used to treat CNS stage infections in 
monkeys using 10 or 14-day dose regimens (Thuita et al., 2012), there may be need to 
investigate alternative treatment regimens comprising of higher daily drug doses which 
are administered for shorter durations to maximise on efficacy and minimise the risks of 
dose-limiting toxicity.    
 
Pharmacokinetic evaluation of plasma samples provided evidence of the 
superiority of IM as compared to oral administration of these compounds. The geometric 
mean plasma Cmax resulting from IM administration of DB829 at 5 mg/kg was 26 times 
(13400/512) greater than the active metabolite (DB829) concentration resulting from 
administration of oral DB868 at 20 mg/kg. Even when DB829 was dosed at 2.5 mg/kg 
IM, resultant plasma DB829 Cmax values were approximately 10 times (5000/512) greater 
than values of the same compound (DB829) resulting from oral dosing of prodrug DB868 
at 20 mg/kg. In terms of systemic availability of active drugs therefore, the comparatively 
poorer performance of orally administered prodrugs in comparison with IM administered 
active drugs is best explained by a report that 50–70% of an oral dose of pafuramidine 
was absorbed (losses: 30-50%) and effectively converted to the active drug (DB75) in 
both rats and monkeys but subject to first-pass metabolism and hepatic retention, limiting 
its systemic bioavailability to 10 to 20% (Midgley et al., 2007).  
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The fact that high efficacies were obtained in IM treated monkeys indicates that 
sufficient quantities of the active drug (DB829) crossed the blood brain barrier (BBB) to 
eliminate trypanosomes from the central nervous system (CNS). Evaluation of CSF 
samples from monkeys that were treated at 5 mg/kg x 5 days confirmed that DB829 was 
indeed detected, with a geometric mean of 13.6 nmol/L (consecutive day-dosing group) 
and 7.3 nmol/L (alternate-day dosing group) at 1 h post LDD. These CSF DB829 
concentrations were not particularly high, especially in comparison with plasma levels of 
the same drug (Table 3). However, DB829 was present in CSF at levels greater than 5 
nmol/L for at least 2 days post LDD (alternate day dosing group) and 21-28 days post 
LDD (consecutive day dosing group). It is proposed therefore that the presence of DB829 
in CSF for relatively long periods led to successful elimination of trypanosomes from the 
CSF/CNS compartment, possibly due to the ability of trypanosomes to accumulate 
potentially toxic active drug levels from surrounding medium (Mathis et al., 2006). CSF 
DB829 levels were not determined for monkeys that were treated with oral DB868; the 
fact that poor overall efficacies were observed suggested that therapeutic concentrations 
of the active drug (DB829) were not attained in the CSF and CNS parenchyma of a 
majority of the monkeys. Studies on the related prodrug, pafuramidine reinforced the 
superiority of parenteral as compared to oral dosing of diamidines: active drug (DB75) 
concentrations were higher (61 nmol/mg of tissue) in the CNS of mice after IV 
administration of pafuramidine as compared to orally dosed mice (13nmol/mg of tissue) 
(Sturk et al., 2004). Thus, although efflux transporters present in the BBB (Krajcsi et 
al.2012) make it difficult for significant levels of active diamidines/other drugs to 
accumulate in the CSF/CNS, our data show that parenteral dosing improved active drug 
levels in CSF possibly through mechanisms such as concentration dependent diffusion 
(Nau et al., 2010) and/or enhanced activity of organic cation transporters (Ming et al., 
2009).  
 
Monkeys that relapsed at various times after oral DB868 treatment manifested 
clinical and clinico-pathological parameters that were distinctly different from primary 
infections in the same individuals. Firstly, the clinical disease in relapsed individuals was 
characterised by more signs of late CNS stage disease than primary infections in the same 
 164
monkeys, evidence of the important role of CNS as source of relapse trypanosomes 
(Thuita et al 2012). Secondly, parasitaemia in the relapsed monkeys hardly reached the 
peak levels observed in primary parasitaemia and was actually more similar in pattern to 
that seen in T. b. gambiense infections in monkeys (Dr David Mwangangi, personal 
communication) and in sleeping sickness in humans which is largely (more than 95%) 
caused by T.b. gambienese (Brun et al., 2011; WHO, 2012; Matovu et al., 2012). 
Parasitaemia loads in Trypanososma brucei spp are determined by density dependent 
parasite differentiation to non-replicating short stumpy forms and parasite killing by the 
hosts immune system (Tyler et al., 2001).  The apparently poor growth characteristics of 
relapse as opposed to primary infections of the same trypanosomes were therefore likely 
indicative of a heightened recognition and faster removal of successive variant antigenic 
types (VATs) by the immune system in the infected monkeys. The trypanosomes 
regained their robust growth characteristics and high parasitaemia loads when they were 
passaged in naive rodents (unpublished observations), indicating that there was no 
permanent change in trypanosome phenotype. Due to their intermittent nature, relapse 
parasitaemia were more difficult to detect by microscopy (van Meirvenne et al., 1999), 
sometimes only being detected when clinical disease was well developed. Importantly, 
confirmed relapse infections were successfully retreated with intravenously administered 
melarsoprol at 3.6 mg/kg x 4 days, highlighting the importance of this old drug in the 
fight against HAT, despite the well documented toxicity issues associated with its use 
(Burri, 2010; 2012)  
A major constraint of preclinical drug studies in animal models is the requirement 
for long post treatment monitoring periodes (more than 300 days in CNS stage HAT 
monkey model) before cure can be declared.  The timelines are even more protracted for 
clinical trials of potential new HAT treatments, with at least 18-24 months needed to 
confirm cure (WHO, 2004). However, our time to relapse data for monkeys treated with 
DB868 at 20 mg/kg, a median 133 (range, 77-161) days post last drug dose (LDD), 
indicates that the protracted timelines are not without justification. In an effort to improve 
the turnover times for compounds in development, primary efficacy endpoint assessments 
at 100 days post LDD have been proposed (Sonja Bernhard, personal communication). In 
our study, however, a primary efficacy endpoint set at 100 days post LDD would have 
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correctly predicted the final efficacy result for oral DB868 at 10 mg/kg group but not for 
the 20 mg/kg group i.e. 2/3 relapses in this group were diagnosed as relapses after the 100 
days post LDD time point. Indeed, a review of larger data sets of monkeys treated with 
different experimental diamidines in our laboratory revealed that a primary endpoint at 
100 days post LDD would have facilitated detection of 80% of all animals that eventually 
relapsed (unpublished data of TRC-KARI), highlighting a potential pitfall of reliance on 
primary efficacy data for decision making. Clearly, the utility of primary endpoint 
efficacy assessments needs to be improved, possibly by combining parasitaemia 
determinations with other surrogate biomarkers of cure assessment including CSF white 
cell counts (Priotto et al., 2012), serum/plasma trypanosome antigen levels as determined 
using TrypTectCIAAT (Karanja et al., 2010). However, these surrogate tests still need to 
be adequately validated to be reliably used as biomarkers of cure/relapse in drug trials.   
 
Haematology changes attributable to trypanosome infection and subsequent 
treatment with diamidines were generally consistent with previous observations in this 
model (Mdachi et al., 2009; Thuita et al., 2012; Maina Ngotho et al., 2011).  In the 
current study, however, we focussed more on total and differential blood white cell 
counts and observed that this parameter remained elevated in monkeys which eventually 
relapsed, suggesting this parameter could be a potential surrogate marker for cure 
assessment. In addition, blood white cell counts, especially lymphocytes and 
granulocytes, were markedly elevated post treatment with melarsoprol. The leucocytosis 
was likely a sequel to rapid destruction of trypanosomes by melarsoprol, release of high 
amounts of trypanosome antigens (antigenaemia) and their stimulatory effects on the 
host’s immune system. Importantly, the elevated leucocyte numbers normalised within 
approximately four days post LDD (Figure 5) and remained at baseline levels for the 
duration of post treatment monitoring; all other parameters remained normal indicating 
that like IM DB829, melarsoprol was curative for monkeys with CNS stage HAT.  
 
Overall therefore, this study has identified IM DB829 at 2.5 mg/kg administered 
for 5 consecutive days, but not oral DB868, as a promising late lead compound that could 
enter the development pipeline as a new therapeutic agent for CNS stage HAT. Despite 
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the fact that prodrugs cross biological membranes like gastrointestinal mucosa better than 
active diamidines (Ansede et al., 2004), we have demonstrated conclusively that 
parenteral administration of diamidines is superior to oral administration of diamidine 
prodrugs in terms of eventual systemic availability of active drugs, thus leading to better 
efficacies against the tissue invasive HAT causing parasites.    
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Chapter 8: General Discussion 
 
The Case for a New HAT Drug 
There is considerable concurrence among stakeholders on the need for new 
sleeping sickness medicines. Several authors, including those from the WHO, have 
published repeatedly on the need for new tools (especially drugs and diagnostics) in order 
to better meet the healthcare needs of sleeping sickness patients as well as other NTDs 
(Werbovetz et al., 2006; Simmaro et al., 2008; 2011; Brun et al., 2010, 2011; Chatelain 
and Ioset; 2011).  The drive for new drugs is largely based on the well documented 
shortcomings of currently available treatments (Burri, 2010) and the need to increase the 
treatment options available for this disease to cater for emergent cases of parasite 
resistance/treatment failure.  The studies reported in this PhD thesis show that two new 
chemical entities (NCEs), an oral prodrug DB868 and its intramuscularly administered 
parent drug CPD-0802, could be recommended to enter regulatory development for first 
and second stage HAT respectively. 
 
Currently, compounds undergoing regulatory development for HAT include 
fexinidazole (phase II/III) and the benzoxaborole SCYX-7158 (phase I).  These 
compounds performed well during preclinical and early phases of clinical development 
(Nare et al., 2010; Toreele et al., 2010; Kaiser et al., 2011; Jacobs et al., 2011), thus 
generating considerable optimism on their chances of successfully completing the drug 
development process. Indeed, it is now believed that a new drug will become available 
within the next 3-5 years (Maser et al., 2012). However, the drug development process 
suffers from a considerably high attrition ratio, with only 1:50 000 NCEs advancing to 
clinical trials from the drug discovery phase (Grewal et al., 2008).  Even after potential 
new therapies have entered clinical trial phase, the attrition ratio remains high. In a study 
by Prentis and Walker (1986), it was reported that out of 197 NCEs developed by seven 
UK pharmaceutical companies up to clinical testing phase, only 35 were eventually 
marketed giving an attrition ratio of 5.6:1. Comparable attrition ratios of 10:1 (Wardell 
and Scheck, 1982) and 13.5:1 (Mattinson et al., 1984) were reported for US and Swiss 
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companies respectively. Although the period since year 2000 has been very good for 
HAT drug research and development (R&D), the considerably high risk of attrition 
should remind us that with only two compounds currently, the HAT drug development 
pipeline is not yet robust enough. 
 
In spite of the scientific evidence and my advocacy for advancing both diamidines 
to regulatory development, it must be mentioned that drug development is a very costly 
undertaking. Actual estimates of developing a new drug up to market authorisation range 
from USD 500-2000 million (Dimasi et al., 2003; Adams and Brantner, 2006) although 
this cost is likely to be lower for drugs developed by the not for profit public private 
partnerships (PPPs). In addition, it takes an estimated 10-12 years to develop a new drug 
(Grewal et al., 2008). On the basis of cost then, it is unlikely that both diamidines could 
actually end up in regulatory development- rather a best case scenario would see only one 
of the two drugs funded for development. If it came to a choice between the two, 
conventional thinking would favour the parent drug DB829 on the basis of its activity 
against second stage disease. This is shown by target product profiles (TPPs) in use by 
the consortium for Parasitic Drugs Development (CPDD) and Drugs for Neglected 
Diseases initiative (DNDi) (sample TPP: appendix) which usually include activity against 
second stage disease top of the list of desirable attributes of potential new therapies 
(http://www.dndi.org/diseases/hat/target-product-profile.html, Susan Jones, personal 
communication). However, the orally active drug DB868 would also have its supporters, 
including myself. I consider arguments for oral HAT medicines, presented in this thesis 
and elsewhere, quite compelling.  A key plank in these arguments is that an oral medicine 
would make it possible to reduce hospitalization times and, in a best case scenario, 
completely render it unnecessary for a proportion of the patients.  Such an outcome 
would have the ripple effect of reducing healthcare costs at the national level, thus 
freeing up financial resources to take care of other pressing healthcare concerns such as 
malaria.  It would also free up more time for patients’ relatives/attendants to engage in 
economic activities that strengthen the household economy, as compared to spending a 
lot of time taking care of hospitalized patients.  In view of high poverty levels in disease 
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endemic countries, an efficacious oral drug would, in my view, be favourable even if it 
was only active against first stage HAT. 
If a potential advantage of an efficacious oral take home medicine would be to 
reduce the proportion of patients requiring hospitalization, the question of which patient 
categories (first or second stage) could benefit most needs to be considered. An oral take 
home medicine, if available, is likely to be prescribed only for those patients who are not 
moribund or in any way so incapacitated as to make hospitalization mandatory.  In 
general, first stage patients fit the description of those who are likely to benefit from such 
medicines better than second stage patients.  It must also be mentioned that barriers to 
early diagnosis of HAT are progressively being removed. One of these barriers, war and 
conflict, contributes to the spread of HAT through displacement of large populations of 
people and their livestock some of which are infected carriers (Kuzoe, 1993; Ford, 2007). 
Insecurity also makes certain regions/villages in HAT endemic countries inaccessible to 
health personnel thus hindering efforts to carry out proper surveillance; in areas where 
active surveillance has been carried out effectively HAT cases are increasingly diagnosed 
while still in first stage (Chappuis et al., 2010). It is encouraging to note that major long 
running conflicts in Angola and South Sudan have been resolved recently and the 
security situation has also improved in the DRC. Another hindrance to early diagnosis of 
HAT has been lack or poor knowledge of the disease symptoms among the general 
population. This drawback has been innovatively addressed in Kenya through education 
of schoolchildren as a way to disseminate vital disease information to the community 
(Julia Karuga, personal communication). Primary healthcare workers have also been 
targeted for education in a campaign to improve early detection of HAT (Dr Grace 
Murilla, personal communication). While the impact of these initiatives has not been 
independently evaluated, it is believed that supplying the right information to those who 
need it should help to improve early case detection which in turn would increase the 
proportions of patients likely to benefit from an oral drug for 1st stage HAT. 
 
Based on recent successes in reducing the incidence and prevalence of HAT, 
some authors currently believe that elimination of HAT as a disease of public health 
significance is an achievable goal (Nimo, 2010; Aksoy, 2011; Simmaro et al., 2011). In 
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order to achieve this noble goal, however, the stakeholders must find a way to keep the 
HAT control agenda alive despite the dwindling case numbers. We must find a way to 
avoid falling into a similar pitfall as happened in the 1960s when success was followed 
by a period of uncertainty and in some cases neglect of vital disease surveillance 
activities, leading to resurgence in the disease in the 1970s to 1990s (Simmaro et al., 
2008; Nimo, 2010). The WHO needs to continue the excellent coordinating and 
motivating role it has had on National Disease Control Programmes (NDCPs) as well as 
being the link between drug manufacturers and HAT endemic countries. In addition, 
regional groupings such as the Eastern Africa Network for Trypanosomiasis (EANETT) 
and the HAT Platform need to continue to meet to facilitate sharing of vital disease 
control information between members. Importantly, however, the development of new 
drugs must continue to be pursued despite the increased difficulties of carrying out 
clinical trials (Burri, 2012) and the challenge of finding donors for HAT R&D in the face 
of the reduced case numbers.  
 
Perhaps the most important reason why development of new drugs needs to 
remain a priority is the whole question of parasite resistance to existing agents. The case 
of resistance to melarsoprol is well documented (Maser et al., 1999; Brun et al., 2001; De 
Koning, 2001; Maina et al., 2006; Barret et al., 2011). In addition, the first anecdotal 
reports of treatment failures with eflornithine monotherapy are already emerging from 
some HAT foci (Barret et al., 2011). Resistance to melarsoprol and eflornithine (this 
would likely also affect NECT), would make it possible to get second stage HAT patients 
for whom there would be no available treatment - a scenario that must be avoided at all 
costs. However, the good news is that important developments have occurred in the 
chemotherapy of HAT in the recent past. These include the development and inclusion of 
the nifurtimox eflornithine combination therapy (NECT) in the essential medicines list of 
the WHO for the management of T. b. gambiense HAT (Priotto et al., 2009; WHO, 
2012). In addition, the ten-day melarsoprol treatment schedule that was already in use for 
T. b. gambiense HAT (Burri et al., 2000) has been evaluated against T. b. rhodesiense 
HAT in Tanzania and Uganda (Kuepfer et al., 2012). The results of these clinical trials 
indicated that the 10-day melarsoprol schedule had an efficacy of 96% at the 12 month 
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post treatment follow-up time point and did not expose patients to a greater risk of 
encephalopathic syndromes compared to the standard melarsoprol treatment schedules 
(Kuepfer et al., 2012). A number of molecules including the diamidines reported in this 
thesis and proposed new formulations of old drugs (Kennedy, 2012) have shown promise 
in preclinical development.  The development of better treatment schedules of current 
drugs as well as new safe and efficacious treatments must remain a priority in order to 
“dim the lights (Nimo, 2010)” on HAT. 
 
Understanding the Determinants of Diamidine Toxicity 
DB289 (pafuramidine) has so far been the only new generation diamidine 
developed by CPDD to enter clinical testing. The clinical trials were conducted in the 
DRC, Angola and South Sudan. DB289 performed well in phase I/II clinical trials 
(http://clinicaltrials.gov/ct2/show/NCT00803933), and became the first oral drug to enter 
the pivotal phase III clinical trial where its efficacy was insignificantly different from that 
of intramuscular pentamidine (Paine et al., 2010; Burri, 2010, Maser et al., 2012). 
However, while the phase III clinical trial for HAT was still in progress, an extra phase I 
clinical trial was initiated in South Africa (SA) at the request of the Federal Drug Agency 
(FDA) of the USA in order to generate additional safety data to support registration of the 
drug for Pneumocystis jiroveci pneumonia.  In this new study, DB289 was dosed at 100 
mg/kg bid for an extended 14 days as compared to 5 (phase I/II) and 10 days (phase III) 
clinical trials for HAT (http://clinicaltrials.gov/ct2/results?intr=%22DB289%22; 
http://clinicaltrials.gov/ct2/show/NCT00619346?intr=%22DB289%22&rank=5). Liver 
and more importantly delayed kidney toxicity were observed in this new phase I study, 
necessitating termination of the DB289 development programme (Paine et al., 2010).  
The phase III clinical trials data was then unblinded at which point two out of three 
nephrotoxicity cases were identified as possibly related to DB289; no such cases were 
reported for pentamidine (Dr Allison Harril, personal communication). Significantly, 
though, nephrotoxicity was also not reported for phase I/II DB289 clinical trials for HAT. 
Naturally, the determinants of DB289 (and by extension diamidine) toxicity needed to be 
elucidated in order to aid selection of next-in-class compounds that could be safely used 
in humans. 
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Insights from the Monkey HAT Model 
Pharmacological investigations carried out in vervet monkeys on DB289, DB844, 
DB1058, DB868 and DB829 suggested that members of the class (diamidines) exhibit 
differential toxicity profiles. Based on cumulative doses administered to un-infected 
monkeys during the toxicity study and cumulative doses that were curative in the 1st stage 
HAT model, DB868 exhibited a maximum tolerated dose (MTD): minimum curative 
dose (MCD) ratio of 14:1 (300:21). On the other hand, pafuramidine was administered at 
a maximum dose of 10 mg/kg x 10 days (CD = 100 mg/kg) and was fully curative (3/3) 
against 1st stage HAT when administered at 10 mg/kg x 5 days (Mdachi et al., 2009) 
indicating an approximate MTD: MCD ratio of 2:1. DB844, another of the prodrugs, 
turned out to have an insufficient therapeutic index for the targeted 2nd stage disease 
indication (Thuita et al., 2012), but was not evaluated against 1st stage HAT which, our 
studies on other prodrugs showed, require significantly less total drug doses. Similar to 
DB844, another prodrug DB1058 was poorly tolerated in un-infected monkeys (data not 
shown) and was therefore not evaluated for efficacy in the monkey model.  The parent 
drug CPD-0802 was tolerated at 5 mg/kg x 5 days (CD = 25 mg/kg) and was fully 
curative at 2.5 mg/kg x 5 days (CD = 25 mg/kg) giving an apparent therapeutic index of 
2:1 for 2nd stage HAT.  On the basis of these data, oral DB868 had the best therapeutic 
index when used against 1st stage HAT and would therefore be an interesting candidate 
for development. The five compounds (Figure 1) are structurally very similar; they differ 
only in the number and location of nitrogen atoms in their phenyl rings (appendix 1). The 
observed differences in their activity profiles highlight the value of structure activity 
relationship studies (SARs) as a strategy for filtering out the poor compounds and 
allowing potentially beneficial ones to progress to the next phase of the drug 
development process. 
 
In addition to differences between compounds, compound dose and duration of 
dosing were identified as important determinants of toxicity (e.g. for DB844 in Thuita et 
al., 2012). These studies relied on standard techniques, including observation for overt 
toxicity, haematology, and assay biomarkers of liver (alanine aminotransferase [ALT] 
and aspartate aminotransferase [AST]) and kidney (blood urea nitrogen [BUN] and 
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creatinine [CREA]) toxicity. In addition, animals that needed to be euthanized were 
subjected to necropsy and histopathology. A wider array of newer biomarkers especially 
for kidney toxicity are available and have been used to study diamidine toxicity in 
rodents (discussed below) but these were not used for the monkey studies. Even with the 
standard techniques employed in the monkey studies, however, the relationship between 
dose and toxicity was clearly demonstrated for the different compounds described in this 
thesis. In my view, these findings may partly explain why more pronounced toxicity, 
including delayed kidney toxicity, was observed in human volunteers who received a 
higher cumulative dose of pafuramidine (100 mg BID x 14 days) as compared to those 
who received the lesser doses (100 mg BID for 10 days or less) during the clinical trial 
phase for HAT. During the phase I/II DB289 clinical trials, all the volunteers and/or 
patients were assessed to have tolerated the drug well, with only mild and self-limiting 
side effects whose frequency and severity were comparable in the pafuramidine-treated 
and placebo or comparison drug treatment (pentamidine) group (Immtech data cited in 
Nyunt et al., 2009). In the clinical setting, adverse drug reactions (ADRs) that exhibit 
clear dose dependence and can be reproduced in experimental animals are termed “Type 
A” ADRs (Thompson et al., 2012). These types of ADRs can theoretically be avoided by 
identifying and keeping below the “threshold” for toxicity which, on the evidence of 
toxicity and efficacy studies in monkeys, would be best achieved through relatively short 
dosing regimens of 5-7 days duration. A recent clinical trial (ISRCTN55042030) 
attempted to reduce dosing for pentamidine to three days compared to the standard 7 to 
10 day period at 4 mg/kg (Burri 2010) based on previous pharmacokinetic studies of 
pentamidine in T. b. gambiense patients (Bronner et al., 1991). 
 
At clinical chemistry level, diamidine toxicity in monkeys was characterised by 
changes in the standard biomarkers of both liver and kidney, similarly to the case in 
humans. This is not surprising, considering the phylogenetic closeness between human 
and non-human primates. Aberrations were demonstrated in either ALT or AST for the 
liver as well as blood urea nitrogen (BUN) or creatinine for the kidney.  In my view, the 
challenge for drug developers is to decide whether transient 2-3 fold increases in clinical 
chemistry analytes (e.g. blood urea nitrogen) constitute a significant safety concern to 
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warrant discarding of a new chemical entity.  Achieving the balance between essential 
safety concerns and the possibility that promising therapeutic agents will get discarded 
without adequate review of their potential is not easy. It must be said also that 
pentamidine, which continues to be of benefit to thousands of HAT, leishmaniasis and 
Pneumocystis jiroveci pneumonia does not only cause some degree of reversible liver 
damage but it also causes some nephrotoxicity (Bronner et al., 1991). In conclusion, the 
observations in monkey studies suggest that the new diamidines are not more toxic than 
pentamidine; dose and duration of dosing are the twin issues that must be carefully 
considered in regulatory development of a next-in- class diamidine. 
 
Insights from the Mouse Diversity Panel (MDP) and Rats 
Efforts to understand how diamidines can be safely used therapeutically have also 
involved studies in rats (Wolf et al., 2012) and the development of a new model, the 
mouse diversity panel (MDP) by Dr Allison Harril and colleagues at the Hamner Institute 
for drug safety studies, University of North Carolina (UNC). In their studies, Kristina 
Wolf and colleagues compared the toxicity of DB289 and DB868 in female Sprague-
Dawley rats (8-10weeks). The results signify differences in the toxicity of the two 
compounds. D289 was found to have caused a 12-fold increase in mean ALT 
concentrations in comparison with vehicle (carboxymethyl cellulose), while DB868 
caused no such elevations of ALT. In their study, Wolf and colleagues found no changes 
in the standard biomarkers of kidney toxicity (BUN and CREA) that could be attributed 
to either DB289 or DB868. Novel biomarkers of kidney injury including the kidney 
injury molecule 1 (KIM-1) and full name TIMP I were found to be elevated in DB289 
treated rats, suggesting that these were more sensitive markers of renotoxicity in this 
model. 
 
A new rodent tool, the mouse diversity panel (MDP) was additionally evaluated 
for ability to predict renal toxicity (Dr Allison Harrill, personal communication). Dr 
Harrill and colleagues at the Hamner-University of North Carolina Institute for Drug 
Safety Sciences developed the MDP based on the hypothesis that genetic variability may 
render certain individuals/populations more susceptible to renal injury. This hypothesis 
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arose out of the fact that considerable DB289 renal toxicity was detected only after the 
extended phase I clinical trial in SA but not during clinical trials held in the DRC, Angola 
and South Sudan. In their studies, Harril and colleagues dosed 34 different strains of mice 
with DB289 and found that there were differences in susceptibility among the different 
mouse strains. They noticed that some strains of mice were indeed more susceptible to 
DB289 toxicity and could therefore be very useful in predicting clinically relevant 
toxicities in the evaluations of next-in-class molecules. Harril and colleagues also found 
that the KIM-1 and TIMP were more sensitive biomarker than standard renal clinical 
chemistry biomarkers-urea and creatinine. The addition of the MDP to an array of models 
available for preclinical evaluation of promising drug compounds makes it possible to 
detect agents that may cause toxicity only in certain susceptible patients. When toxicities 
are detected only in certain susceptible patients in the clinical setting (human), they are 
referred to as idiosyncratic drug reactions (IADRs, or Type B) (Thompson et al., 2012). 
 
Improving the Efficiency of Drug Evaluations in the Monkey Model 
Preclinical models are a critical component of R&D programmes. One key area of 
concern has been the need to monitor the monkeys for at least 300 days post last dosing 
in order to confirm cure which in turn slows down turn-atime for the compounds in the 
model.  We hypothesised that loop mediated isothermal amplication (LAMP) of 
trypanosome DNA could be a useful test that would help in reduction of post treatment 
monitoring times.  Preliminary studies on biological samples collected from the monkeys 
of the efficacy studies indicated that LAMP was indeed very sensitive in detecting 
residue DNA in biological fluids. However, clearance of the DNA post treatment 
appeared to be erratic in different individuals, in some cases DNA was detected through 
out the post treatment monitoring period.  This result was essentially similar to a report 
that PCR detected DNA in patients throughput the period of post treatment monitoring 
(Matovu et al., 2012) suggesting that DNA based tests may be good for diagnosis of new 
infections but not so good for detection of cures or relapses post treatment. 
 
In our studies we found that approximately 80% of monkeys that eventually 
relapsed had already been detected by the 3 months post treatment time point (appendix 
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2).  This observation suggested that where several compounds were available to be tested, 
the result at 3 months could be used as a milestone to decide whether to initiate a new 
study in the monkey model or not which would serve to improve turnover time for late 
stage drugs. This approach could be applied until more sensitive biomarkers have been 
identified that could reliably be used to predict cure. Work done so far on an antigen 
based test, TrypTect CIATT showed that about 12 months were needed before antigens 
were totally cleared from serum and CSF of cured monkeys and humans (Karanja et al., 
2010). The search for new biomarkers that can reduce post treatment follow-up has not 
yet yielded results that could be used in drug trials. In the meantime, our results on the 3 
month milestone for efficacy evaluations in the model could help to improve efficiency in 
preclinical monkey model studies. 
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